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CHAPTER I 
 
BACKGROUND 
 
Introduction 
 The process by which viruses cause disease consists of a complex series of steps 
involving many host and viral factors. Virus must employ mechanisms necessary to 
successfully invade a host, replicate in target cells, and subsequently be transmitted to the 
next host. The capacity of a virus to infect some types of cells in the host can lead to the 
production of disease. As such, the first step in the viral replication cycle, attachment of 
the virus to cell-surface receptors, is important for establishing infection and serves a 
critical function in viral pathogenesis. Therefore, studies aimed at gaining an 
understanding of the precise nature of pathogen-receptor interactions can provide 
valuable insights into mechanisms of tissue injury and disease in an infected host. In the 
work presented in this thesis, I use mammalian orthoreoviruses (called reoviruses here), a 
highly tractable experimental model for the study of viral pathogenesis, to gain a better 
understanding of virus-receptor interactions and the influence of these interactions in 
central nervous system (CNS) disease. 
When this work was initiated, it was well established that sialic acid (SA) serves 
as a co-receptor for type 3 (T3) reovirus and allows reovirus to more efficiently attach to 
and infect cultured cells. It was also known that residues 198, 202, and 204 of T3 σ1 
influence the capacity of σ1 to interact with SA. However, whether and how these σ1 
residues engage SA was not known. Moreover, the crystal structure of the SA-binding 
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domain of the σ1 of T3 reovirus had not been determined, and the possible contributions 
of other σ1 residues to SA binding were unclear. Finally, while it was known that SA 
binding enhances reovirus dissemination from the intestine to the CNS and confers 
tropism for bile duct epithelium, the role of SA binding in reovirus infection of the CNS 
was not well understood. 
In Chapter II, I report the crystal structure of the T3 reovirus attachment σ1 
protein in complex with sialylated oligosaccharides. In Chapter III, I present work that 
defines functional SA-binding determinants in the T3 reovirus σ1 attachment protein. In 
Chapter IV, I report that utilization of sialylated glycans by T3 reovirus enhances 
neurovirulence. These findings reveal the structural and molecular basis of T3 σ1-SA 
interactions and suggest that SA-binding enhances reovirus infection of the murine CNS. 
 
Virus-receptor interactions 
Viral attachment to specific host molecules is the initial step in viral infection. 
This process is substantially more complex than a simple binary interaction between virus 
and receptor and often involves multiple viral and cellular determinants. These 
interactions also may be accompanied by dramatic conformational rearrangements of 
viral structural proteins (24, 53, 103, 114, 131) and, in some cases, viral receptors (85). 
Many viruses employ an adhesion-strengthening attachment strategy in which primary 
virus-cell interactions require low-affinity adhesion of the virus to common cell-surface 
molecules that are often carbohydrate in nature (123, 127). This initial phase of 
attachment is then followed by higher-affinity binding to a secondary receptor that 
triggers virus entry through either direct membrane fusion or receptor-mediated 
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endocytosis (31, 114, 124, 131). In addition, several viruses use independent receptors for 
attachment and internalization. For example, adenovirus uses the coxsackievirus and 
adenovirus receptor to attach to host cells (12, 113) and αvβ3 and αvβ5 integrins to 
induce endocytosis (71, 125). 
Receptor engagement can influence many aspects of viral pathogenesis, most 
prominently dissemination and tropism. For example, tropism of human 
immunodeficiency virus (68), poliovirus (92), and SARS-coronavirus (30) is strongly 
influenced by the capacity of these viruses to bind specific receptors. Strains of adeno-
associated virus (AAV) show a pattern of tropism in the CNS dependent on carbohydrate 
binding specificity. AAV4 utilizes α-2,3-linked SA as a receptor and infects ependymal 
cells. In contrast, AAV5 uses α-2,3- and α-2,6-linked SA to infect neurons (55). Thus, 
both proteinaceous and carbohydrate receptors can influence the types of diseases caused 
by viruses. 
 
Carbohydrates as virus receptors 
 A large number of viruses, including many that cause human disease, use 
sialylated oligosaccharides present on proteins or lipids to attach to cells. Given their 
ubiquitous expression on the cell surface and wide distribution on various cell types 
throughout the host, it is not surprising that glycans terminating in SA are an important 
class of virus receptors. For example, coxsackievirus A24 variant and enterovirus 70, 
which cause acute hemorrhagic conjunctivitis and have pandemic potential, attach to 
sialylated oligosaccharides (2, 83). The human JC and BK polyomaviruses cause a fatal 
demyelinating disease and kidney graft loss, respectively, in immunocompromised 
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individuals. Both viruses use glycans terminating in SA as receptors (67, 78). Lastly, 
rotavirus, which is a member of the Reoviridae family, causes severe gastroenteritis in 
children. These viruses vary in SA-binding capacity as judged by sensitivity or resistance 
to neuraminidase treatment (13, 51). Neuraminidase-insensitive strains were thought to 
use non-sialylated receptors. However, the “neuraminidase-insensitive” rotavirus strain 
Wa attaches to the ganglioside GM1 (48). Because of its branched structure, this 
carbohydrate is difficult to cleave with neuraminidase (72, 109). Therefore, SA should be 
considered as a possible receptor component even for viruses whose infectivity is not 
affected by pre-treatment of cells with neuraminidase. 
One of the most well characterized roles of SA in viral pathogenesis is in 
influenza virus infection and disease. Influenza viruses engage SA to infect cells of the 
airway epithelium (108). The specificity of the interactions between the influenza 
hemagglutinin and SA play a key role in tropism and host restriction. Avian influenza 
strains preferentially recognize the α-2,3-linked SA found in intestinal and upper airway 
epithelium of birds. In contrast, and human influenza strains preferentially bind to α-2,6-
linked SA, which is enriched in the lower airway epithelium of humans (43, 107, 108). 
Mutations in the influenza hemagglutinin that change the SA specificity of an avian strain 
(α-2,3-linked SA) to that of a human strain (α-2,6-linked SA) allow an expansion of the 
viral host range to include humans with potentially devastating consequences. This 
insight strengthens the rationale to conduct studies to gain a better understanding of 
mechanisms that viruses use to engage carbohydrate receptors and understand the precise 
function of these receptors in viral pathogenesis. 
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Structure and function of reovirus attachment protein σ1 
 Reoviruses, members of the Reoviridae family, form icosahedral, nonenveloped 
particles that are approximately 850 Å in diameter (26) (Figure I-1). The ten segments of 
dsRNA that compose the reovirus genome are encapsidated within two concentric protein 
shells, the outer capsid and inner core (Figure I-1A). Together, the outer capsid and core 
are composed of eight structural proteins. The bulk of the outer capsid consists of the 
tightly-associated μ1 and σ3 proteins (65). There are turrets formed by the pentameric λ2 
protein at each of the twelve icosahedral vertices of the virion from which the viral 
attachment protein, σ1, extends (6, 23, 33, 39, 42) (Figure I-1B). Three reovirus serotypes 
have been described, which are represented by prototype strains type 1 Lang (T1L), type 
2 Jones (T2J), and type 3 Dearing (T3D) (89, 99). 
The σ1 protein belongs to a class of fiber proteins constructed from triple β-
spirals, a motif that was first identified in the adenovirus fiber (87). Before 
crystallographic structures of σ1 were determined, information about the structure came 
from composite transmission electron micrographs of σ1 molecules purified from virions 
(39) (Figure I-2). These images confirmed earlier predictions of a fiber-like structure of 
σ1 (10) and clearly revealed two distinct morphological domains: a long N-terminal 
fibrous tail that inserts into the virion capsid and a C-terminal globular head that projects 
away from the virion surface. As high-resolution atomic structures of σ1 became 
available (23, 91), the initial model of the morphological domains was revised to include 
a third domain encompassing a region of sequence in the middle portion of the molecule: 
the body domain.  
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Thus, the σ1 protein is a filamentous trimer about 480 Å in length with three discrete 
domains: the tail, body, and head (23, 39, 91) (Figure I-3). 
 
 
FIGURE I-1. Organization and structure of a reovirus virion. (A) Schematic representation 
of a reovirus virion. Outer capsid, inner core, viral attachment protein σ1, the λ2 base into 
which σ1 inserts, and ten viral dsRNA genome segments are indicated. (B) Cryo-electron 
microscopic image reconstruction of a reovirus virion. Major outer capsid proteins are 
pseudocolored and indicated. σ1 molecules are represented schematically. Image adapted 
from Nason et al. (76). 
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Residues 1 to 160 encompass the σ1 tail domain, which inserts into the virion 
capsid (23, 42) (Figure I-3). This region of the molecule is predicted to form an α-helical 
coiled coil (35, 81). The σ1 body domain encompasses residues 170 to 309 and is 
comprised of a β-spiral repeat motif interrupted by a short α-helical coiled coil (91) 
(Figure I-3). The globular head domain of σ1 incorporates residues 310 to 455 and folds 
FIGURE I-2. Computer-processed negative-stain electron micrographs of σ1. (A) 
Composite electron micrograph of σ1. N and C termini, head and tail domains, and regions 
of observed flexibility of the molecule are indicated. (B) Individual electron micrographs 
of σl molecules, highlighting distinct morphologies: (a) the head appears multi-lobed; (b) 
the tail is kinked immediately adjacent to the head; (c) the tail is kinked near its midpoint. 
Images adapted from Fraser et al. (38). 
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into an 8-stranded β-barrel (23, 57, 91, 101) (Figure I-3). Sequences in the σ1 body 
domain mediate SA binding by type 3 strains (21, 91), whereas sequences in the σ1 head 
domain engage junctional adhesion molecule A (JAM-A) (57) (Figure I-3).  
JAM-A (F11R/JAM/JAM1) serves as a receptor for all three reovirus serotypes (8, 
18). JAM-A is a member of the immunoglobulin (Ig) superfamily postulated to regulate 
formation of intercellular tight junctions (66, 70, 126). The molecule contains two 
extracellular Ig-like domains, a short transmembrane region, and a cytoplasmic tail 
possessing a PDZ-domain-binding motif (70, 126) (Figure I-4). There are three 
recognized JAM family members (JAM-A, JAM-B, and JAM-C) (4, 5, 25, 64, 75). Both 
the murine (m) and human (h) homologs of JAM-A function as reovirus receptors (8, 18); 
JAM-B and JAM-C do not confer reovirus receptor activity. 
The σ1 protein exhibits a substantial degree of flexibility, which can be attributed 
to regions that partition the main σ1 domains (34, 39, 80) (Figure I-2 and I-3). T3D σ1 
contains a four-residue insertion between the two most C-terminal β-spiral repeats that lie 
just below the σ1 head that confers flexibility in this region (19, 23, 39). Sequence 
alignments of T1L and T2J σ1 predict six-residue insertions at this same position (23). 
The second region of flexibility is observed towards the middle of the σ1 protein and is 
thought to correspond to the junction between the α-helical coiled-coil tail and the β-
spiral body of the protein (Figure I-3). A third region of flexibility is found in the N-
terminal portion of the protein, which may form the virion-insertion domain (23, 39, 46, 
81) (Figure I-2 and I-3). 
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Interactions of σ1 with SA 
 The earliest evidence that reoviruses engage cell-surface SA was gathered from 
hemagglutination (HA) assays, a sensitive assay for SA-binding capacity, in the early 
1960’s (63). Reoviruses exhibit the capacity to agglutinate erythrocytes of several 
mammalian species (63). Subsequent studies revealed that terminal α-linked SA residues 
on the protein glycophorin A mediate T3 reovirus agglutination of erythrocytes (44, 84). 
Accordingly, neuraminidase treatment of erythrocytes, which removes cell-surface SA,  
 
FIGURE I-3. Full-length model of reovirus σ1. A full-length depiction of σ1 was generated 
by modeling a predicted trimeric a-helical coiled coil and linking it to the N-terminus of the 
largest crystallized fragment of σ1 (residues 246-455 of strain T3D σ1) (91). The three 
monomers of the crystallized fragment are shown in blue, red, and yellow; the model is 
shown in grey. Tail, body, and head regions are indicated. Regions of flexibility are marked 
by arrows. A sequence polymorphism that confers susceptibility to cleavage by intestinal 
proteases is indicated with an asterisk. The approximate locations of binding sites for sialic 
acid and junctional adhesion molecule-A (JAM-A) are shown. Amino (N)- and carboxy (C)-
termini are indicated. 
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decreases the HA capacity of strain T3D (44). In addition, SA serves as an important 
coreceptor for reovirus binding to and infection of certain types of cells in culture, such 
as murine erythroleukemia (MEL) cells (22, 98).  
FIGURE I-4. Crystal structures of the hJAM-A and mJAM-A extracellular domains. (A-B) 
Ribbon drawings of the hJAM-A dimer (A) and the mJAM-A dimer (B), with one monomer 
shown in orange and the other in blue. Disulfide bonds are shown in green. Dimerization is 
mediated by the membrane-distal D1 immunoglobulin domain. Both human and murine 
JAM-A serve as reovirus receptors. Images adapted from Prota et al (86) (A) and Kostrewa 
et al (60) (B) by Eva Kirchner. 
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Although naturally circulating strains of reovirus incapable of binding SA exist, 
the majority of field isolates do exhibit the capacity to interact with SA and agglutinate 
erythrocytes (27). Sequence analysis and assays of SA-binding capacity revealed that 
sequence polymorphisms within the σ1 body domain at residues 198, 202, and 204 
determine the capacity of field-isolate strains to bind SA (27, 97). This genetic linkage 
was further strengthened by the finding that non-SA binding reovirus strains could be 
adapted to infect and replicate in MEL cells, which require binding to SA to support 
infection. When the S1 genes of these non-SA binding strains were analyzed, sequence 
changes were observed in a discrete region of σ1 corresponding to a putative SA-binding 
domain (22). Structural studies of T3 reovirus σ1 performed as a part of this thesis 
demonstrated more specifically that interactions between σ1 and SA involve residues at 
the N-terminal portion of the body domain, between β-spiral repeats 2 and 3, where the 
SA moiety docks into a shallow pocket that is formed mainly by residues in the third β-
spiral repeat (91) (Figure I-3). Interestingly, the T3 σ1 SA-binding domain is highly 
permissive for glycan-binding and can engage α-2,3-, α-2,6-, and α-2,8-linked SA 
moieties (91). 
The carbohydrate receptors for other serotypes of reovirus have not been as well 
characterized. While it is known that T1 reoviruses also bind to SA in some contexts, it is 
apparent that that the nature of the carbohydrate engaged by T1 and T3 reovirus strains 
differ. For example, T1L, but not T3D, binds to the apical surface of microfold (M) cells, 
but not to enterocytes, in tissue sections of rabbit Peyer’s patches (49). Pre-treatment of 
the tissue sections with neuraminidase or with lectins that specifically recognize α-2-3-
linked sialic acid inhibits infection by T1L, a property that segregates with the S1 gene. 
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More recently, glycan microarrays along with crystallographic studies of T1 reovirus σ1 
have revealed that, in contrast to T3 reovirus, sequences in the head domain of the T1 σ1 
protein are responsible for binding to the sialylated ganglioside, GM2 (90).  
 
Adhesion-strengthening mechanism of reovirus attachment to cells 
 The first evidence that σ1 contains two distinct receptor-binding domains came 
from the realization that the SA-binding domain of T3 σ1 genetically mapped to the body 
domain of the σ1 protein (22, 27). To gain a better understanding of the function of SA in 
reovirus attachment and tropism, in vitro studies using monoreassortant viruses 
containing the S1 gene of either non-SA-binding strain T3C44 (28) (strain T3SA-) or SA-
binding strain T3C44-MA (22) (strain T3SA+) and all other gene segments from T1L (7). 
T3SA- and T3SA+ demonstrate cell-specific interactions attributed to the S1 gene 
segments of their respective T3 parental strains, with T3SA+, but not T3SA-, capable of 
hemagglutination and growth in MEL cells. In concordance with these results, studies 
using surface plasmon resonance demonstrated that T3SA+ binds SA with a KD of ~ 5 x 
10-9 M, while T3SA- displays no specific interaction with SA (7). 
These reovirus strains also exhibit differences in binding and growth in other cells 
in culture. Although both T3SA+ and T3SA- replicate with equivalent efficiency in L 
cells, T3SA+ replicates 100-fold more efficiently in HeLa cells than does T3SA- (7). 
Moreover, the avidity of these strains for L cells is nearly equivalent (KD 3 x 10-11 M) as 
shown by radioligand binding assays, but the avidity of T3SA+ for HeLa cells is five-fold 
higher than that of T3SA- (7). Kinetic binding studies indicate that the capacity to engage 
SA functionally serves to increase the kon of virus attachment to HeLa cells. Binding of 
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T3SA+ to HeLa cells proceeds through a time-dependent adhesion-strengthening process, 
which is initially characterized by a rapid kon and koff, and then transitions to a higher-
avidity binding state with a slower koff (7). Preincubation of virus with sialyllactose 
dramatically reduces the efficiency of T3SA+ infection, yet has no effect on T3SA- 
infectivity (7). Therefore, the enhanced infectivity of T3SA+ is mediated by the 
interaction of σ1 with cell-surface SA. However, this SA-mediated enhancement of 
T3SA+ infection is only effective during the initial phases of virus-cell interaction, since 
sialyllactose does not inhibit productive binding of T3SA+ after the first 30 min of virus 
adsorption (7). In contrast, Fab fragments of an antibody directed to the σ1 head 
efficiently neutralize infection of either T3SA+ or T3SA-, even when added at late times 
during adsorption (7).  
Results of binding studies using T3SA+ and T3SA- indicate that the interaction of 
reovirus with the cell surface is complex, with multiple cellular molecules engaging σ1 in 
an elegantly coordinated process that determines the outcome of the attachment event. 
These insights have led to the current model of reovirus attachment in which receptors 
are engaged by a multistep adhesion-strengthening process in which σ1 first binds to an 
abundant cell-surface carbohydrate with low affinity (7), which is followed by high-
affinity interactions with JAM-A or other proteinaceous receptors that remain to be 
indentified(6, 8) . 
 
Reovirus tropism and neuropathogenesis 
 Reoviruses exhibit a broad host range in nature, infecting many mammalian 
species, including humans (26). However, while reoviruses have the capacity to infect 
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humans, disease is restricted to the very young (69, 111). Reoviruses infect most children 
(110) and can cause mild respiratory or gastrointestinal illnesses (26). In addition, 
reoviruses serve as important models for studies of viral replication and pathogenesis and 
in particular for analysis of viral determinants of CNS injury. 
 Reoviruses enter animal hosts by both respiratory and enteric routes (119). 
Following peroral inoculation of newborn mice, reoviruses adhere selectively to surface 
projections on the luminal surface of M cells (119, 128-130) (Figure I-5). These epithelial 
cells overlie the Peyer’s patches in the intestine. Ultrastructural studies of the fate of virus 
in the intestinal tract suggest that virions are endocytosed by M cells and subsequently 
transported across these cells within cytoplasmic vesicles (128). Upon reaching the 
submusocal zone beneath the M cells, viruses can either spread to intestinal tissue in 
close proximity by infecting the basal surface of intestinal epithelial cells (95, 96, 120) or 
disseminate to secondary sites in the host by neural, lymphoid, or hematogenous 
pathways.  
 T1 reovirus spreads to the CNS by hematogenous routes to infect ependymal cells, 
leading to non-lethal hydrocephalus (115, 121, 122). In contrast, T3 reovirus spreads 
primarily via axonal transmission to the CNS (73, 115), infects neurons, and causes lethal 
encephalitis (73, 115, 121, 122). Following intramuscular (IM) inoculation into the hind 
limb, T3D spreads to the spinal cord through the sciatic nerve (115). The σ1-encoding S1 
gene dictates these serotype-specific disease patterns (115, 121, 122), most likely via 
selective recognition of cell-surface receptors by σ1.  
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FIGURE I-5. Reovirus T1L binds and infects M cells that overlie Peyer’s patches. (A) An 
electron micrograph demonstrating T1L virions (arrow) adhering to the luminal (L) surface of 
an M cell (M) in a closed ileal loop 30 minutes after virus inoculation. The M cell surrounds a 
mononuclear cell (N) and borders two absorptive (A) cells that lack adherent virus (x13,400). 
Inset: higher magnification of M cell surface with adherent virions (x38,800). (B) A 
photomicrograph of adult mouse intestine 48 h after inoculation with 5 x 109 PFU T1L 
demonstrates reovirus antigen-positive (arrowhead) M cells (m) overlying Peyer’s patches 
(PP). Images adapted from Wolf et al (130) (A) and Rubin et al (95) (B). 
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Although the functions in disease pathogenesis of the two known reovirus 
receptors (JAM-A and SA) are not completely understood, careful in vivo studies have 
been performed that have enhanced an understanding of the roles played by these 
receptors in reovirus infection in the host. Studies using JAM-A-knockout mice indicate 
that JAM-A is dispensible for reovirus growth in the intestine following peroral 
inoculation but is required for efficient hematogenous spread from primary to secondary 
sites of replication (3). In addition, JAM-A is required for reovirus infection of vascular 
endothelial cells, which may provide a portal into the bloodstream. Studies comparing 
pathogenesis in newborn mice of reovirus strains that differ in glycan utilization (strains 
T3SA+ and T3SA-) revealed that SA-binding enhances spread from the intestine to 
peripheral sites of replication such as the liver, spleen, and brain (9). Furthermore, the 
capacity to bind SA confers reovirus tropism for bile duct epithelium (9). However, it is 
not known whether SA-binding influences reovirus dissemination, tropism, and 
replication within the CNS. 
 
Significance of the research 
Receptor utilization is an important determinant of many aspects of reovirus 
disease, including dissemination and tropism. Mechanisms underlying reovirus spread to 
and within the CNS are not well understood. Examination of carbohydrate coreceptor 
utilization by reovirus in the pathogenesis of neural injury will improve an understanding 
of how carbohydrates function as viral receptors and define mechanisms by which 
neurotropic viruses infect the host. Many clinically important neurotropic viruses produce 
neural injury similar to that caused by reovirus. Knowledge of pathologic mechanisms 
  
 
17
gained from this research may establish general principles of viral neuropathogenesis, 
thereby improving our ability to develop antiviral therapeutics. Morever, an enhanced 
understanding of the molecular interactions that occur between σ1 and its cellular 
receptors will aid in the continued development of reovirus as an oncolytic agent and 
vaccine vector. 
 My work focused on elucidating the molecular basis of SA binding by T3 
reovirus and defining the contribution of SA engagement to reovirus neuropathogenesis. 
Using structure-guided mutagenesis, I defined a discrete network of residues in T3 σ1, 
centered on Arg202, that are required for SA binding. Furthermore, data gathered from in 
vivo experiments comparing strains that differ in the capacity to bind SA suggest that SA-
binding enhances reovirus neurovirulence by allowing more efficient infection of CNS 
tissues. These studies have enhanced an understanding of mechanisms of viral attachment 
to cell-surface glycans and CNS disease caused by neurotropic viruses. 
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CHAPTER II 
 
CRYSTAL STRUCTURE OF REOVIRUS ATTACHMENT PROTEIN σ1 IN 
COMPLEX WITH SIALYLATED OLIGOSACCHARIDES 
 
Introduction 
Previous studies revealed that sequences in the T3D σ1 body domain bind to 
carbohydrates (21). Sequence analysis of reovirus variants identified three residues, 
Asn198, Arg202, and Pro204, which genetically segregate with the capacity of T3 σ1to 
interact with SA. These residues lie near the midpoint of the protein, at the lower end of 
the body domain, about 100 Å away from residues in the head that interact with JAM-A. 
Previous structural analyses of T3D σ1 (23, 57, 101) were based on constructs that did 
not include this putative carbohydrate-binding site. It is therefore unclear how σ1 
achieves its specificity for SA, or whether σ1 undergoes rearrangements after engaging 
its carbohydrate receptor. 
To enhance an understanding of mechanisms by which viral attachment proteins 
engage cell-surface glycans, we determined the crystal structure of T3D σ1 in complex 
with α-2,3-sialyllactose, α-2,6-sialyllactose, and α-2,8-disiallylactose. All three 
carbohydrates terminate in SA but feature different linkages that are present in various 
physiologic glycans. These studies shed light on the structural basis of σ1-SA interactions 
and define a new carbohydrate-binding structural motif in a viral attachment protein. 
The research described in this chapter was performed in collaboration with the 
laboratory of Dr. Thilo Stehle (Universitat Tübingen). Dirk Reiter (Universitat Tübingen) 
purified, crystallized, and solved the structure of the C-terminal half of T3D σ1 alone and 
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in complex with α-2,3-sialyllactose, α-2,6-sialyllactose, and α-2,8-disiallylactose. Dirk 
also prepared the structural figures shown in this chapter. I assisted in construct design, 
helped to choose glycans to soak with σ1, and contributed to data interpretation. Based on 
information gathered from the crystal structures, I performed functional studies to 
determine what residues in T3 σ1 are important for mediating binding to SA. Results 
from these experiments are presented in Chapter III. 
 
Results 
Construct Design and Structure Determination - The σ1 protein belongs to a class of 
fiber proteins constructed from triple β-spirals, a motif that was first identified in the 
adenovirus fiber (117). In a previous study, we crystallized a smaller region of σ1, 
spanning residues 246 to 455 and containing three β-spiral repeats as well as the globular 
head domain (23). While this structure provided no insights into the carbohydrate-binding 
region of σ1, it served as a basis to predict that β-spiral repeats form the entire body 
domain of the protein (residues 167-309) (23). Near residue 170, the body domain 
transitions into a long α-helical coiled-coil region that forms the N-terminal tail domain 
(residues 1-156). 
To determine the structure of a longer fragment of σ1 including the predicted 
sialic-acid binding residues 198, 202, and 204, we designed a construct for the expression 
of residues 170-455. This construct excluded the long α-helical coiled-coil region to 
simplify protein expression, purification, and crystallization. Prototype strain T3D σ1 is 
sensitive to trypsin-mediated cleavage after Arg245 (20). However, a sequence 
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polymorphism occurring in the majority of T3 field-isolate strains, Thr249Ile, renders the 
protein resistant to trypsin (20). A construct containing Ile249 was therefore used in our 
study. Trimerization was promoted by using a hexahistidine-tagged trimerization domain, 
a modified GCN4 sequence (47), at the N-terminus of the expressed protein. This domain 
was proteolytically removed before final purification and crystallization. 
 
Overall Structure of σ1 - The structure of σ1 residues 170 to 455 reveals a highly 
elongated, symmetric trimer that measures about 200 Å in length (Table II-1 and Figure 
II-1A and II-1B). Tail residues N-terminal to amino acid 170, which were not included in 
the crystallized protein, are predicted to form an α-helical coiled-coil structure that adds 
another 200 Å in length to the protein (Figure II-1C). As expected, the structure of the 
globular head domain (residues 310 to 455) is essentially identical to that described 
previously (23). However, the body domain displays a number of unusual features. 
Although sequence-based predictions suggested that this region would be composed of 
eight consecutive triple β-spiral repeats (23), we find that the body domain contains a 
mixture of α-helical coiled-coil and β-spiral repeats (Figure II-1). Four β-spiral repeats at 
the N-terminus (β1-β4, residues 170 to 235) are followed by a short α-helical coiled-coil 
(cc, residues 236 to 251) and three additional β-spiral repeats (β5-β7, residues 252 to 
309) (Figure II-2). Inspection of the sequence indicates a likely reason for the deviation 
from the β-spiral fold at the center of the body (Figure II-2B). Three hydrophilic residues 
(Thr236, Ser244, and Ser252) are located at positions that are typically occupied by 
hydrophobic side chains in β-spirals. Moreover, Ser241 replaces a characteristic proline 
or glycine at the turn in a β-spiral repeat. While some deviations from the β-spiral 
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consensus sequence can be tolerated, even residues replacing the glycine or proline (e.g., 
residues Gln224 or Thr278), the cumulative effect of the four non-consensus residues 
results in a β-spiral no longer being the optimal fold. The α-helical coiled-coil structure 
contains two heptad-repeat sequences, starting with Phe239 and ending with Gln251 
(Figure II-2A and II-2C).  
 
 
Table II-1. Data collection and refinement statistics for σ1-oligosaccharide structures. 
 
σ1 in complex with  α-2,3-sl  α-2,6-sl  α-2,8-di-sl  
Space group  P21212  P21212  P21212  
 a = 87.15  a = 87.61  a = 87.19 
Unit cell dimensions (Å) b = 333.18  b = 333.06 b = 331.84  
 c = 58.49  c = 58.29  c = 58.13  
Unit cell angles (°)  α = β = γ = 90  α = β = γ = 90  α = β = γ = 90  
Resolution range (Å)  38.6-2.25  48.05-2.79  48.06-2.28  
Completeness (%)  95.37  98.65  96.03  
Total reflections  369038 547842 277926 
Unique reflections  78324 43203 75913 
Rmerge (%)# 10.8 6.2 9.6 
I/ σI  13.5 18.6  18.6  
Rwork (%)*   15.77  15.69  17.31 
Rfree (%)* 19.89 20.48 22.03 
r.m.s.d. bond lengths (Å)  0.006  0.007 0.006 
r.m.s.d. bond angles (°)  0.960 1.12 1.01 
 
r.m.s.d., root-mean-square deviation. sl, sialyllactose. 
* Rwork = Rfree = Σ| |Fobs(hkl) | - |Fcalc (hkl) | | / Σ |Fobs (hkl). Rfree was calculated with 5% of the data. 
# Rmerge = Σ | I - <I> |/ ΣI 
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FIGURE II-1. Structure of T3D σ1. (A) Ribbon drawing of the T3D σ1 body and head domains 
in complex with α-2,3-sialyllactose. The σ1 monomers are shown in red, blue, and yellow. The 
body domain consists of seven triple β-spiral repeats (β1- β7) and an α-helical coiled-coil domain 
(cc) that is inserted between β-spiral repeats β4 and β5. The bound α-2,3-sialyllactose is shown in 
stick representation and colored in orange. (B) Molecular surface of the σ1 structure, shown in 
semitransparent white coloring. (C) Model of full-length σ1, including a computer-generated 
trimeric α-helical coiled coil structure spanning σ1 residues 1-160 at the N-terminus (91). 
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FIGURE II-2. Structural features of the T3D σ1 body domain and sequence alignments with 
T1L and T2J σ1. (A) Close-up view of the α-helical coiled-coil that separates β-spirals 4 and 5 in 
the T3D σ1 body domain. The coiled-coil region is shown as a stick model, while the adjacent β-
spiral repeats are depicted as a ribbon drawing. A simulated annealing omit difference map for one 
chain is shown with a radius of 2.2 Å and a contour level of 3σ. (B) The residues are aligned 
according to the triple β-spiral consensus sequence (a-o), with typically hydrophobic residues (c, 
e, g, k, and m) indicated in cyan and the position in the β-turn usually occupied by proline or 
glycine (j) in green. (C) Sequence analysis of the coiled-coil region in the body domain. Residues 
239-252 are organized in heptads (a-g), and the coiled-coil consensus is indicated with typically 
hydrophobic residues (a and d) highlighted in cyan (91).  
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Structure of σ1 in Complex with α-2,3-Sialyllactose - To elucidate the structural basis of 
the interaction of the reovirus attachment protein σ1 with its carbohydrate coreceptor, we 
prepared a complex by soaking crystals of σ1 with 10 mM α-2,3-sialyllactose, a 
compound that terminates in α-linked SA. The subsequent structure, determined at 2.25 Å 
resolution (Table II-1), unambiguously demonstrated the location of the carbohydrate in 
an unbiased difference electron-density map (Figure II-3A). The oligosaccharide binds in 
a shallow groove next to the loop connecting the second and third β-spiral repeats. The 
σ1 protein contains three identical binding sites, one on each chain, and all three are 
occupied by α-2,3-sialyllactose molecules, with the SA making identical and extensive 
contacts in each chain (Figure II-3B and II-3C). The lactose moieties face different 
directions, probably as a result of internal flexibility and participation in crystal contacts 
(Figure II-3C). 
SA contains four characteristic functional groups: a carboxylate at C1, a hydroxyl 
group at C4, an N-acetyl group at C5, and a glycerol chain at C6. All four groups are 
recognized by σ1 (Figure II-3B). Arg202 forms a bidentate salt bridge with the carboxyl 
group. A single hydrogen bond links the hydroxyl group at C4 to the carbonyl of Gly205. 
The amide of the N-acetyl group is engaged in a hydrogen bond with the backbone 
carbonyl of Leu203, and the N-acetyl methyl group is facing into a partially hydrophobic 
cavity. The glycerol chain lies parallel to the peptide backbone, forming direct hydrogen 
bonds with the backbone carbonyl of Ile201 and the amide nitrogen of Leu203. In some 
of the binding sites, the glycerol chain forms water-mediated hydrogen bonds with the 
Asn210 side chain and the amide nitrogen of Ile211. We note that Arg202, which was 
previously shown to influence SA binding (22), provides a key contact to the ligand.  
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FIGURE II-3. Interactions between σ1 and SA. (A) Simulated annealing omit difference density 
map contoured at 3σ and displayed with a radius of 2.2 Å around the bound α-2,3-sialyllactose. 
The sugar moieties are labeled Sia (sialic acid), Gal (galactose), and Glc (glucose) here and in 
subsequent figures. (B) Detailed interactions between σ1 and the terminal sialic acid of α-2,3-
sialyllactose. Residues in the binding region are drawn in ball and stick representation, while the 
rest of the protein is shown as a ribbon drawing. The σ1 residues forming hydrogen bonds or salt 
bridges with the ligand are shown in green, and residues forming van der Waals contacts are 
shown in cyan. The side chain of Asn189 (colored dark blue) is contributed by a neighboring σ1  
monomer (see also Figure 1A). Sialic acid is shown in ball-and-stick representation, with carbons 
colored orange, oxygens colored red, and nitrogens colored blue. Bridging waters are shown as 
orange spheres. Hydrogen bonds and salt bridges are represented with broken lines. (C) 
Superposition of all three bound ligands into a single binding site. The superposition was 
performed using σ1 residues only. While the orientation of the terminal sialic acid is nearly 
identical, the lactose moieties are facing in different orientations as a result of their participation in 
different crystal contacts (91). 
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Moreover, Pro204, which also had been implicated in SA binding (22), is part of a 
structure that shapes the ligand-binding site. 
 
Structures of σ1 in Complex with α-2,6-Sialyllactose and α-2,8-Disialyllactose - As 
contacts in the complex of σ1 with α-2,3-sialyllactose exclusively involve the SA moiety, 
we hypothesized that σ1 should be capable of binding SA in different naturally occurring 
linkages, including α-2,6- and α-2,8-linked SA. We therefore determined crystal 
structures of σ1 in complex with α-2,6-sialyllactose (Figure II-4A) and α-2,8-
disialyllactose (Figure II-4B). Refinement statistics for both structures are provided in 
Table II-1. In each case, only two of the binding sites are occupied, as the third is 
partially blocked by crystal contacts. For the α-2,6-sialyllactose complex, the electron 
density allowed us to unambiguously identify all three sugar residues (Figure II-4A). The 
electron density for the α-2,8-disialyllactose complex did not allow us to model the 
terminal glucose. Comparison of these structures with each other and with the α-2,3-
sialyllactose complex shows that the terminal SA is bound in the same conformation and 
with identical contacts in all three cases. However, the remaining moieties of the glycans 
differ in conformation and contacts with σ1. The α-2,3-sialyllactose and α-2,8-
disialyllactose ligands assume an elongated shape in which the lactose groups face away 
from the protein (Figure II-3C and Figure II-4B). Inspection of the α-2,8-disialyllactose 
complex shows that the N-acetyl group of the second SA forms a hydrogen bond to the 
side chain of Ser195. In contrast, σ1 binds α-2,6-sialyllactose in a folded-back 
conformation (Figure II-4A). This conformation is stabilized by an intramolecular 
hydrogen bond and the galactose O2 and O3 hydroxyl groups, which form hydrogen  
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FIGURE II-4. The σ1 protein in complex with SA in different linkages. (A) View into the 
carbohydrate-binding site of the complex of σ1 with α-2,6-sialyllactose. (B) View into the 
carbohydrate-binding site of the complex of σ1 with α-2,8-disialyllactose. The orientation in panel 
(A) differs by 60 degrees along a vertical axis from the orientations shown in panel (B) and Figure 
3 to provide a clearer view into of the binding site. In both panels, σ1 residues directly contacting 
the ligand are shown in green, and surrounding residues making van der Waals contacts are shown 
in cyan. The ligands are shown in ball-and-stick representation, with carbons colored orange, 
oxygens colored red, and nitrogens colored blue. Hydrogen bonds are represented with broken 
black lines. The maps are simulated annealing omit difference density maps contoured at 3σ and 
displayed with a radius of 2.2 Å around the ligands (91). 
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bonds to the backbone carbonyl atoms of Ser195 and Leu194, respectively. Collectively, 
these results confirm that the sialic-acid-binding site of T3D σ1 is in the body domain of 
the attachment protein as suggested by genetic and functional evidence from previous 
studies (22, 27). Furthermore, while T3D σ1 exhibits a broad SA binding capacity, the 
contacts made between σ1 and the SA moieties of the oligosaccharides are highly 
conserved. 
 
Discussion 
 The σ1 protein uses a complex network of contacts to engage terminal SA, which 
is a common feature of all three glycans used in this study. The interactions involve σ1 
residues at the lower end of the body domain, between β-spirals 2 and 3. At this location, 
the SA moiety docks into a shallow pocket that is formed mainly by residues in the third 
β-spiral. All four functional groups of SA make contacts with σ1 through an elaborate 
network of hydrogen bonds and van der Waals interactions. Although all three ligands 
used for complex formation with σ1 contain additional carbohydrates, these moieties 
make very few interactions. The complex with α-2,8-disialyllactose identified a hydrogen 
bond between the N-acetyl group of the second SA and the side chain of Ser195 (Figure 
II-4B). However, the results from mutagenesis experiments, presented in Chapter III, 
demonstrate that a Ser195Ala mutation has no effect on either HA capacity or viral 
growth. Therefore, the observed contact is unlikely to have physiologic relevance. The 
interactions between σ1 and α-2,6-sialyllactose identified two hydrogen bonds that link 
the galactose to the protein and may help to stabilize the folded-back conformation of the 
ligand (Figure II-4A). As both contacts involve main chain atoms of σ1, their functional 
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significance cannot be easily probed by site-directed mutagenesis. Nevertheless, it is 
likely that the observed contacts lead to a modest increase in the affinity of σ1 for 
compounds terminating in α-2,6-linked SA. It is unclear if such an increase in affinity is 
biologically significant. 
A large collection of structures of viruses or viral attachment proteins in complex 
with sialylated oligosaccharide receptors is available (14, 17, 32, 36, 41, 78, 79, 104-106, 
123, 132, 133), and these have produced significant insights into mechanisms of SA 
binding, receptor specificity, and viral pathogenesis. However, the interactions observed 
between T3D σ1 and SA differ in important ways from those found in all other virus-
receptor complexes, offering new insights into the parameters that guide viral attachment 
and specificity. In all cases in which structures are available, the receptors are bound by a 
globular domain in a region that projects farthest from the viral capsid and is easily 
accessible for interactions with the cell surface. In contrast, the highly elongated T3D σ1 
protein engages its carbohydrate ligand at its midpoint, about 150 Å away from the 
region that projects farthest from the virion. Although the σ1 protein possesses some 
flexibility at defined regions (23, 39), the location of the SA-binding site would not 
appear optimal for engagement of membrane-bound receptors that feature sialylated 
ligands close to the membrane. The region of JAM-A that is engaged by the σ1 head 
domain is fairly close to the membrane (57). Even when allowing for considerable 
flexibility between the σ1 head and body, it is difficult to envision a conformation in 
which the tail of σ1 is still inserted into the virus and the SA binding site can closely 
approach the membrane. However, σ1 could more easily engage SA that projects far 
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above the membrane, perhaps by being located on a large protein or projecting from 
prominent loops.  
Prior to this study, structural information had been available only for the C-
terminal portion of the σ1 protein (23). Based on analysis of that structure, as well as 
sequence comparisons with the related adenovirus fiber protein, full-length σ1 was 
predicted to fold into three distinct regions: an N-terminal α-helical coiled coil (termed 
the tail), a region containing eight consecutive β-spiral repeats (the body), and a globular 
β-barrel (the head). Our structural analysis of a fragment comprising the body and head 
domains show that this model must be revised, as we find an insertion of a short α-helical 
coiled coil that interrupts the β-spiral sequence in the body, replacing one β-spiral repeat 
with a helical structure. Thus, it is clear that the structure of σ1 features several 
transitions between α-helical and β-spiral regions. This topological relationship differs 
from that of the adenovirus fiber, in which the shaft domain is thought to consist entirely 
of β-spiral repeats (88). Examination of the T3D body domain sequence shows that it 
contains a nearly perfect heptad repeat pattern, which is typical for α-helical coiled coils, 
in a short stretch of 14 residues (Figure II-2). A similar pattern is observed in the T1L and 
T2J σ1 sequences, but a proline residue within the consensus makes it unlikely that these 
proteins also feature a continous α-helical coiled coil at the equivalent location. 
To our knowledge, the structures presented here are the first examples of any 
fibrous viral protein engaging a ligand via its repetitive fiber region. Other viral 
attachment proteins contain fibrous- or stalk-like structures, but they usually engage 
receptors with globular head domains placed on top of these structural elements, as 
observed in complexes of adenovirus fiber proteins with their receptors (85). Globular 
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head domains offer higher variability in engaging ligands and can more easily create 
recessed binding pockets suitable for high-affinity binding. Instead, fiber-like structures 
generally feature short connections between their repeating units and a relatively flat 
surface, limiting binding options. However, inspection of the β-spirals in σ1 reveals 
subtle modifications in a single repeat that allow it to create a shallow binding site for SA. 
One of the hallmarks of β-spirals is a highly conserved β-turn between two strands, 
involving residues at positions g, h, i, and j (Figure II-2). The residue at position j is 
usually a proline or glycine. This turn is enlarged by two amino acids in the σ1 repeat that 
engages SA, transforming the turn into a small loop (Figure II-5).  
 
 
FIGURE II-5.  Structural adaption of the binding site. (A) Superposition of all seven β-spiral 
repeats. Repeat β3, which is shown in darker shading, interacts with sialic acid and deviates 
markedly in its structure from the other repeats. Conserved hydrophobic residues are colored in 
blue, the position in the β-turn that is usually occupied by proline or glycine is shown in magenta. 
Arg202 and Pro204, which are part of repeat β3, are highlighted in red and yellow, respectively. 
(B) Superposition of a prototypical β-spiral repeat (β6) onto the sialic acid binding repeat β3. 
Amino acids are shown in ball and stick representation, and residues Arg202 and Pro204 in β3 are 
labeled. Panel B is enlarged to provide a clearer view (91). 
  
 
32
Interestingly, Pro204 introduces a kink after a β-strand, causing the chain to 
deviate from the β-spiral motif at this position to provide a pocket for the ligand. Thus, 
alteration of the typical repeating motif identifies a ligand-binding site in the case of σ1. 
It is conceivable that similar aberrations in other fibrous protein sequences also might 
indicate binding sites. The location of a SA binding site in an elongated fiber-like 
structure also raises the possibility of creating a small SA binding cassette that could be 
transferred into a variety of trimeric fiber-like proteins constructed from α-helical coiled 
coils or β-spirals. Our work thus enhances an understanding of reovirus-glycan 
interactions and may also guide the construction of new SA binding platforms to 
facilitate structure-function analyses and SA-mediated cell targeting. 
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CHAPTER III 
 
SIALIC ACID BINDING DETERMINANTS IN THE σ1 ATTACHMENT PROTEIN 
OF SEROTYPE 3 REOVIRUS 
 
Introduction 
 Residues Asn198, Arg202, and Pro204 of T3D σ1 have been implicated in SA 
binding by sequence comparisons of reovirus strains that differ in SA coreceptor 
utilization (27, 98) and genetic analysis of reovirus mutants adapted to growth in MEL 
cells (22). To determine whether these sequences influence SA binding by T3 reovirus in 
an otherwise isogenic background, I used structure-guided mutagenesis to identify 
residues in σ1 that functionally engage SA. 
In this study, I generated a panel of T3D mutant viruses containing point 
mutations in the σ1 protein. I tested the capacity of these viruses to bind to SA by 
assessing the hemagglutination capacity of each virus. In complementary experiments, I 
tested the capacity of these viruses to replicate in MEL cells, which require SA-binding 
for productive infection. The results reveal that residues 198, 202, 203, 204, and 205 are 
required for functional binding to SA by reovirus. 
My findings, along with the structural studies presented in Chapter II, identify a 
discrete SA-binding domain in σ1 and a network of residues that are required for 
mediating σ1-SA interactions. I acknowledge the contributions of Takeshi Kobayashi 
(Osaka University) and Elizabeth Halvorson (Wake Forest University) for generating 
virus strains rsT3D-σ1N198D, rsT3D-σ1R202W, and rsT3D-σ1P204L. 
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Results 
Residues in Reovirus σ1 Required for Sialic Acid Binding - To identify sequences that 
influence SA binding, I used plasmid-based reverse genetics (58, 59) to introduce point 
mutations into the σ1 protein of reovirus strain T3D. Mutant viruses were isolated 
following co-transfection of murine L929 cells with RNA-encoding plasmids 
corresponding to the T3D L1-L3, M1-M3, and S2-S4 genes and a plasmid corresponding 
to the σ1-encoding S1 gene incorporating site-specific mutations. Thus, each recombinant 
virus is isogenic, with the exception of the S1 gene and its protein product, σ1. Guided by 
the structure of the σ1-SA complexes shown in Chapter II, I engineered individual 
alanine substitutions of amino acids ranging from Asn189 to Asn210. By their location in 
the structure, we hypothesized that these residues would be required for functional SA 
binding. In addition, substitutions N198D, R202W, and P204L, which have been 
implicated in SA binding by sequence comparisons of reovirus strains that differ in SA 
utilization (27, 98) and genetic analysis of reovirus mutants adapted to growth in MEL 
cells (22), were engineered to define the effect of these polymorphisms in an otherwise 
isogenic background. 
 After confirming the σ1-encoding S1 gene nucleotide sequences, the mutant 
viruses were tested for HA capacity (Figure III-1) and growth in L929 cells and MEL 
cells (Figure III-2). In comparison to rsT3D, rsT3D-σ1N198D, rsT3D-σ1R202A, rsT3D-
σ1R202W, rsT3D-σ1L203A, rsT3D-σ1P204A, rsT3D-σ1P204L, and rsT3D-σ1G205A 
produced little or no agglutination of calf erythrocytes, a sensitive assay for SA binding 
(27). However, rsT3D-σ1N189A, rsT3D-σ1S195A, and rsT3D-σ1N210A produced HA 
titers that were comparable to those of wild-type rsT3D. Each of the point-mutant viruses 
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produced approximately 1000-fold yields of viral progeny after growth in L929 cells 
(Figure III-2A), a cell line that does not require sialic-acid-binding for reovirus to 
replicate (98). In contrast, those containing mutations N198D, R202A, R202W, L203A, 
P204A, P204L, and G205A displayed attenuated growth in MEL cells (Figure III-2B), a 
cell line permissive only to SA binding reovirus strains (98). These findings indicate that 
viruses with mutations of residues 198, 202, 203, 204, and 205 are altered in SA binding 
efficiency, suggesting that these residues serve a functional role in T3D σ1-SA 
interactions. 
 
FIGURE III-1. HA assay of T3D σ1 point mutants. Purified reovirus virions (1011 particles) were 
serially diluted in 0.05 ml of PBS in 96-well U-bottom microtiter plates. Bovine erythrocytes were 
washed twice with PBS and resuspended at a concentration of 1% (vol/vol) in PBS. Erythrocytes 
(0.05 ml) were added to wells containing virus and incubated at 4°C for at least 2 h. HA titer is 
expressed as 1011 particles divided by the number of particles/HA unit. One HA unit equals the 
number of particles sufficient to produce HA. *, P < 0.05 in comparison to T3D by Student’s t test 
(91). 
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FIGURE III-2. Identification of σ1 residues required for binding to cell-surface SA. (A) Infection 
of murine fibroblast (L929) cells or (B) murine erythroleukemia (MEL) cells by wild-type or 
point-mutant viruses. Cells were adsorbed with virus at an MOI of 1 PFU/cell. Following 
incubation at room temperature for 1 h, the inoculum was removed, and cells were incubated at 
37°C for 24 and 48 h. Viral titers were determined by plaque assay. The results are expressed as 
viral yields (log10 titer at t = 24 or 48 h minus log10 titer at t = 0 h) for triplicate samples. Error 
bars indicate S.D. *, P < 0.05 in comparison to T3D by Student’s t test (91). 
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Discussion 
Naturally occurring sequence variability at three amino acid positions (residues 
198, 202, and 204) has been linked to the SA-binding capacity of T3 σ1 (22, 28). Our 
structures, presented in Chapter II, readily identify two of these residues, Arg202 and 
Pro204, as key determinants of SA binding. The side chain of Arg202 forms a salt bridge 
with the SA carboxylate group, while the Pro204 side chain stacks against the Arg202 
guanidinium group. Moreover, the carbonyl oxygen in the peptide bond linking Leu203 
and Pro204 forms a hydrogen bond with SA. Substitutions of either Arg202 or Pro204, as 
seen in the R202W and P204L variants, would be predicted to decrease the affinity for 
SA, which is confirmed by the mutagenesis data. In contrast, the critical role of residue 
198 in ligand recognition is not apparent from the crystal structures. Mutagenesis data 
(Figure III- and Figure III-), in conjunction with previous results (22), clearly 
demonstrate that Asn198 is required for successful SA-dependent infection, with viruses 
carrying an N198D mutation having substantially reduced infectivity in MEL cells. 
However, the crystal structures show that Asn198 is not involved in direct or water-
mediated contacts with any of the three oligosaccharides. Furthermore, the Asn198 side 
chain is solvent-exposed, forming a single hydrogen bond with the Asn189 side chain. 
However, mutation of Asn189 to alanine does not affect SA binding (Figure III- and 
Figure III-), suggesting that the observed Asn198-Asn189 hydrogen bond is not relevant 
for ligand recognition. It is possible that the introduction of a negatively charged side 
chain at position 198, as is the case with the N198D mutation, leads to long-range 
electrostatic effects or structural rearrangements that indirectly affect receptor binding. 
However, given the distance of Asn198 from the binding site and its surface-exposed 
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location, this possibility appears remote. It is more likely that Asn198 serves as a contact 
point with a part of the functionally relevant glycan, which has not been included in the 
structural analysis. Although my results define the interactions of σ1 with terminal SA, 
the actual receptor may be a more complex sialylated glycan, perhaps carrying several 
branches. Such complex receptor structures, which can be attached to proteins or lipids, 
are true ligands for several adenoviruses and polyomaviruses (78, 79, 82). Therefore, 
Asn198 may well define a second receptor contact point for reovirus σ1.  
Taken together, results from this study identify reovirus SA binding determinants 
in T3 σ1. This work enhances an understanding of the molecular basis of T3 σ1-SA 
interactions and establishes a foundation for future studies aimed at identifying the 
physiologically relevant sialylated glycans bound by reovirus in vivo. 
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CHAPTER IV 
 
UTILIZATION OF SIALYLATED GLYCANS AS CORECEPTORS ENHANCES THE 
NEUROVIRULENCE OF SEROTYPE 3 REOVIRUS 
 
Introduction 
While all reovirus serotypes engage JAM-A (18, 86), they differ in carbohydrate 
coreceptor utilization, suggesting that carbohydrate binding by σ1 influences reovirus 
pathology in the CNS. Studies comparing the pathogenesis in newborn mice of reovirus 
strains that differ in glycan utilization revealed that SA-binding enhances spread from the 
intestine to peripheral sites of replication such as the liver, spleen, and brain (9). In 
addition, the capacity to bind SA confers reovirus tropism for bile duct epithelium (9). 
However, it is not known whether SA-binding influences reovirus dissemination, tropism, 
and replication within the CNS. 
In this study, we sought to define the function of carbohydrate binding in reovirus 
neuropathogenesis. I monitored survival of newborn mice inoculated with wild-type T3D 
and T3D-σ1R202W, a T3D point-mutant virus that does not bind SA (91), and quantified 
viral loads in various organs of infected animals. I found that the wild-type virus was 
more virulent and produced higher titers in neural tissues than the mutant virus following 
intramuscular (IM) or intracranial (IC) inoculation. Furthermore, I found that the wild-
type virus displayed an increased capacity to infect and replicate in primary cultures of 
cortical neurons in an SA-dependant manner. Collectively, these results suggest that 
binding to SA enhances the kinetics of reovirus replication in neural tissues and point to a 
functional role for sialylated glycan engagement in reovirus neurovirulence. 
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The research described in this chapter was performed in collaboration with other 
investigators. I performed the animal experiments and infectivity studies, and collected 
organs for histopathological analysis. Dr. Ty Abel (Department of Pathology, 
Microbiology, and Immunology at the Vanderbilt University School of Medicine) guided 
the histologic analyses of brain sections and captured representative images. Drs. Jennifer 
Konopka and Andrea Pruissjers (Department of Pediatrics at the Vanderbilt University 
School of Medicine) assisted in the extraction and culture of mouse cortical neurons. Dirk 
Reiter in the Thilo Stehle laboratory (Universitat Tübingen) prepared the structural 
figures shown in this chapter. 
 
Results 
SA binding enhances reovirus neurovirulence and spinal cord injury- To determine 
whether SA binding influences reovirus neuropathogenesis, we monitored survival and 
clinical signs of disease in two-day-old mice following IM inoculation with 5 × 106 PFU 
of either T3D or T3D-σ1R202W (Figure IV-1A). Reovirus strain T3D-σ1R202W 
contains a point mutation in σ1 that ablates SA-binding capacity (91). Mice were 
observed for 21 days after inoculation and euthanized when moribund. Significantly 
fewer mice infected with T3D survived in comparison to those infected with T3D-
σ1R202W. The survival frequency of mice infected with T3D was 25.9% compared with 
63.6% for mice infected with T3D-σ1R202W (P < 0.005). These results suggest that SA 
binding enhances reovirus virulence. 
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FIGURE IV-1.  SA-binding capacity enhances reovirus virulence and paralysis following IM 
inoculation. Newborn C57/BL6 mice were inoculated in the right hindlimb with 5 × 106 PFU of 
either T3D or T3D-σ1R202W (R202W). (A) Mice (n = 22-27 for each virus strain) were 
monitored for survival for 21 days. *, P < 0.005 as determined by log-rank test in comparison to 
T3D. (B) Mice were monitored for development of reovirus-induced AFP on day 8 post-
inoculation (n = 32-44 for each virus strain). Complete paralysis was first observed at this time 
point; survival frequencies of wild-type and mutant-infected mice at this time point were 
comparable. (C) On day 8 post-inoculation, spinal cords of infected mice were resected. 
Consecutive lumbosacral sections of the inferior spinal cord were stained with hematoxylin and 
eosin (H&E) or polyclonal reovirus antiserum (Reovirus). Representative sections of spinal cord 
matched for lumbar depth are shown. Scale bars, 5.0 mm. Boxes indicate areas of enlargement in 
the middle panel. Scale bars, 1.0 mm. 
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Following IM inoculation of newborn mice, T3 reovirus causes acute flaccid 
paralysis (AFP) between 8 and 10 days post-inoculation (45). Infected mice exhibit 
ipsilateral, followed by contralateral, hindlimb paralysis as a consequence of injury 
within the anterior horn of the spinal cord associated with motor neuron loss and spread 
of viral antigen (45). We observed differences in development of AFP in mice infected 
with wild-type and mutant virus. On day 8 post-inoculation, mice infected with wild-type 
virus displayed hindlimb paralysis at a five-fold greater frequency than those infected 
with the mutant virus (33% vs. 6%, respectively) (Figure IV-1B). Furthermore, the 
percentage of mice infected with wild-type virus exhibiting bilateral hindlimb paralysis 
was almost four times greater than that in mice infected with the mutant virus (11% vs. 
3%, respectively) (Figure IV-1B). These data are concordant with results gathered from 
the survival experiments and provide further evidence that SA binding enhances reovirus 
virulence. 
To investigate whether enhanced virulence and AFP development in mice 
infected with wild-type virus compared with mutant virus corresponds with more 
extensive reovirus infection and tissue damage in the spinal cord, we compared histologic 
sections of spinal cords resected from mice inoculated intramuscularly with 5 × 106 PFU 
of either T3D or T3D-σ1R202W (Figure IV-1C). Transverse sections of the inferior 
spinal cord were sectioned and processed for H&E staining or staining for reovirus 
antigen. Following H&E staining, spinal cords of mice infected with wild-type virus 
displayed more widespread injury, as indicated by increased apoptotic bodies, reactive 
endothelium, inflammatory infiltrates, and neurons with eosinophilic cytoplasmic 
inclusions. Immunohistochemistry for reovirus antigen showed correspondingly more 
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abundant and intense staining in mice infected with wild-type virus compared with spinal 
cords from mice infected with the mutant virus. These findings suggest that binding to 
SA leads to increased reovirus infection and injury to motor neurons in the spinal cord. 
 
SA binding influences reovirus replication at sites of secondary infection- To better 
understand how SA-binding capacity influences reovirus virulence, we inoculated two-
day-old mice intramuscularly with 5 × 106 PFU of either T3D or T3D-σ1R202W and 
quantified viral titers in the hindlimb, spinal cord, brain, and liver on days 2, 4, 8, and 10 
post-inoculation (Figure IV-2A). In the hindlimb muscle, titers of both viruses were 
comparable, except on day 4 when the mutant virus produced higher titers than the wild-
type virus (P < 0.005). In the spinal cord and brain, the mutant virus produced 
significantly higher titers than the wild-type virus at day 4 (P < 0.05). However, on days 
8 and 10, titers of the wild-type virus were significantly higher than those of the mutant 
(P < 0.05). Interestingly, titers in the liver of mice infected with the wild-type virus were 
significantly less than those in mice infected with the mutant virus throughout the 
experimental time course of infection (P < 0.05 on day 2 and P < 0.005 on days 4 and 8). 
To determine whether SA-binding capacity influences the kinetics of 
hematogenous spread, we again inoculated two-day-old mice intramuscularly with 5 × 
106 PFU of either T3D or T3D-σ1R202W. In this experiment, we quantified viral titers in 
the heart and spleen (Figure IV-3A) and monitored viral genome copies in the serum 
(Figure IV-3B). On day 4 post-inoculation, the wild-type virus produced higher titer in 
the heart, but lower titer in the spleen in comparison to the mutant virus. On day 10 post-
inoculation, the wild-type virus produced higher titer than the mutant virus in the spleen.  
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FIGURE IV-2.  SA binding is associated with higher peak titers of reovirus in neural 
tissues. Newborn C57/BL6 mice were inoculated in the right hindlimb with 5 × 106 PFU 
of either T3D or T3D-σ1R202W. At days 2, 4, 8, and 10 post-inoculation, mice were 
euthanized, hindlimb muscle, spinal cord, brain, and liver were resected, and viral titers in 
organ homogenates were determined by plaque assay. Results are expressed as mean viral 
titers for 6-9 animals for each time point. Error bars indicate SEM. *, P < 0.05 and **, P < 
0.005, as determined by Mann-Whitney test in comparison to T3D. 
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FIGURE IV-3. Binding to SA is not required for dissemination by hematogenous routes. 
Newborn C57/BL6 mice were inoculated in the right hindlimb with 5 × 106 PFU of either 
T3D or T3D-σ1R202W. (A) At days 2, 4, 8, and 10 post-inoculation, mice were 
euthanized, and heart and spleen were resected. Viral titers in organ homogenates were 
determined by plaque assay. Results are expressed as mean viral titers for 7 to 10 animals 
for each time point. Error bars indicate SEM. *, P < 0.05 as determined by Mann-
Whitney test in comparison to T3D. (B) At days 2, 4, 8, and 10 post-inoculation, mice 
were euthanized, blood was collected, and viral genome copies in serum were 
determined by RT-qPCR. Results are expressed as mean viral genome copies per animal 
for 3 to 5 animals at each time point. Error bars indicate SEM. 
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Although these differences are statistically significant, because of the modest magnitude 
of the differences, they may not be physiologically important. Furthermore, the number 
of viral genome copies detected in the serum of mice infected with either virus also was 
comparable. Thus, SA-binding capacity enhances overall peak titers in the murine CNS. 
However, utilization of SA is not required for infection of the liver and does not appear to 
influence hematogenous dissemination in mice. 
 
SA binding enhances reovirus neurovirulence and replication in the brain- 
Differences in titers produced by T3D and T3D-σ1R202W in the spinal cord and brain 
could result from more efficient spread of wild-type virus from the muscle to the CNS, 
enhanced replication of wild-type virus in the CNS, or both effects. To distinguish 
between these possibilities, we inoculated three-day-old mice intracranially with 2 PFU 
of either wild-type or mutant virus. We monitored infected mice for survival and clinical 
signs of disease for 21 days and quantified viral loads in the brain at days 4, 8, and 12 
following inoculation (Figure IV-4). We again observed that mice infected with the wild-
type virus displayed a lower frequency of survival (33%) compared with those infected 
with the mutant virus (85%) (P < 0.001) (Figure IV-4A). In addition, wild-type virus 
produced higher titers in the brain than did the mutant following IC inoculation (Figure 
IV-4B), reaching statistical significance on day 8 post-inoculation (P < 0.05). Taken 
together, these findings suggest that SA binding enhances reovirus virulence by 
accelerating viral replication in the CNS. 
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FIGURE IV-4. SA-binding capacity enhances reovirus neurovirulence and replicative 
capacity following IC inoculation. Newborn C57/BL6 mice were inoculated intracranially 
with 2 PFU of either T3D or T3D-σ1R202W. (A) Mice (n = 18-21 for each virus strain) 
were monitored for survival for 21 days. **, P < 0.001 as determined by log-rank test in 
comparison to T3D. (B) At days 4, 8, and 12 post-inoculation, viral titers in brain 
homogenates were determined by plaque assay. Results are expressed as mean viral titers 
for 4 to 7 animals for each time point. Error bars indicate SEM. *, P < 0.05, as determined 
by Mann-Whitney test in comparison to T3D. 
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SA binding does not alter reovirus tropism in the brain- To test whether σ1-SA 
interactions are required for neural tropism of T3 reovirus, we compared histologic 
sections of brains resected from mice inoculated intracranially with 100 PFU of either 
T3D or T3D-σ1R202W (Figure IV-5). Brains chosen for histologic analysis were 
matched anatomically based on the size and shape of landmarks such as the hippocampus 
as well as displaying comparable viral titers. The intensity of reovirus antigen staining as 
well as the cellular distribution of reovirus antigen was similar in brain sections from 
mice infected with either T3D or T3D-σ1R202W. Characteristic reovirus tropism 
involving several areas of the brain including the cortex, the C2-C4 region of the 
hippocampus, and the thalamus was apparent in mice infected with either virus (Figure 
IV-5A). In addition, involvement of the cerebellum, specifically infection of the Purkinje 
cells, was observed in brain sections of mice infected with either virus (Figure IV-5B). 
Therefore, SA-binding capacity of T3 reovirus does not influence targeting of reovirus to 
specific regions within the brain, but rather appears to influence replication efficiency in 
brain tissue. 
SA binding enhances infection of and replication in murine primary cortical 
neurons- Results gathered thus far reveal that SA-binding enhances the capacity of 
reovirus to replicate in the brain following IM or IC inoculation. We hypothesized that 
this difference is attributable to enhanced infection and replication in neurons by SA-
binding reovirus strains. To test this hypothesis, we quantified infection of primary 
cortical neuron cultures using an immunoflorescence assay (Figure IV-6A and Figure IV-
6B) and compared titers of T3D and T3D-σ1R202W following replication in primary  
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FIGURE IV-5. Binding to SA does not alter reovirus tropism in the brain. Newborn 
C57/BL6 mice were inoculated intracranially with 100 PFU of either T3D or T3D-
σ1R202W (R202W). On day 8 post-inoculation, brains of infected mice were resected. The 
brains were bisected, and the left hemispheres were processed for histopathology and the 
right hemispheres were prepared for viral titer determination by plaque assay. Consecutive 
coronal sections of the brain were stained with hematoxylin and eosin (H&E) or polyclonal 
reovirus antiserum (Reovirus). Representative sections of brain hemisphere, matched for 
hippocampal depth, (A) and cerebellum (B) are shown. Scale bars, 1.0mm. T3D-infected 
brain sections are from the right hemisphere of a brain with a viral titer of 8 × 108 PFU, and 
R202W-infected brain sections are from the right hemisphere of a brain with a viral titer of  
3.5 × 108 PFU. 
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cortical neuron cultures at 24, 48, and 72 h post-infection (Figure IV-6C). Primary 
cultures of mouse cortical neurons were established using cerebral cortices of C57/BL6 
embryos at developmental day E15 and cultured for 7 days prior to infection (3). Wild-
type virus infected a significantly higher percentage of cortical neurons (5%) in 
comparison to the mutant (1%) (P < 0.0001) (Figure IV-6A and Figure IV-6B). 
Concordantly, at 24 h post-infection, yields of wild-type and mutant virus were 
comparable (Figure IV-6C). However, by 48 and 72 h post-infection, wild-type virus 
produced significantly higher yields than those produced by the mutant (Figure IV-6C). 
These findings suggest that engagement of SA by reovirus enhances infection and 
replication efficiency in neurons. 
To confirm the importance of SA binding for infectivity and replication of 
primary cultures of neurons, cells were treated with A. ureafaciens neuraminidase to 
remove cell-surface SA. A. ureafaciens neuraminidase is a broad-spectrum enzyme that 
cleaves α-2,3-, α-2,6-, and α-2,8- terminally-linked SA present on glycan chains (116). 
Neuraminidase treatment diminished the infectivity and replication of wild-type virus to 
the levels observed for the mutant virus (Figure IV-6A, IV-6B, and IV-6C). These 
findings demonstrate that both replication and infectivity of primary neuronal cultures by 
T3 reovirus is enhanced by SA binding. Collectively, these results suggest that the 
capacity of reovirus to bind cell-surface SA enhances the efficiency with which the virus 
infects cells in the murine CNS. 
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FIGURE IV-6. SA-binding capacity increases the efficiency of reovirus infection of primary 
cortical neurons. Cortical neurons were harvested from C57/BL6 mouse embryos at 
developmental day E15.5 and cultured for 5-7 days prior to infection. (A) Neurons were 
adsorbed with either T3D or T3D σ1-R202W at an MOI of 1000 PFU/cell following pre-
treatment with either PBS or 40 mM A. ureafaciens neuraminidase and incubated for 21 h. 
Cells were stained with TUJ1 neural-specific marker to detect neurons (red), DAPI to detect 
nuclei (blue), and polyclonal reovirus antiserum to detect reovirus antigen (green) and 
visualized using indirect immunofluorescence microscopy. Representative wells from duplicate 
experiments are shown. (B) The percentage of infected cells was quantified by dividing the 
number of neurons exhibiting reovirus staining by the total number of cell nuclei exhibiting 
DAPI staining in three fields of 400X view in triplicate wells (n=2). Fields of view contained 
between 200 and 600 nuclei. Error bars indicate SEM. *, P < 0.0001, as determined by Student 
t test in comparison to T3D. (C) Neurons were adsorbed with either T3D or T3D σ1-R202W at 
an MOI of 1 PFU/cell. Titers of virus in cell lysates were determined by plaque assay at the 
indicated times post-adsorption. Results are expressed as mean viral yield for duplicate 
samples. Error bars indicate SD. *, P < 0.05, as determined by Student t test in comparison to 
T3D. 
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Discussion 
In this study, I found that the capacity to bind cell-surface SA enhances the 
neurovirulence of T3 reovirus. Following either IM or IC inoculation of newborn mice, 
wild-type strain T3D was more virulent and produced higher titers in neural tissues 
compared with non-SA-binding mutant virus T3D-σ1R202W. Furthermore, mice infected 
with wild-type virus displayed a higher frequency of AFP and enhanced tissue injury 
compared with mutant-infected mice. The key finding of this study is that SA-binding 
capacity dictates increased reovirus infectivity and replicative capacity in murine neurons. 
These data suggest that SA binding enhances the neurovirulence of T3 reovirus by 
mediating efficient infection of target cells in the CNS, resulting in increased replication 
and pathology. 
I found that wild-type T3D displays increased infectivity and replicative capacity 
in primary cultures of murine cortical neurons, a phenotype that is dependent on cell-
surface SA. Binding of T3 reovirus strains to SA facilitates viral attachment through low-
affinity adhesion that places the virus on the cell surface where access to the higher-
affinity, but lower-abundance, proteinaceous receptor is thermodynamically favored (7). 
This adhesion-strengthening mechanism may be the basis for the enhanced replication 
and neurovirulence of T3D. Although the proteinaceous receptor on neurons for T3 
reovirus is not known, my findings suggest that its engagement likely requires initial low-
affinity glycan binding to anchor the virus to the cell surface. We favor this scenario 
because neuraminidase treatment of primary murine cortical neurons decreases but does 
not abolish infection or replication (Figure IV- 6), consistent with the existence of other 
host mediators of attachment and cell entry. 
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I previously identified residues in T3 σ1 that are required for functional binding 
of reovirus to SA, i.e., binding that results in productive infection (91). Using reverse 
genetics, I introduced structure-guided mutations in the T3 σ1 molecule and characterized 
the resultant mutant viruses using assays to quantify SA-binding capacity. This analysis 
highlighted the importance of Arg202 in the interaction of T3 σ1 with SA. The Arg202 
sidechain forms a bidentate salt bridge with the carboxylate moiety of SA, which is an 
important electrostatic contact between the protein and its carbohydrate ligand. 
Replacement of Arg202 with a tryptophan in T3D-σ1R202W would remove the 
electrostatic interaction between the arginine and SA and introduce a structural clash with 
the glycan (Figure IV-7). It is therefore unlikely that the mutant can bind to SA, even in 
the improbable case that the overall structure of the binding site is not altered by the 
mutation. This model provides a structural framework for understanding the decreased 
virulence displayed by T3D-σ1R202W. 
Following IM inoculation, wild-type T3D produced lower titers in the livers of 
infected mice than did non-SA binding stain T3D-σ1R202W (Figure IV-2). This is an 
interesting result because previous studies from our laboratory revealed that SA binding 
confers tropism of reovirus for bile duct epithelium and reovirus-induced injury to the 
liver (9). The SA-binding strain used in that study, T3SA+, produces higher titers in liver 
tissue than its non-SA-binding counterpart, T3SA-, at early times after infection. 
However, SA-binding-capacity is not strictly required for infection and replication in the 
liver, as T3SA- produces titers in the liver that approximate those of T3SA+ at late times 
of infection (3, 9). It is possible that the genetic backgrounds of the strains used by 
Barton et al (9) (T1L) and here (T3D) account for the observed differences. It is also 
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possible that the routes of inoculation, peroral (9) vs. IM (current study) influence hepatic 
tropism. We also noted that T3D-σ1R202W produced higher titers than wild-type virus in 
the spinal cord and brain of infected mice on day 4 post-inoculation. Since reovirus is 
delivered initially to the CNS by hematogenous routes (3, 15), it is possible that 
bloodstream dissemination of the mutant virus is subtly enhanced in comparison to wild-
type virus, although if so, this difference was not sufficient to permit detection in our 
assays. 
Data presented in this study and others (9) indicate that the capacity of T3 
reovirus to bind cell-surface SA can target the virus to specific sites of infection and lead 
to enhanced replication and disease. These observations suggest that SA-binding capacity 
confers a fitness advantage for reovirus. For example, it is possible that an SA-mediated 
replication enhancement leads to increased viral shedding and transmission of virus from 
host to host. However, there are naturally circulating strains of reovirus that do not bind 
to SA (28), suggesting that SA-binding capacity is a balanced polymorphism in nature 
that also imposes a fitness cost. For example, SA-binding capacity diminishes reovirus 
infection of polarized human airway epithelial cells (38). Strain T3SA+ does not 
efficiently infect these cells, whereas T3SA- does. Moreover, neuraminidase pre-
treatment to remove cell-surface SA enhances infection of airway epithelial cells (38). 
Determination of the precise contribution of SA binding to viral fitness will require 
competition studies using strains that vary solely in SA-binding capacity and populations 
of susceptible mice. 
For many viruses, including several important human pathogens, glycan 
engagement plays an important role in infection and pathogenesis. Here, I demonstrate 
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that utilization of sialylated glycans as coreceptors enhances the neurovirulence of T3 
reovirus. This study broadens an understanding of mechanisms of reovirus attachment to 
neuronal cells and supports the hypothesis that T3 reovirus-glycan interactions are key 
determinants of reovirus neurovirulence in the CNS. 
 
FIGURE IV-7. Comparison of T3D and T3D-σ1R202W σ1 interactions with the terminal 
SA of α(2,3) sialyllactose. (A) Ribbon drawing of the T3D σ1 body and head domains in 
complex with α(2,3) sialyllactose. The σ1 monomers are shown in red, blue, and yellow. The 
body domain consists of seven triple β-spiral repeats (β1–β7) and an α-helical coiled-coil 
domain (cc) that is inserted between β-spiral repeats β4 and β5. The bound α(2,3) 
sialyllactose is shown in stick representation and colored in orange (enclosed by the red box). 
(B) An enlarged view of the T3D σ1 SA-binding domain. The σ1 residue 202 of a single σ1 
monomer is drawn in stick representation, while the remainder of the monomer is shown as a 
ribbon tracing. The other monomers are shown in a surface-shaded representation. The SA 
moiety of α(2,3) sialyllactose is shown in stick representation, with carbons colored orange, 
oxygens colored red, and nitrogens colored blue. Residue Arg202 (cyan) of wild-type T3D 
forms a salt bridge with the carboxylate group of SA (91). This bond is represented by a 
dashed red line, illustrating that it is likely lost when Arg202 is replaced with a tryptophan 
(yellow) in T3D-σ1R202W.  
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CHAPTER V 
 
SUMMARY AND FUTURE DIRECTIONS 
 
Virus attachment to host cells is the first step in viral replication and serves a 
central role in determining viral tropism and disease. Defining the precise interactions 
that mediate virus-receptor engagement is crucial for understanding the mechanisms 
underlying viral pathogenesis. Although it is known that carbohydrate interactions 
influence reovirus dissemination and tropism in vivo, little is understood about the 
function of these molecules in reovirus tropism and pathogenesis within the CNS. Studies 
of pathogen-receptor interactions can therefore provide valuable insight into mechanisms 
of injury and disease in an infected host and improve our ability to develop antiviral 
therapeutics. The work described in this dissertation was performed to enhance an 
understanding of the structural basis of interactions between σ1 and SA and determine 
the role of SA binding in reovirus virulence within the CNS. 
The data presented in this thesis support the following conclusions: 1) T3 reovirus 
attachment to SA is achieved through binding of β-spiral repeats 2 and 3 of σ1 to the 
glycan (Chapter II); 2) residues Asn198, Arg202, Leu203, Pro204, and Gly205 of σ1 are 
required for mediating σ1-SA interactions (Chapter III); and 3) SA binding enhances 
reovirus neurovirulence (Chapter IV). This chapter summarizes the data presented in this 
dissertation and highlights future directions for this research. 
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Molecular mechanisms of reovirus attachment to SA 
Results from Chapter II and III reveal the structural and molecular basis for T3 
reovirus σ1-SA interactions. In Chapter II, I present the first structure of the SA-binding 
domain of T3 σ1 alone and in complex with carbohydrates that naturally occur on human 
cells. Structures of the σ1-glycan complexes represent the first examples of any 
filamentous viral attachment protein engaging a ligand via repetitive sequence motifs in 
its fiber region. The findings in Chapter III identify a network of residues that are 
required for mediating σ1-SA interactions. 
Future studies should be directed toward identifying the physiologically relevant 
glycans engaged by T3 reovirus in vivo. Glycan arrays done in collaboration with Ten 
Feizi (Imperial College) and the Stehle laboratory (Universitat Tübingen) have identified 
potential candidates: GD1a, GD1b, and GM3. Interestingly, these three gangliosides also 
constitute a large portion of the gangliosides expressed in the CNS and differ in their 
expression among various neural cell types during development (61, 62). To test the 
hypothesis that one or more of these gangliosides are natural ligands for T3 reovirus in 
the CNS, several experiments should be performed. Infection of murine primary cortical 
neurons is SA-dependent (40). Therefore, these cells can be used to identify soluble 
glycans that inhibit reovirus infection of neurons. In complementary experiments, 
antibodies against the ganglioside candidates could be used to test whether blockade of 
glycan binding impedes reovirus infection of cortical neurons. In either case, the effect of 
the soluble glycans or glycan-specific antibodies on reovirus infectivity could be 
measured by FFU or replication assays. Should results from experiments using murine 
primary cortical neurons pinpoint particular glycans required for reovirus infection of 
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neurons, the next step could be to validate the results in vivo by assessing virulence and 
virus replication in reovirus-infected animals that do not express the candidate glycans. 
Animals that do not express GD1a (GD3/GT3 synthase deficient), GD1b (GD3/GT3 
synthase deficient), and GM3 (GM3 synthase deficient) have been generated (50) and 
would be useful models for these experiments. 
An additional important unanswered question that remains from my work is the 
precise function of σ1 residue Asn198 in σ1-SA interactions. The current crystal 
structures of σ1 in complex with various oligosaccharides do not show an interaction 
with Asn198 and SA despite its requirement for reovirus binding to SA (91). To 
determine the function of Asn198 in σ1-SA interactions and gain insight into the native 
carbohydrate engaged by T3 reovirus, crystallographic studies should be conducted using 
T3D σ1 protein. The protein should be expressed in E. coli, purified, and crystallized. 
The T3D σ1 crystals should then be soaked with various physiologically relevant 
carbohydrates (for example GD1a, GD1b, and GM3 depending on the results of the 
functional assays), and the structures of the resulting complexes should be solved. These 
studies will help identify the native carbohydrate coreceptor for T3 reovirus and will 
further an understanding of protein-ligand interactions. This work is currently ongoing in 
collaboration with the Stehle laboratory (Universitat Tübingen). 
 
The role of carbohydrate-binding in reovirus serotype-specific neuropathogenesis 
The dramatic differences exhibited by T1 and T3 reovirus strains in viral tropism 
and disease in mice segregate with the σ1-encoding S1 gene (29, 112, 121, 122). 
Although JAM-A serves as a proteinaceous receptor for both T1 and T3 serotypes (8, 18), 
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utilization of carbohydrate coreceptors is serotype specific (7, 21, 22, 27, 49). This 
observation highlights the possibility that carbohydrate coreceptor engagement influences 
reovirus tropism and pathogenesis in infected animals. Results presented in Chapter IV 
demonstrate that reovirus engagement of sialylated glycans enhances T3 reovirus 
neurovirulence, but it is not known whether carbohydrate coreceptor engagement 
contributes to the differences in pathogenesis observed between T1 and T3 reovirus 
strains.  
To define the contribution of carbohydrate coreceptor engagement to the 
serotype-specific differences in CNS tropism and pathogenesis, reoviruses expressing 
T1/T3 chimeric σ1 proteins should be generated and compared in studies of virulence and 
viral replication in mice. To perform these experiments, a panel of T1/T3 chimeric 
reoviruses with exchanges of carbohydrate-binding domains in σ1 protein should be 
generated and characterized for receptor-binding specificity in vitro (Table V-1 and 
Figure V-1). Once receptor-binding specificity has been confirmed, in vivo studies should 
be conducted comparing virulence, disease development, tropism, and replication in 
mice. If serotype-specific carbohydrate engagement influences tropism and 
dissemination, the T1/T3 chimeric σ1 viruses should display phenotypes that segregate 
with the carbohydrate-binding domain. Accordingly, chimeric viruses with the T1 
carbohydrate-binding specificity should more closely resemble the CNS tropism of T1 
reovirus, and chimeric viruses with the T3 carbohydrate-binding specificity should be 
similar to T3 reovirus. These studies will shed light on the role of carbohydrate binding in 
serotype-specific tropism and dissemination. 
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Table V-1. Predicted glycan specificity of T1/T3 σ1 β-spiral exchange chimeras. 
 
Chimera T1 glycan 
specificity 
T3 glycan 
specificity 
T1L + - 
T3D - + 
T1-X1 + + 
T3-X2 - - 
T1-X3 + + 
T1-X4 + - 
T3-X5 - - 
T3-X6 - + 
 
T1 and T3 refer to the backbone of the S1 gene from which the construct is derived.  
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Experiments using JAM-A knockout mice and cortical neurons have 
demonstrated that binding to JAM-A is not required for reovirus infection of the brain or 
reovirus neurovirulence following IC inoculation (3). Furthermore, while SA-binding 
FIGURE V-1. Construct design of T1/T3 σ1 chimeras to exchange SA-binding domains. 
Proposed reciprocal β-spiral exchanges between T1L (red) and T3D (blue) σ1 proteins are 
depicted. The exchanges will be made at regions of conserved sequences or structural motifs 
at three junctions denoted J1, J2, and J3. 
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enhances the efficiency of infection of CNS tissues, it is not strictly required for infection 
(9, 40). These findings suggest that there is a neural-specific receptor engaged by T3 
reovirus strains yet to be identified. Although there is some evidence to suggest that 
sequences in the σ1 head domain of T3 reovirus strains influence reovirus neurovirulence 
and tropism in the CNS (11, 56), the precise role of the σ1 domains in the dichotomous 
patterns of tropism and spread exhibited by T1 and T3 reovirus strains is unknown. To 
define the contribution of each of the domains of σ1 to the serotype specific differences 
in CNS tropism and pathogenesis, reoviruses expressing T1/T3 chimeric σ1 proteins 
should be generated and compared in studies of virulence and viral replication in mice. 
To perform these experiments, a panel of T1/T3 chimeric reoviruses with reciprocal 
exchanges of the head, body, and tail domains of T1 and T3 σ1 proteins should be 
generated and characterized for receptor-binding specificity in vitro (Table V-2 and 
Figure V-2). Once receptor-binding specificity has been confirmed, in vivo studies should 
be conducted comparing virulence, disease development, tropism, and replication in 
mice. Studying this panel of σ1 chimeric viruses will give insight into which domains of 
σ1 are required for reovirus tropism, dissemination, and disease, and enhance an 
understanding of the how the discrete domains of σ1 work in concert to dictate reovirus 
pathogenesis. 
 
Conclusions 
With this research, we sought to establish a precise understanding of virus-
receptor interactions in reovirus target-cell selection and pathogenesis. Research 
presented in this dissertation encompasses structural analyses, molecular genetics, and  
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Table V-2. Predicted neural tropism and glycan specificity of T1/T3 σ1 domain 
exchange chimeras. 
 
 
Chimera T1 neural 
tropism 
T3 neural 
tropism 
T1 glycan 
specificity 
T3 glycan 
specificity
T1L + - + - 
T3D - + - + 
131 + - + + 
313 - + - - 
113 - + - - 
331 + - + + 
133 - + - + 
311 + - + - 
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FIGURE V-2. Construct design of T1/T3 σ1 domain exchange chimeras. Proposed 
reciprocal β-spiral exchanges between T1L (red) and T3D (blue) σ1 proteins are depicted. 
The exchanges will be made at regions of conserved sequences or structural motifs at 
junctions denoted J1 and J3. 
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in vivo studies to provide a thorough assessment of the structure and function of reovirus 
attachment protein σ1 and its sialylated glycan coreceptors on the cell-surface. 
Results from this research have enhanced an understanding of mechanisms of 
reovirus attachment to neuronal cells and the molecular interactions and structural 
features that mediate receptor engagement by viral attachment proteins. The long-term 
goal of this work is to identify and understand key pathogen-host molecular interactions 
that dictate how reovirus targets cells and disseminates to cause disease in the host. 
Therefore, the findings presented here can be used as a platform for future studies aimed 
at elucidating the basis of reovirus serotype-specific differences in spread and infection of 
the CNS. In addition, knowledge generated by this research adds to the reovirus field by 
elucidating the role of carbohydrate binding in reovirus neuropathogenesis. The broader 
implications of this work will be to contribute to an understanding of how neurotropic 
viruses interact with cellular receptors to cause disease in the CNS, and perhaps aid in the 
development of novel anti-viral therapies directed at blocking the attachment step. My 
research also will aid in the continued development of reovirus as an oncolytic agent and 
vaccine vector. An in-depth understanding of mechanisms used by reovirus to engage 
cell-surface receptors and how these interactions influence cell-targeting may lead to 
improved reovirus vectors with enhanced selectivity. 
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CHAPTER VI 
 
MATERIALS AND METHODS 
 
Cells 
L929 cells (100) were maintained in Joklik's minimum essential medium (Sigma-
Aldrich) supplemented to contain 5% fetal bovine serum (FBS), 2 mM L-glutamine, 100 
U/ml of penicillin, 100 µg/ml of streptomycin, and 25 ng/ml of amphotericin B. MEL 
cells, previously designated T3cl.2 cells (94), were maintained in Ham's F-12 medium 
(CellGro) supplemented to contain 10% fetal bovine serum, 2 mM L-glutamine, 100 
U/ml penicillin, 100 µg/ml streptomycin, and 25 ng/ml amphotericin B. BHK-T7 cells 
(16) were grown in DMEM (Invitrogen) supplemented to contain 5% FBS, 2 mm L-
glutamine, 2% minimal essential medium amino acid solution (Invitrogen), and 1 mg/ml 
geneticin (Invitrogen). 
 
Viruses 
Recombinant reoviruses were generated by plasmid-based reverse genetics (58, 
59). Reovirus strains rsT3D (wild type), rsT3D-σ1N198D, rsT3D-σ1R202W, and rsT3D-
σ1P204L were recovered using monolayers of L929 cells at approximately 90% 
confluence (3 × 106 cells) in 60-mm dishes (Costar) infected with recombinant vaccinia 
virus rDIs-T7pol (52) at a multiplicity of infection (MOI) of ~ 0.5 TCID50. At 1 h post-
infection, cells were co-transfected with ten plasmid constructs representing the cloned 
T3D genome using 3 µl of TransIT-LT1 transfection reagent (Mirus) per µg of plasmid 
  
 
67
DNA (58). Reovirus strains rsT3D-σ1N189A, rsT3D-σ1S195A, rsT3D-σ1R202A, 
rsT3D-σ1L203A, rsT3D-σ1P204A, rsT3D-σ1G205A, and rsT3D-σ1N210A were 
recovered using BHK-T7 cells at 90% confluence (approximately 3 × 106 cells) seeded in 
60-mm dishes. Cells were co-transfected with five plasmids representing the cloned T3D 
genome using 3 μl of TransIT-LT1 transfection reagent (Mirus) per µg of plasmid DNA 
(59). The amount of each plasmid used for transfection was identical to that described for 
L929 cell transfections. Following 3 to 5 days of incubation, recombinant viruses were 
isolated from transfected cells by plaque purification using monolayers of L929 cells 
(118). 
The σ1 mutant viruses were generated by altering pT7-S1T3D (58) using 
QuikChange (Stratagene) site-directed mutagenesis. Sequences of the mutant viruses 
were determined using viral RNA from purified virions and subjected to Onestep reverse 
transcription-PCR (RT-PCR) (Qiagen) using L1- or S1-specific primers. The purified 
PCR products were subjected to sequence analysis for the presence of the introduced 
mutation in the S1 gene segment and the noncoding signature mutation in the L1 gene 
segment (58). 
Purified reovirus virions were prepared using second-passage L929-cell lysate 
stocks of twice plaque-purified reovirus as described (42). Viral particles were Freon-
extracted from infected cell lysates, layered onto CsCl gradients, and centrifuged at 
62,000 × g for 18 h. Bands corresponding to virions (1.36 g/cm3) (102) were collected 
and dialyzed in virion-storage buffer (150 mM NaCl, 15 mM MgCl2, 10 mM Tris-HCl 
pH 7.4). The concentration of reovirus virions in purified preparations was determined 
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from an equivalence of one OD unit at 260 nm equals 2.1 × 1012 virions (102). Viral titers 
were determined by plaque assay using L929 cells (118). 
 
Protein Expression and Purification 
The expression of soluble and properly folded T3D σ1 trimers was facilitated by 
appending a trypsin-cleavable trimerization domain based on the GCN4 leucine zipper 
(47) N-terminally to a cDNA encoding the entire σ1 body and head domains (amino acids 
170-455). The construct was cloned into the pQE-80L expression vector, which encodes 
a non-cleavable N-terminal hexahistidine-tag. The protein was expressed in E. coli 
Rosetta 2 DE3 (Novagen) at 20°C for 16 h post-induction or by autoinduction at 20°C for 
48-72 h. Bacteria were lysed by two passages through an EmulsiFlex (Avestin) 
homogenizer and purified by Ni-IMAC using His-Trap-FF columns (GE-Healthcare). 
The immobilized protein was eluted by on-column digestion with 0.1 mg/ml trypsin at a 
flowrate of 0.1ml/min for 12 h. Size-exclusion chromatography (Superdex-200, GE-
Healthcare) was used as the final purification step. 
 
X-ray Structure Determination 
Crystals of T3D σ1 were grown using 15% PEG200, 0.1M MES (pH 6.5) as a 
precipitant. The crystals belong to space group P21212 and contain one trimer in the 
asymmetric unit. Complexes with carbohydrate ligands were prepared by soaking crystals 
with the respective carbohydrate prior to data collection. The crystals were transferred 
into mother liquor supplemented with 10 mM carbohydrate, incubated for 5 min, and 
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cryoprotected by incubation for 15 s in 35% PEG200, 0.1M MES, 10 mM carbohydrate 
(pH 6.5). 
Diffraction data were collected at the beamlines PXI (SLS) and ID14-4 (ESRF). 
Diffraction data were integrated and scaled using XDS (54), and the structure was solved 
by molecular replacement with AMoRe (77) using the structure of the T3D σ1 head 
(PDB ID 1KKE) as a search model. Refinement was performed with Refmac5 (74) and 
Phenix (1), and model building was done in Coot (37). Ligands were placed into 
weighted Fo-Fc difference density maps at a contour level of 3σ and refined using the 
CCP4 library and user-defined restraints. Coordinates and structure factors for all three 
complexes have been deposited in the PDB data bank (www.rcsb.org) with accession 
codes 3S6X (complex with α-2,3-sialyllactose), 3S6Y (complex with α-2,6-sialyllactose) 
and 3S6Z (complex with α-2,8-di-sialyllactose). 
 
HA Assay 
Purified reovirus virions (1011 particles) were distributed into 96-well U-bottom 
microtiter plates (Costar) and serially diluted twofold in 0.05 ml of phosphate-buffered 
saline (PBS). Calf erythrocytes (Colorado Serum Co.) were washed twice with PBS and 
resuspended at a concentration of 1% (vol/vol). Erythrocytes (0.05 ml) were added to 
wells containing virus particles and incubated at 4°C for at least 2 h. A partial or 
complete shield of erythrocytes on the well bottom was interpreted as a positive HA 
result; a smooth, round button of erythrocytes was interpreted as a negative result. HA 
titer is expressed as 1011 particles divided by the number of particles/HA unit. One HA 
unit equals the number of particles sufficient to produce HA. HA titers from three 
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independent experiments were compared using an unpaired Student’s t test as applied in 
Microsoft Excel. P values of less than 0.05 were considered statistically significant. 
 
Reovirus Infection of L929 and MEL Cells 
L929 cells or MEL cells (2 × 105 cells/well) were plated in 24-well plates (Costar) 
and incubated at 37°C for at least 2 h. Cells were adsorbed with reovirus strains at an 
MOI of 1 plaque forming units (PFU)/cell. Following incubation at room temperature for 
1 h, cells were washed three times with PBS and incubated at 37°C for 24 or 48 h. 
Samples were frozen and thawed twice, and viral titers were determined by plaque assay 
(118). For each experiment, samples were infected in triplicate. Mean values from three 
independent experiments were compared using an unpaired Student’s t test as applied in 
Microsoft Excel. P values of less than 0.05 were considered statistically significant. 
 
Infection of mice 
C57BL/6J mice were obtained from Jackson Laboratory to establish breeding 
colonies. Newborn mice 2-3 days old were inoculated intramuscularly or intracranially 
with purified reovirus diluted in PBS. IM inoculations (5 μl) were delivered into the right 
hindlimb, and IC inoculations (5 μl) were delivered into the left cerebral hemisphere, in 
both cases using a Hamilton syringe and 30-gauge needle. For analysis of viral virulence, 
mice were monitored for symptoms of disease for 21 days post-inoculation. For virulence 
experiments, mice were euthanized when found to be moribund (defined by rapid or 
shallow breathing, lethargy, or paralysis). Death was not used as an endpoint. For 
analysis of virus replication, mice were euthanized at various intervals following 
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inoculation, and organs were collected into 1 ml of PBS and homogenized by freezing, 
thawing, and sonication. For analysis of viremia, mice were euthanized and decapitated at 
various intervals following inoculation, and whole blood was collected from the neck into 
a 1 ml syringe containing 100 μl Alsever’s solution (Sigma). Viral titers in organ 
homogenates were determined by plaque assay using L929 cells (118). 
For experiments in which viral titers were determined in an organ or blood, the 
Mann-Whitney test was used to calculate two-tailed P values. This test is appropriate for 
experimental data that display a non-Gaussian distribution (93). P values of less than 0.05 
were considered to be statistically significant. When all values are less than the limit of 
detection, a Mann-Whitney test P value cannot be calculated. Statistical analyses were 
performed using Prism software (GraphPad Software, Inc.). 
All animal husbandry and experimental procedures were performed in accordance 
with Public Health Service policy and approved by the Vanderbilt University School of 
Medicine Institutional Animal Care and Use Committee. 
 
Preparation of cortical neuron cultures from embryonic mice 
Primary cultures of mouse cortical neurons were established using cerebral cortices of 
C57/BL6 embryos at developmental day E15 (3). Fetuses were decapitated, brains were 
removed, and cortical lobes were dissected and submerged in Hanks’ balanced salt 
solution (Gibco) on ice. Cortices were incubated in 0.6 mg/ml trypsin solution at room 
temperature for 30 min, washed twice, and manually dissociated twice using a Pasteur 
pipette. Viable cells were plated at a density of 2.5 × 105 cells/ml in 24-well plates. Wells 
were treated prior to plating with a 10 μg/ml poly-D-lysine solution (BD Biosciences) 
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and a 1.64 μg/ml laminin solution (BD Biosciences). Cultures were incubated for the first 
24 h in neurobasal medium (Gibco) supplemented to contain 10% FBS (Gibco), 0.6 mM 
L-glutamine, 50 units/ml penicillin, and 50 μg/ml streptomycin. Cultures were thereafter 
maintained in neurobasal medium supplemented to contain B27 (Gibco), 50 units/ml 
penicillin, and 50 μg/ml streptomycin. One-half of the medium was replaced with fresh 
medium every 3 to 4 days. Neurons were cultivated for 7 days prior to use. 
 
Assessment of reovirus infectivity by indirect immunofluorescence 
Monolayers of murine cortical neurons (2.5 × 105 cells/well) seeded in 24-well 
plates were adsorbed with reovirus at an MOI of 1000 PFU/cell at room temperature for 1 
h. Cells were incubated with either PBS or 40 mU Arthrobacter ureafaciens 
neuraminidase at 37°C for 1 h and washed three times with PBS prior to virus adsorption. 
Following removal of the virus inoculum, cells were washed with PBS and incubated in 
complete medium at 37°C for 21 h to permit completion of a single cycle of viral 
replication. Monolayers were fixed with 1 ml of methanol at -20°C for at least 30 min, 
washed twice with PBS, and blocked with 0.1% Tween-20 (Sigma) and 20% normal goat 
serum (Vector Laboratories) in PBS. Cells were washed once with PBS and stained with 
polyclonal rabbit anti-reovirus serum at a 1:1000 dilution in PBS-0.5% Triton X-100 at 
room temperature for 1 h. Neurons were visualized after washing three times with PBS 
and staining with a monoclonal mouse anti-β-tubulin antibody (TUJ1; Covance) at a 
1:1000 dilution in PBS-0.5% Triton X-100 at room temperature for 1 h. Monolayers were 
washed twice with PBS-0.5% Triton X-100 and incubated with a 1:1000 dilution of 
Alexa488-labeled anti-rabbit and Alexa546-labeled anti-mouse IgG (Invitrogen). Nuclei 
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were stained with 4′,6-diamidino-2-phenylindole (DAPI; Invitrogen) at a 1:10,000 
dilution. Monolayers were washed with PBS, and infected cells were visualized by 
indirect immunofluorescence using an Axiovert 200 fluorescence microscope (Carl Zeiss). 
 
Assessment of reovirus replication by plaque assay 
Murine primary cortical neurons (105 cells/well) were adsorbed with reovirus 
strains at an MOI of 1 PFU/cell. Cells were incubated with either PBS or 40 mU A. 
ureafaciens neuraminidase at 37°C for 1 h and washed three times with PBS prior to 
virus adsorption. Following incubation with virus at room temperature for 1 h, cells were 
washed three times with PBS and incubated at 37°C for 24, 48, or 72 h. Samples were 
frozen and thawed twice, and viral titers were determined by plaque assay using L929 
cells (118). For each experiment, samples were infected in triplicate. Viral yields were 
calculated according to the following formula: log10yieldtx = log10(PFU/ml)tx − 
log10(PFU/ml)t0, where tx is the time postinfection. Mean values from two independent 
experiments were compared using an unpaired Student’s t test as applied in Microsoft 
Excel. P values of less than 0.05 were considered to be statistically significant. 
 
Quantification of viral RNA using RT-qPCR 
Total RNA was extracted from 200 μl of whole blood/Alsever's mixture using the 
High Pure Viral RNA kit (Roche). RNA was eluted into a final volume of 40 μl. RT-
qPCR was performed using an ABI 7000 sequence detection system (Applied 
Biosystems) and EZ RT-PCR (Roche) according to the manufacturer's instructions with 
minor modifications. Reovirus RNA was quantified using 10 μl of RNA extract. Forward 
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(S4 83F, 5′-CGCTTTTGAAGGTCGTGTATCA-3′) and reverse (S4 153R, 5′-
CTGGCTGTGCTGAGATTGTTTT-3′) primers corresponding to the viral S4 gene were 
used for RT and qPCR amplification. The S4-specific fluorogenic probe used was 5′-
dFAM-AGCGCGCAAGAGGGATGGGA-BHQ-1-3′ (Biosearch Technologies). RT was 
performed at 50°C for 2 min, followed by incubation at 60°C for 30 min. The reaction 
was terminated by incubation at 95°C for 5 min. Subsequently, 40 cycles of qPCR were 
performed at 95°C for 15 s followed by incubation at 60°C for 30 s. Standard curves 
relating threshold cycle values to copies of plasmid DNA template were generated using 
10-fold dilutions of a T3D S4-encoding plasmid (pT7-T3D S4) (58). The concentration 
of viral RNA in each sample was extrapolated from standard curves. The final S4 RNA 
copy number was calculated by multiplying the copy number obtained by extrapolation 
from the standard curve by four to account for using one-quarter of the extracted RNA as 
a template. 
 
Histology and immunohistochemical staining for reovirus antigen 
Newborn mice 2-3 days old were inoculated intramuscularly or intracranially with 
reovirus diluted in PBS. Mice were euthanized 8 days post-inoculation, and organs were 
resected and incubated in 10% formalin at room temperature for 24 to 48 h. Fixed organs 
were embedded in paraffin, and consecutive 6 mm sections were stained with 
hematoxylin and eosin for evaluation of histopathologic changes or processed for 
immunohistochemical detection of reovirus proteins (9). 
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Abstract
Many viruses attach to target cells by binding to cell-surface glycans. To gain a better understanding of strategies used by
viruses to engage carbohydrate receptors, we determined the crystal structures of reovirus attachment protein s1 in
complex with a-2,3-sialyllactose, a-2,6-sialyllactose, and a-2,8-di-siallylactose. All three oligosaccharides terminate in sialic
acid, which serves as a receptor for the reovirus serotype studied here. The overall structure of s1 resembles an elongated,
filamentous trimer. It contains a globular head featuring a compact b-barrel, and a fibrous extension formed by seven
repeating units of a triple b-spiral that is interrupted near its midpoint by a short a -helical coiled coil. The carbohydrate-
binding site is located between b-spiral repeats two and three, distal from the head. In all three complexes, the terminal
sialic acid forms almost all of the contacts with s1 in an identical manner, while the remaining components of the
oligosaccharides make little or no contacts. We used this structural information to guide mutagenesis studies to identify
residues in s1 that functionally engage sialic acid by assessing hemagglutination capacity and growth in murine
erythroleukemia cells, which require sialic acid binding for productive infection. Our studies using s1 mutant viruses reveal
that residues 198, 202, 203, 204, and 205 are required for functional binding to sialic acid by reovirus. These findings provide
insight into mechanisms of reovirus attachment to cell-surface glycans and contribute to an understanding of carbohydrate
binding by viruses. They also establish a filamentous, trimeric carbohydrate-binding module that could potentially be used
to endow other trimeric proteins with carbohydrate-binding properties.
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Introduction
Viral infections are initiated by specific attachment of a virus
particle to receptors at the surface of the host cell. This process,
which serves to firmly adhere the virus to its cellular target, is
rarely a bimolecular interaction between one viral attachment
protein and one receptor. In most cases, several receptors are
employed, and recognition events are frequently accompanied by
substantial structural rearrangements that serve to expose new
binding sites, strengthen the initial interaction, and prime the virus
for cell entry. Structure-function analyses of virus-receptor
interactions have provided detailed insights into the attachment
strategies of viruses belonging to several different families [1–18].
However, much less is known about structure-function interrela-
tionships between different binding sites for distinct receptors on
the same viral attachment molecule.
Reoviruses are useful experimental models for studies of virus-
receptor interactions and viral pathogenesis. Moreover, the recent
development of plasmid-based reverse genetics for reovirus
provides an opportunity to manipulate these viruses for oncolytic
and vaccine applications. Reoviruses form icosahedral particles
approximately 850 A˚ in diameter. At the virion five-fold symmetry
axes, the trimeric attachment protein, s1, extends from penta-
meric turrets formed by the l2 protein. A similar arrangement of a
trimeric attachment protein inserted into a pentameric base is also
observed for the adenovirus attachment protein, fiber. The s1
protein is about 400 A˚ long and consists of three discrete domains,
termed tail, body, and head [19]. Residues 1 to 160 encompass the
tail domain, which partially inserts into the virion capsid [20–22].
This region of the molecule is predicted to form an a-helical
coiled-coil structure. The body domain encompasses residues 170
to 309 and contains b-spiral repeat motifs [22]. Lastly, the globular
head domain incorporates residues 310 to 455 and folds into an 8-
stranded b-barrel [22,23].
Reovirus attachment is thought to proceed via a two-step
adhesion-strengthening mechanism, in which s1 first engages
widely distributed carbohydrate receptors with lower affinity. The
three prototype reovirus strains, type 1 Lang (T1L), type 2 Jones
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(T2J), and type 3 Dearing (T3D) recognize different carbohydrate
structures, which may account for the serotype-specific differences
in routes of spread in the host and end-organ tropism. In the case
of serotype 3 (T3) reoviruses, the carbohydrate bound is a-linked
sialic acid [24–26]. This initial contact, which has lower affinity
and may allow for lateral diffusion of the particle at the membrane
[27], is followed by high-affinity interactions with junctional
adhesion molecule-A (JAM-A) [28], a component of tight junctions
[29–31]. All reoviruses, including prototype and field-isolate
strains, use JAM-A as a high-affinity receptor [28,32,33]. Firm
adherence to the cell triggers uptake of the particle, which is
dependent on b1 integrins [34,35].
Discrete regions of s1 mediate binding to its cell-surface
receptors. Structural and functional analyses show that the s1
head, which projects farthest from the virus capsid, engages JAM-
A [33,36,37]. In contrast, sequences in the s1 body bind to
carbohydrates [38]. Sequence analysis of reovirus variants
identified three residues, Asn198, Arg202, and Pro204, as likely
critical for the interaction of T3 s1 with sialic acid. These residues
lie near the midpoint of the protein, at the lower end of the body
domain, about 100 A˚ away from residues in the head that interact
with JAM-A. Earlier structural analyses of T3D s1 [22,23,36]
were based on constructs that did not include this putative
carbohydrate-binding site. It is therefore currently unclear how s1
achieves its specificity for sialic acid, whether the large distance
between the two receptor-binding sites on s1 is relevant for
binding, or whether s1 undergoes rearrangements after engaging
its carbohydrate receptor.
To enhance an understanding of mechanisms by which viral
attachment proteins engage cell-surface glycans, we determined
the crystal structure of T3D s1 in complex with a-2,3-
sialyllactose, a-2,6-sialyllactose, and a-2,8-disiallylactose. All three
carbohydrates terminate in sialic acid but feature different linkages
that are present in various physiologic glycans. In addition, we
used plasmid-based reverse genetics to engineer reoviruses that
express mutagenized forms of s1 to define residues required for
functional binding to sialic acid. These studies shed light on the
structural basis of s1-sialic acid interactions and define a new
carbohydrate-binding structural motif in a viral attachment
protein.
Results
Construct Design and Structure Determination
The s1 protein belongs to a class of fiber proteins constructed
from triple b-spirals, a motif that was first identified in the
adenovirus fiber [39]. In a previous study, we crystallized a smaller
region of s1, spanning residues 246 to 455 and containing three b-
spiral repeats as well as the globular head domain [22]. While this
structure provided no insights into the carbohydrate-binding
region of s1, it served as a basis to predict that b-spiral repeats
form the entire body domain of the protein (residues 167–309)
[22]. Near residue 170, the body domain transitions into a long a-
helical coiled-coil region that forms the N-terminal tail domain
(residues 1–156).
To determine the structure of a longer fragment of s1 including
the predicted sialic-acid binding residues 198, 202, and 204, we
designed a construct for the expression of residues 170–455. This
construct excluded the long a-helical coiled-coil region to simplify
protein expression, purification, and crystallization. Prototype
strain T3D s1 is sensitive to trypsin-mediated cleavage after
Arg245 [40]. However, a sequence polymorphism occurring in the
majority of T3 field-isolate strains, Thr249Ile, renders the protein
resistant to trypsin [40]. A construct containing Ile249 was
therefore used in our study. Trimerization was promoted by using
a hexahistidine-tagged trimerization domain, a modified GCN4
sequence [41], at the N-terminus of the expressed protein. This
domain was proteolytically removed before final purification and
crystallization.
Overall Structure of s1
The structure of s1 residues 170 to 455 reveals a highly
elongated, symmetric trimer that measures about 200 A˚ in length
(Table 1 and Figure 1A,B). Tail residues N-terminal to amino acid
170, which were not included in the crystallized protein, are
predicted to form an a-helical coiled-coil structure that adds
another 200 A˚ in length to the protein (Figure 1C). As expected,
Author Summary
Human reoviruses bind first with low affinity to a
carbohydrate receptor that brings the virus in close
proximity to the host cell. This interaction then facilitates
high-affinity binding to a second receptor, the tight junction
component junctional adhesion molecule-A (JAM-A). While
all human reoviruses bind JAM-A, they differ in carbohy-
drate receptor specificity, and this difference may influence
the distinct disease patterns of reovirus serotypes. We
present here the structure of the attachment protein of type
3 reovirus in complex with carbohydrates that naturally
occur on human cells. Our results show that the protein
forms an elongated trimer, with the carbohydrate binding
site being located close to the midpoint of the molecule in a
fiber-like region. Our findings provide insights into mech-
anisms of reovirus attachment to cell-surface glycans and
contribute to an understanding of carbohydrate binding by
viruses. They also establish a filamentous, trimeric carbohy-
drate-binding module that could potentially be used to
introduce carbohydrate-binding properties into other
trimeric proteins.
Table 1. Data collection and refinement statistics.
s1 in complex with a-2,3-sl a-2,6-sl a-2,8-di-sl
Space group P21212 P21212 P21212
Unit cell dimensions (A˚) a = 87.15 a = 87.61 a = 87.19
b = 333.18 b = 333.06 b = 331.84
c = 58.49 c = 58.29 c = 58.13
Unit cell angles (u) a=b= c= 90 a= b= c= 90 a= b= c= 90
Resolution range (A˚) 38.6–2.25 48.05–2.79 48.06–2.28
Completeness (%) 95.37 98.65 96.03
Total reflections 369038 547842 277926
Unique reflections 78324 43203 75913
Rmerge (%)
# 10.8 6.2 9.6
I/sI 13.5 18.6 18.6
Rwork (%)* 15.77 15.69 17.31
Rfree (%)* 19.89 20.48 22.03
r.m.s.d. bond lengths (A˚) 0.006 0.007 0.006
r.m.s.d. bond angles (u) 0.960 1.12 1.01
r.m.s.d., root-mean-square deviation. sl, sialyllactose.
*Rwork = Rfree = S| |Fobs(hkl) | - |Fcalc (hkl) | |/S |Fobs (hkl). Rfree was calculated
with 5% of the data.
#Rmerge = S | I - ,I. |/SI
doi:10.1371/journal.ppat.1002166.t001
Structure of Reovirus Attachment Protein
PLoS Pathogens | www.plospathogens.org 2 August 2011 | Volume 7 | Issue 8 | e1002166
the structure of the globular head domain (residues 310 to 455) is
essentially identical to that described previously [22]. However,
the body domain displays a number of unusual features. Although
sequence-based predictions suggested that this region would be
composed of eight consecutive triple b-spiral repeats [22], we find
that the body domain contains a mixture of a-helical coiled-coil
and b-spiral repeats (Figure 1). Four b-spiral repeats at the N-
terminus (b1–b4, residues 170 to 235) are followed by a short a-
helical coiled-coil (cc, residues 236 to 251) and three additional b-
spiral repeats (b5-b7, residues 252 to 309) (Figure 2). Inspection of
the sequence indicates a likely reason for the deviation from the b-
spiral fold at the center of the body (Figure 2B). Three hydrophilic
residues (Thr236, Ser244, and Ser252) are located at positions that
are typically occupied by hydrophobic side chains in b-spirals.
Moreover, Ser241 replaces a characteristic proline or glycine at
the turn in a b-spiral repeat. While some deviations from the b-
spiral consensus sequence can be tolerated, even residues replacing
the glycine or proline (e.g., residues Gln224 or Thr278), the
cumulative effect of the four non-consensus residues results in a b-
spiral no longer being the optimal fold. The a-helical coiled-coil
structure contains two heptad-repeat sequences, starting with
Phe239 and ending with Gln251 (Figure 2A,C).
Structure of s1 in Complex with a-2,3-Sialyllactose
To elucidate the structural basis of the interaction of the
reovirus attachment protein s1 with its carbohydrate coreceptor,
we prepared a complex by soaking crystals of s1 with 10 mM a-
2,3-sialyllactose, a compound that terminates in a-linked sialic
acid. The subsequent structure, determined at 2.25 A˚ resolution
(Table 1), unambiguously demonstrated the location of the
carbohydrate in an unbiased difference electron-density map
(Figure 3A). The oligosaccharide binds in a shallow groove next to
the loop connecting the second and third b-spiral repeats. The s1
protein contains three identical binding sites, one on each chain,
and all three are occupied by a-2,3-sialyllactose molecules, with
the sialic acid making identical and extensive contacts in each
chain (Figure 3B,C). The lactose moieties face different directions,
probably as a result of internal flexibility and participation in
crystal contacts (Figure 3C).
Sialic acid contains four characteristic functional groups: a
carboxylate at C1, a hydroxyl group at C4, an N-acetyl group at
C5, and a glycerol chain at C6. All four groups are recognized by
s1 (Figure 3B). Arg202 forms a bidentate salt bridge with the
carboxyl group. A single hydrogen bond links the hydroxyl group
at C4 to the carbonyl of Gly205. The amide of the N-acetyl group
Figure 1. Structure of T3D s1. (A) Ribbon drawing of the T3D s1 body and head domains in complex with a-2,3-sialyllactose. The s1 monomers
are shown in red, blue, and yellow. The body domain consists of seven triple b-spiral repeats (b1–b7) and an a-helical coiled-coil domain (cc) that is
inserted between b-spiral repeats b4 and b5. The bound a-2,3-sialyllactose is shown in stick representation and colored in orange. (B) Molecular
surface of the s1 structure, shown in semitransparent white coloring. (C) Model of full-length s1, including a computer-generated trimeric a-helical
coiled coil structure spanning s1 residues 1–160 at the N-terminus.
doi:10.1371/journal.ppat.1002166.g001
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is engaged in a hydrogen bond with the backbone carbonyl of
Leu203, and the N-acetyl methyl group is facing into a partially
hydrophobic cavity. The glycerol chain lies parallel to the peptide
backbone, forming direct hydrogen bonds with the backbone
carbonyl of Ile201 and the amide nitrogen of Leu203 and in some
of the binding sites water-mediated hydrogen bonds with the
Asn210 side chain and the amide nitrogen of Ile211. We note that
Arg202, which was previously shown to influence sialic acid
binding [42], provides a key contact to the ligand. Moreover,
Pro204, which also had been implicated in sialic acid binding [42],
is part of a structure that shapes the ligand-binding site.
Structures of s1 in Complex with a-2,6-Sialyllactose and
a-2,8-Disialyllactose
As contacts in the complex of s1 with a-2,3-sialyllactose
exclusively involve the sialic acid moiety, we hypothesized that s1
should be capable of binding sialic acid in different naturally
occurring linkages, including a-2,6- and a-2,8-linked sialic acid.
We therefore determined crystal structures of s1 in complex with
a-2,6-sialyllactose (Figure 4A) and a-2,8-disialyllactose (Figure 4B).
Refinement statistics for both structures are provided in Table 1.
In each case, only two of the binding sites are occupied, as the
third is partially blocked by crystal contacts. For the a-2,6-
sialyllactose complex, the electron density allowed us to unam-
biguously identify all three sugar residues (Figure 4A). The
electron density for the a-2,8-disialyllactose complex did not allow
us to model the terminal glucose. Comparison of these structures
with each other and with the a-2,3-sialyllactose complex shows
that the terminal sialic acid is bound in the same conformation and
with identical contacts in all three cases. However, the remaining
moieties of the glycans differ in conformation and contacts with
s1. The a-2,3-sialyllactose and a-2,8-disialyllactose ligands
assume an elongated shape in which the lactose groups face away
from the protein (Figure 3C, Figure 4B). Inspection of the a-2,8-
disialyllactose complex shows that the N-acetyl group of the
second sialic acid forms a hydrogen bond to the side chain of
Ser195. In contrast, s1 binds a-2,6-sialyllactose in a folded-back
conformation (Figure 4A). This conformation is stabilized by an
Figure 2. Structural features of the T3D s1 body domain and sequence alignments with T1L and T2J s1. (A) Close-up view of the a-
helical coiled-coil that separates b-spirals 4 and 5 in the T3D s1 body domain. The coiled-coil region is shown as a stick model, while the adjacent b-
spiral repeats are depicted as a ribbon drawing. A simulated annealing omit difference map for one chain is shown with a radius of 2.2 A˚ and a
contour level of 3s. (B) The residues are aligned according to the triple b-spiral consensus sequence (a–o), with typically hydrophobic residues (c, e, g,
k, and m) indicated in cyan and the position in the b-turn usually occupied by proline or glycine (j) in green. (C) Sequence analysis of the coiled-coil
region in the body domain. Residues 239–252 are organized in heptads (a–g), and the coiled-coil consensus is indicated with typically hydrophobic
residues (a and d) highlighted in cyan.
doi:10.1371/journal.ppat.1002166.g002
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intramolecular hydrogen bond and the galactose O2 and O3
hydroxyl groups, which form hydrogen bonds to the backbone
carbonyl atoms of Ser195 and Leu194, respectively.
Residues in Reovirus s1 Required for Sialic Acid Binding
To identify sequences that influence sialic acid binding, we used
plasmid-based reverse genetics [43,44] to introduce point
mutations into the s1 protein of reovirus strain T3D. Mutant
viruses were isolated following co-transfection of murine L929 cells
with RNA-encoding plasmids corresponding to the T3D L1-L3,
M1-M3, and S2-S4 genes and a plasmid corresponding to the s1-
encoding S1 gene incorporating site-specific mutations. Thus, each
recombinant virus is isogenic, with the exception of the S1 gene
and its protein product, s1. Guided by the structure of the s1-
sialic acid complexes, we engineered individual alanine substitu-
tions of amino acids ranging from Asn189 to Asn210. By their
location in the structure, we hypothesized that these residues
would be required for functional sialic acid binding. In addition,
substitutions N198D, R202W, and P204L, which have been
implicated in sialic acid binding by sequence comparisons of
reovirus strains that differ in sialic acid utilization [26,45] and
genetic analysis of reovirus mutants adapted to growth in murine
erythroleukemia (MEL) cells [42], were engineered to define the
effect of these polymorphisms in an otherwise isogenic
background.
After confirming the s1-encoding S1 gene nucleotide sequenc-
es, the mutant viruses were tested for hemagglutination (HA)
capacity (Figure 5) and growth in L929 cells and MEL cells
(Figure 6). In comparison to rsT3D, rsT3D-s1N198D, rsT3D-
s1R202A, rsT3D-s1R202W, rsT3D-s1L203A, rsT3D-
s1P204A, rsT3D-s1P204L, and rsT3D-s1G205A produced little
or no agglutination of calf erythrocytes, a sensitive assay for sialic
acid binding [26]. However, rsT3D-s1N189A, rsT3D-s1S195A,
and rsT3D-s1N210A produced HA titers that were comparable
to those of wild-type rsT3D. Each of the point-mutant viruses
produced approximately 1000-fold yields of viral progeny after
growth in L929 cells (Figure 6), a cell line that does not require
sialic acid binding for reovirus to replicate [45]. In contrast, those
containing mutations N198D, R202A, R202W, L203A, P204A,
P204L, and G205A displayed attenuated growth in MEL cells
(Figure 6), a cell line permissive only to sialic acid binding reovirus
strains [45]. These findings indicate that viruses with mutations of
residues 198, 202, 203, 204, and 205 are altered in sialic acid
binding efficiency, suggesting that these residues serve a functional
role in T3D s1-sialic acid interactions.
Discussion
Although all known reovirus strains engage cells by binding to
the tight junction protein JAM-A [33], the major reovirus
serotypes differ in the routes of dissemination in the host and
Figure 3. Interactions between s1 and sialic acid. (A) Simulated
annealing omit difference density map contoured at 3s and displayed
with a radius of 2.2 A˚ around the bound a-2,3-sialyllactose. The sugar
moieties are labeled Sia (sialic acid), Gal (galactose), and Glc (glucose)
here and in subsequent figures. (B) Detailed interactions between s1
and the terminal sialic acid of a-2,3-sialyllactose. Residues in the binding
region are drawn in ball and stick representation, while the rest of the
protein is shown as a ribbon drawing. The s1 residues forming
hydrogen bonds or salt bridges with the ligand are shown in green, and
residues forming van der Waals contacts are shown in cyan. The side
chain of Asn189 (colored dark blue) is contributed by a neighboring s1
monomer (see also Figure 1A). Sialic acid is shown in ball-and-stick
representation, with carbons colored orange, oxygens colored red, and
nitrogens colored blue. Bridging waters are shown as orange spheres.
Hydrogen bonds and salt bridges are represented with broken lines. (C)
Superposition of all three bound ligands into a single binding site. The
superposition was performed using s1 residues only. While the
orientation of the terminal sialic acid is nearly identical, the lactose
moieties are facing in different orientations as a result of their
participation in different crystal contacts.
doi:10.1371/journal.ppat.1002166.g003
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tropism for host tissues [46–48]. These differences are linked to the
s1-encoding S1 gene segment and most likely attributable to
serotype-specific interactions of s1 with different cell-surface
receptors. T3 reoviruses require sialic acid as a coreceptor, but the
context in which sialic acid is bound is unknown. To define this
interaction, we determined crystal structures of reovirus s1 in
complex with three sialylated glycans that incorporate a terminal
sialic acid moiety in different linkages. These structural analyses
were complemented with mutagenesis experiments that establish
the physiologic relevance of the observed interactions.
The s1 protein uses a complex network of contacts to engage
terminal sialic acid, which is a common feature of all three glycans
studied here. The interactions involve s1 residues at the lower end
of the body domain, between b-spirals 2 and 3. At this location,
the sialic acid moiety docks into a shallow pocket that is formed
mainly by residues in the third b-spiral. All four functional groups
of sialic acid make contacts with s1 through an elaborate network
of hydrogen bonds and van der Waals interactions. Mutations that
alter these contacts lead to significantly reduced sialic acid binding
as assessed by HA profiles and diminished infection of MEL cells.
Although all three ligands used for complex formation with s1
contain additional carbohydrates, these make very few interac-
tions. The complex with a-2,8-disialyllactose identified a hydrogen
bond between the N-acetyl group of the second sialic acid and the
side chain of Ser195 (Figure 4B). However, the results from
mutagenesis experiments demonstrate that a Ser195A mutation
has no effect on either HA capacity or viral growth. Therefore, the
observed contact is unlikely to have physiologic relevance. The
interactions between s1 and a-2,6-sialyllactose identified two
hydrogen bonds that link the galactose to the protein and may help
to stabilize the folded-back conformation of the ligand (Figure 4A).
As both contacts involve main chain atoms of s1, their functional
significance cannot be easily probed by site-directed mutagenesis.
Nevertheless, it is likely that the observed contacts lead to a modest
increase in the affinity of s1 for compounds terminating in a-2,6-
linked sialic acid. It is unclear if such an increase is biologically
significant.
Naturally occurring sequence variability at three amino acid
positions (residues 198, 202, and 204) has been linked to the sialic
acid-binding capacity of T3 s1 [26,42]. Our structures readily
identify two of these residues, Arg202 and Pro204, as key
Figure 5. HA assay of T3D s1 point mutants. Purified reovirus
virions (1011 particles) were serially diluted in 0.05 ml of PBS in 96-well
U-bottom microtiter plates. Bovine erythrocytes were washed twice
with PBS and resuspended at a concentration of 1% (vol/vol) in PBS.
Erythrocytes (0.05 ml) were added to wells containing virus and
incubated at 4uC for at least 2 h. HA titer is expressed as 1011 particles
divided by the number of particles/HA unit. One HA unit equals the
number of particles sufficient to produce HA. *, P,0.05 in comparison
to T3D (Student’s t test).
doi:10.1371/journal.ppat.1002166.g005
Figure 4. s1 in complex with sialic acid in different linkages. (A)
View into the carbohydrate-binding site of the complex of s1 with a-
2,6-sialyllactose. (B) View into the carbohydrate-binding site of the
complex of s1 with a-2,8-disialyllactose. The orientation in panel (A)
differs by 60 degrees along a vertical axis from the orientations shown
in panel (B) and Figure 3 to provide a clearer view into of the binding
site. In both panels, s1 residues directly contacting the ligand are
shown in green, and surrounding residues making van der Waals
contacts are shown in cyan. The ligands are shown in ball-and-stick
representation, with carbons colored orange, oxygens colored red, and
nitrogens colored blue. Hydrogen bonds are represented with broken
black lines. The maps are simulated annealing omit difference density
maps contoured at 3s and displayed with a radius of 2.2 A˚ around the
ligands.
doi:10.1371/journal.ppat.1002166.g004
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determinants of sialic acid binding. The side chain of Arg202
forms a salt bridge with the sialic acid carboxylate group, while the
Pro204 side chain stacks against the Arg202 guanidinium group.
Moreover, the carbonyl oxygen in the peptide bond linking
Leu203 and Pro204 forms a hydrogen bond with the sialic acid.
Substitutions of either Arg202 or Pro204, as seen in the R202W
and P204L variants, would decrease the affinity for sialic acid, and
this is confirmed by the mutagenesis data. In contrast, the critical
role of residue 198 in ligand recognition is not apparent from the
crystal structures. Our mutagenesis data (Figure 5 and Figure 6), in
conjunction with previous results [42], clearly demonstrate that
Asn198 is required for successful sialic acid-dependent infection,
with viruses carrying an N198D mutation having substantially
reduced infectivity in MEL cells. However, the crystal structures
show that Asn198 is not involved in direct or water-mediated
contacts to any of the three oligosaccharides. Furthermore, the
Asn198 side chain is solvent-exposed, forming a single hydrogen
bond with the Asn189 side chain. Mutation of Asn189 to alanine
does not affect sialic acid binding (Figure 5 and Figure 6),
suggesting that the observed Asn198-Asn189 hydrogen bond is not
relevant for ligand recognition. It is possible that the introduction
of a negatively charged side chain at position 198, as is the case
with the N198D mutation, leads to long-range electrostatic effects
or structural rearrangements that indirectly affect receptor
binding. However, given the distance of Asn198 from the binding
site and its surface-exposed location, this possibility appears
remote. We think it more likely that Asn198 serves as a contact
point with a part of the functionally relevant glycan, which has not
been included in the structural analysis. Although our results
define the interactions of s1 with terminal sialic acid, the actual
receptor may be a more complex sialylated glycan, perhaps
carrying several branches. Such complex receptor structures,
which can be attached to proteins or lipids, have recently been
identified as the true ligands for several adenovirus and
polyomavirus capsid proteins [16–18]. Therefore, Asn198 may
well define a second receptor contact point for reovirus s1.
A large collection of structures of viruses or viral attachment
proteins in complex with sialylated oligosaccharide receptors is
available, and these have produced significant insights into
mechanisms of sialic acid binding, receptor specificity, and viral
pathogenesis [1–3,5,9,11,14,16–18,49–52]. However, the interac-
tions observed between T3D s1 and sialic acid differ in important
ways from those found in all other virus-receptor complexes,
offering new insights into the parameters that guide viral
attachment and specificity. In all cases in which structures are
available, the receptors are bound by a globular domain in a
region that projects farthest from the viral capsid and is easily
accessible for interactions with the cell surface. In contrast, the
highly elongated T3D s1 protein engages its carbohydrate ligand
at its midpoint, about 150 A˚ away from the region that projects
farthest from the virion. Although the s1 protein possesses some
flexibility at defined regions [19,22], the location of the sialic acid-
binding site would not appear optimal for engagement of
membrane-bound receptors that feature sialylated ligands close
to the membrane. The region of JAM-A that is engaged by the s1
head domain is fairly close to the membrane [36]. Even when
allowing for considerable flexibility between the s1 head and
body, it is difficult to envision a conformation in which the tail of
s1 is still inserted into the virus and the sialic acid binding site can
closely approach the membrane. However, s1 could more easily
engage sialic acid that projects far above the membrane, perhaps
by being located on a large protein or projecting from prominent
loops.
Prior to this study, structural information had been available
only for the C-terminal portion of the s1 protein [22]. Based on
analysis of that structure, as well as sequence comparisons with the
related adenovirus fiber protein, full-length s1 was predicted to
fold into three distinct regions: an N-terminal a-helical coiled coil
(termed the tail), a region containing eight consecutive b-spiral
repeats (the body), and a globular b-barrel (the head). Our
structural analysis of a fragment comprising the body and head
domains show that this model must be revised, as we find an
insertion of a short a-helical coiled coil that interrupts the b-spiral
sequence in the body, replacing one b-spiral repeat with a helical
structure. Thus, it is clear that the structure of s1 features several
transitions between a-helical and b-spiral regions. This topological
relationship differs from that of the adenovirus fiber, in which the
shaft domain is thought to consist entirely of b-spiral repeats [39].
Examination of the T3D body domain sequence shows that it
contains a nearly perfect heptad repeat pattern, which is typical for
a-helical coiled coils, in a short stretch of 14 residues (Figure 2). A
similar pattern is observed in the T1L and T2J s1 sequences, but
a proline residue within the consensus makes it unlikely that these
proteins also feature a continous a-helical coiled coil at the
equivalent location.
To our knowledge, the structures presented here are the first
examples of any fibrous viral protein engaging a ligand via its
repetitive fiber region. Other viral attachment proteins contain
fibrous- or stalk-like structures, but they usually engage receptors
with globular head domains placed on top of these structural
elements, as observed in complexes of adenovirus fiber proteins
with their receptors [7,15,18]. Globular head domains offer higher
variability in engaging ligands and can more easily create recessed
binding pockets suitable for high-affinity binding. Instead, fiber-
like structures generally feature short connections between their
repeating units and a relatively flat surface, limiting binding
options. However, inspection of the b-spirals in s1 reveals subtle
modifications in a single repeat that allow it to create a shallow
binding site for sialic acid. One of the hallmarks of b-spirals is a
highly conserved b-turn between two strands, involving residues at
positions g, h, i, and j (Figure 2). The residue at position j is usually
a proline or glycine. This turn is enlarged by two amino acids in
the s1 repeat that engages sialic acid, transforming the turn into a
small loop (Figure 7). Interestingly, Pro204 introduces a kink after
a b-strand, causing the chain to deviate from the b-spiral motif at
this position to provide a pocket for the ligand. Thus, alteration of
the typical repeating motif identifies a ligand-binding site in the
case of s1. It is conceivable that similar aberrations in other
fibrous protein sequences might also indicate binding sites. The
location of a sialic acid binding site in an elongated fiber-like
structure also raises the possibility of creating a small sialic acid
binding cassette that could be transferred into a variety of trimeric
fiber-like proteins constructed from a-helical coiled coils or b-
spirals. Our work thus enhances an understanding of reovirus-
Figure 6. Identification of s1 residues required for binding to cell-surface sialic acid. (A) Infection of murine fibroblast (L929) cells or (B)
murine erythroleukemia (MEL) cells by wild-type or point-mutant viruses. Cells were adsorbed with virus at an MOI of 1 PFU/cell. Following
incubation at room temperature for 1 h, the inoculum was removed, and cells were incubated at 37uC for 24 and 48 h. Viral titers were determined
by plaque assay. The results are expressed as viral yields (log10 titer at t = 24 or 48 h minus log10 titer at t = 0 h) for triplicate samples. Error bars
indicate S.D. *, P,0.05 in comparison to T3D (Student’s t test).
doi:10.1371/journal.ppat.1002166.g006
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glycan interactions and may also guide the construction of new
sialic acid binding platforms to facilitate structure-function
analyses and sialic acid-mediated cell targeting.
Materials and Methods
Protein Expression and Purification
The expression of soluble and properly folded T3D s1 trimers
was facilitated by appending a trypsin-cleavable trimerization
domain based on the GCN4 leucine zipper [41] N-terminally to a
cDNA encoding the entire s1 body and head domains (amino
acids 170–455). The construct was cloned into the pQE-80L
expression vector, which encodes a non-cleavable N-terminal
hexahistidine-tag. The protein was expressed in E. coli Rosetta 2
DE3 (Novagen) at 20uC for 16 h post-induction or by autoinduc-
tion at 20uC for 48–72 h. Bacteria were lysed by two passages
through an EmulsiFlex (Avestin) homogenizer and purified by Ni-
IMAC using His-Trap-FF columns (GE-Healthcare). The immo-
bilized protein was eluted by on-column digestion with 0.1 mg/ml
trypsin at a flowrate of 0.1 ml/min for 12 h. Size-exclusion
chromatography (Superdex-200, GE-Healthcare) was used as the
final purification step.
X-ray Structure Determination
Crystals were grown using 15% PEG200, 0.1 M MES (pH 6.5)
as a precipitant. The crystals belong to space group P21212 and
contain one trimer in the asymmetric unit. Complexes with
carbohydrate ligands were prepared by soaking crystals with the
respective carbohydrate prior to data collection. The crystals were
transferred into mother liquor supplemented with 10 mM
carbohydrate, incubated for 5 min, and cryoprotected by
incubation for 15 s in 35% PEG200, 0.1 M MES, 10 mM
carbohydrate (pH 6.5).
Diffraction data were collected at the beamlines PXI (SLS) and
ID14-4 (ESRF). Diffraction data were integrated and scaled using
XDS [53], and the structure was solved by molecular replacement
with AMoRe [54] using the structure of the T3D s1 head (PDB
ID 1KKE) as a search model. Refinement was performed with
Refmac5 [55] and Phenix [56], and model building was done in
Coot [57]. Ligands were fitted into weighted Fo-Fc difference
density maps at a contour level of 3s and refined using the CCP4
library and user-defined restraints. Coordinates and structure
factors for all three complexes have been deposited in the PDB
data bank (www.rcsb.org) with accession codes 3S6X (complex
with a-2,3-sialyllactose), 3S6Y (complex with a-2,6-sialyllactose)
and 3S6Z (complex with a-2,8-di-sialyllactose).
Cells
L929 cells [58] were maintained in Joklik’s minimum essential
medium (Sigma-Aldrich) supplemented to contain 5% fetal bovine
serum, 2 mM L-glutamine, 100 U/ml of penicillin, 100 mg/ml of
streptomycin, and 25 ng/ml of amphotericin B. MEL cells,
previously designated T3cl.2 cells [59], were maintained in Ham’s
F-12 medium (CellGro) supplemented to contain 10% fetal bovine
serum, 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml
streptomycin, and 25 ng/ml amphotericin B.
Viruses
Recombinant reoviruses were generated by plasmid-based
reverse genetics [43,44]. Reovirus strains rsT3D (wild type),
rsT3D-s1N198D, rsT3D-s1R202W, and rsT3D-s1P204L were
recovered using monolayers of L929 cells at approximately 90%
confluence (36106 cells) in 60-mm dishes (Costar) infected with
rDIs-T7pol [60] at an MOI of ,0.5 TCID50. At 1 h post-
infection, cells were co-transfected with ten plasmid constructs
representing the cloned T3D genome using 3 ml of TransIT-LT1
transfection reagent (Mirus) per mg of plasmid DNA [43]. Reovirus
strains rsT3D-s1N189A, rsT3D-s1S195A, rsT3D-s1R202A,
rsT3D-s1L203A, rsT3D-s1P204A, rsT3D-s1G205A, and
Figure 7. Structural adaption of the binding site. (A) Superposition of all seven b-spiral repeats. Repeat b3, which is shown in darker shading,
interacts with sialic acid and deviates markedly in its structure from the other repeats. Conserved hydrophobic residues are colored in blue, the
position in the b-turn that is usually occupied by proline or glycine is shown in magenta. Arg202 and Pro204, which are part of repeat b3, are
highlighted in red and yellow, respectively. (B) Superposition of a prototypical b-spiral repeat (b6) onto the sialic acid binding repeat b3. Amino acids
are shown in ball and stick representation, and residues Arg202 and Pro204 in b3 are labeled. Panel B is enlarged to provide a clearer view.
doi:10.1371/journal.ppat.1002166.g007
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rsT3D-s1N210A were recovered using BHK-T7 cells at 90%
confluence (approximately 36106 cells) seeded in 60-mm dishes.
Cells were co-transfected with five plasmids representing the
cloned T3D genome using 3 ml of TransIT-LT1 transfection
reagent (Mirus) per mg of plasmid DNA [44]. The amount of each
plasmid used for transfection was identical to that described for
L929 cell transfections. Following 3 to 5 days of incubation,
recombinant viruses were isolated from transfected cells by plaque
purification using monolayers of L929 cells [61]. For the
generation of s1 mutant viruses, pT7-S1T3D [43] was altered
by QuikChange (Stratagene) site-directed mutagenesis. To con-
firm sequences of the mutant viruses, viral RNA was extracted
from purified virions and subjected to Onestep RT-PCR (Qiagen)
using L1- or S1-specific primers. (Primer sequences are available
from the corresponding authors upon request.) The purified PCR
products were subjected to sequence analysis for the presence of
the introduced mutation in the S1 gene segment and the
noncoding signature mutation in the L1 gene segment [43].
Purified reovirus virions were prepared using second-passage
L929-cell lysate stocks of twice plaque-purified reovirus as
described [20]. Viral particles were Freon-extracted from infected
cell lysates, layered onto CsCl gradients, and centrifuged at
62,0006 g for 18 h. Bands corresponding to virions (1.36 g/cm3)
[62] were collected and dialyzed in virion-storage buffer (150 mM
NaCl, 15 mM MgCl2, 10 mM Tris-HCl pH 7.4). The concen-
tration of reovirus virions in purified preparations was determined
from an equivalence of one OD unit at 260 nm equals 2.161012
virions [62]. Viral titers were determined by plaque assay using
L929 cells [61].
HA Assay
Purified reovirus virions (1011 particles) were distributed into 96-
well U-bottom microtiter plates (Costar) and serially diluted
twofold in 0.05 ml of PBS. Calf erythrocytes (Colorado Serum
Co.) were washed twice with PBS and resuspended at a
concentration of 1% (vol/vol). Erythrocytes (0.05 ml) were added
to wells containing virus particles and incubated at 4uC for at least
2 h. A partial or complete shield of erythrocytes on the well
bottom was interpreted as a positive HA result; a smooth, round
button of erythrocytes was interpreted as a negative result. HA
titer is expressed as 1011 particles divided by the number of
particles/HA unit. One HA unit equals the number of particles
sufficient to produce HA. HA titers from three independent
experiments were compared using an unpaired Student’s t test as
applied in Microsoft Excel. P values of less than 0.05 were
considered statistically significant.
Reovirus Infection of L929 and MEL Cells
L929 cells or MEL cells (26105 cells/well) were plated in 24-
well plates (Costar) and incubated at 37uC for at least 2 h. Cells
were adsorbed with reovirus strains at an MOI of 1 PFU/cell.
Following incubation at room temperature for 1 h, cells were
washed three times with PBS and incubated at 37uC for 24 or
48 h. Samples were frozen and thawed twice, and viral titers were
determined by plaque assay [61]. For each experiment, samples
were infected in triplicate. Mean values from three independent
experiments were compared using an unpaired Student’s t test as
applied in Microsoft Excel. P values of less than 0.05 were
considered statistically significant.
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Nonstructural protein 1s is a critical determinant of hematogenous dissemination by type 1 reoviruses,
which reach the central nervous system (CNS) by a strictly blood-borne route. However, it is not known whether
1s contributes to neuropathogenesis of type 3 reoviruses, which disseminate by both vascular and neural
pathways. Using isogenic type 3 viruses that vary only in 1s expression, we observed that mice survived at a
higher frequency following hind-limb inoculation with 1s-null virus than when inoculated with wild-type
virus. This finding suggests that 1s is essential for reovirus virulence when inoculated at a site that requires
systemic spread to cause disease. Wild-type and 1s-null viruses produced comparable titers in the spinal
cord, suggesting that 1s is dispensable for invasion of the CNS. Although the two viruses ultimately achieved
similar peak titers in the brain, loads of wild-type virus were substantially greater than those of the 1s-null
mutant at early times after inoculation. In contrast, wild-type virus produced substantially higher titers than
the 1s-null virus in peripheral organs to which reovirus spreads via the blood, including the heart, intestine,
liver, and spleen. Concordantly, viral titers in the blood were higher following infection with wild-type virus
than following infection with the 1s-null mutant. These results suggest that differences in viral brain titers
at early time points postinfection are due to limited virus delivery to the brain by hematogenous pathways.
Transection of the sciatic nerve prior to hind-limb inoculation diminished viral spread to the spinal cord.
However, wild-type virus retained the capacity to disseminate to the brain following sciatic nerve transection,
indicating that wild-type reovirus can spread to the brain by the blood. Together, these results indicate that 1s
is not required for reovirus spread by neural mechanisms. Instead, 1s mediates hematogenous dissemination
within the infected host, which is required for full reovirus neurovirulence.
Many viral diseases occur as a consequence of systemic dis-
semination within the infected host. Some viruses, such as
herpes simplex virus (20, 28) and rabies virus (3, 39), spread
within their hosts by neural routes. Others, including human
immunodeficiency virus (42) and measles virus (47), use he-
matogenous pathways to spread systemically. Although the
general principles of virus dissemination are understood, little
is known about the viral and cellular determinants that govern
virus spread. Defining the mechanisms used by viruses to dis-
seminate within their hosts is essential to an understanding of
how viruses cause systemic disease and may foster develop-
ment of therapeutics that arrest viral replication prior to the
seeding of target tissues.
Mammalian orthoreoviruses (reoviruses) are highly tracta-
ble models for studies of viral pathogenesis. Reoviruses are
nonenveloped, icosahedral viruses that contain 10 segments of
double-stranded RNA (dsRNA) (24). In newborn mice, type 1
and type 3 reoviruses invade the central nervous system (CNS)
following oral or intramuscular inoculation but use different
routes and produce distinct pathological consequences. Type 1
reoviruses access the CNS by hematogenous routes and infect
ependymal cells, causing ependymitis and hydrocephalus (41,
45, 46). Type 3 reoviruses spread to the CNS by neural routes
(41) and infect neurons, causing lethal encephalitis (22, 41).
However, type 3 reoviruses also use hematogenous routes to
disseminate to other organs, including the heart, liver, and
spleen (1, 12). Serotype-specific differences in neurotropism
and disease segregate with the viral S1 dsRNA gene segment
(10, 38), which encodes attachment protein 1 and nonstruc-
tural protein 1s (33, 44). Receptor engagement is critical for
target cell selection by many viruses, suggesting that the 1
attachment protein is the primary determinant of viral tropism.
However, 1s is required for hematogenous dissemination of
type 1 reovirus to sites of secondary replication in mice (6).
Because of the serotype-specific differences in reovirus tro-
pism, routes of spread, and outcome of infection, it is possible
that the 1s protein from different serotypes mediates sero-
type-specific functions.
Protein 1s is a 14-kDa nonstructural protein encoded by
the viral S1 gene segment (7, 11, 33). The 1s open reading
frame (ORF) completely overlaps the 1 coding sequence;
however, 1s lies in a different reading frame (7–9, 11, 33).
Little amino acid sequence identity exists among the 1s pro-
teins from the different reovirus serotypes (7, 9). The only
feature of the 1s protein that is conserved across the sero-
types is a cluster of positively charged amino acids near the
amino terminus (7, 9). For type 3 reovirus, this cluster func-
tions as a nuclear localization signal (15). The 1s protein has
* Corresponding author. Mailing address: Lamb Center for Pediat-
ric Research, D7235 MCN, Vanderbilt University School of Medicine,
Nashville, TN 37232. Phone: (615) 343-9943. Fax: (615) 343-9723.
E-mail: terry.dermody@vanderbilt.edu.
† Present address: Institute for Virus Research, Kyoto University,
Kyoto 606-8507, Japan.
 Published ahead of print on 14 September 2011.
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been implicated in reovirus-induced cell cycle arrest at the
G2/M boundary (29, 30) and may function in reovirus neuro-
virulence by influencing reovirus-induced apoptosis in the mu-
rine CNS (16). However, interpreting these studies of 1s
function is complicated because the 1s-null mutant virus used
in previous experiments is not isogenic to the parental strain
from which it was derived (32). Thus, a role for 1s in the
pathogenesis of type 3 reovirus is undefined.
In this study, we used plasmid-based reverse genetics to
generate a 1s-null reovirus to determine how 1s influences
systemic dissemination of type 3 reovirus. Following intramus-
cular inoculation, mice infected with the 1s-null mutant sur-
vive at a higher frequency than those infected with wild-type
virus. This result suggests that 1s is a determinant of reovirus
virulence when reovirus is inoculated at a site that requires
systemic dissemination. Wild-type and mutant viruses pro-
duced equivalent titers in the spinal cord, indicating that 1s is
not required for reovirus invasion of the CNS. Although the
two viruses produced similar peak titers in the brain, titers of
the 1s-null mutant in the brain were markedly lower than
those of wild-type virus at early times postinfection. Viral
blood titers were substantially higher following infection with
wild-type virus than those produced by the 1s-null mutant. In
addition, titers of 1s-null virus in organs that reovirus accesses
via the bloodstream, including the heart, intestine, liver, and
spleen, were substantially lower than those produced by wild-
type virus. These data suggest that 1s is essential for reovirus
hematogenous spread within an infected host but dispensable
for dissemination by neural routes. Sectioning the sciatic nerve
prior to hind-limb inoculation diminished but did not eliminate
spread of wild-type virus to the brain. However, dissemination
of 1s-null virus to the brain was almost completely abolished
following sciatic nerve transection. These data indicate that
reovirus accesses the brain by a combination of hematogenous
and neural routes. Collectively, the results described in this
study suggest that reovirus trafficking to the brain via hema-
togenous dissemination precedes spread by neural routes and
that blood-borne viral transport is essential for reovirus neu-
rovirulence.
MATERIALS AND METHODS
Cell lines. HeLa cells were maintained in Dulbecco modified Eagle medium
supplemented to contain 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100
U/ml of penicillin, 100 g/ml streptomycin, and 25 ng/ml of amphotericin B
(Invitrogen). L929 cells were maintained in Joklik’s minimum essential medium
supplemented to contain 10% FBS, 2 mM L-glutamine, 100 U/ml of penicillin,
100 g/ml streptomycin, and 25 ng/ml of amphotericin B.
Viruses. Recombinant reoviruses were generated using plasmid-based reverse
genetics (19). Monolayers of L929 cells at approximately 90% confluence (3 
106 cells) in 60-mm-diameter dishes (Corning) were infected with rDIs-T7 pol at
a multiplicity of infection (MOI) of 0.5 50% tissue culture infective doses
(TCID50) per cell. At 1 h postinfection, cells were cotransfected with nine
plasmid constructs representing cloned gene segments from the strain type 3
Dearing (T3D) genome—pT7-L1T3D (2 g), pT7-L2T3D (2 g), pT7-L3T3D (2
g), pT7-M1T3D (1.75 g), pT7-M2T3D (1.75 g), pT7-M3T3D (1.75 g),
pT7-S2T3D (1.5 g), pT7-S3T3D (1.5 g), and pT7-S4T3D (1.5 g)—in com-
bination with 2 g of pBacT7-S1T3D or pBacT7-S1T3D 1s-null. For each, 3 l
of TransIT-LT1 transfection reagent (Mirus) was used per g of plasmid DNA.
Following 5 days of incubation, recombinant virus was isolated from transfected
cells by plaque purification using monolayers of L929 cells (43). For generation
of 1s-deficient virus, pBacT7-S1T3D (T3D S1; GenBank accession number
HM159619) was altered by QuikChange (Stratagene) site-directed mutagenesis.
To confirm sequences of the mutant virus, viral RNA was extracted from purified
virions and subjected to OneStep reverse transcription-PCR (RT-PCR) (Qia-
gen) using S1-specific primers. Primer sequences are available from the corre-
sponding author upon request. PCR products were analyzed following electro-
phoresis in Tris-borate-EDTA agarose gels or purified and subjected directly to
sequence analysis. The presence of a noncoding signature mutation in the L1
gene of viruses generated by plasmid-based rescue was confirmed using RT-PCR
and L1-specific primers (19).
Purified reovirus virions were generated using second- or third-passage L929
cell lysate stocks of twice-plaque-purified reovirus as described previously (13).
Viral particles were Freon extracted from infected cell lysates, layered onto 1.2-
to 1.4-g/cm3 CsCl gradients, and centrifuged at 62,000  g for 18 h. Bands
corresponding to virions (1.36 g/cm3) (36) were collected and dialyzed in virion
storage buffer (150 mM NaCl, 15 mM MgCl2, 10 mM Tris-HCl [pH 7.4]). The
concentration of reovirus virions in purified preparations was determined from
the following equivalence: 1 optical density at 260 nm (OD260) unit  2.1  1012
virions (36). Viral titer was determined by plaque assay using L929 cells (43).
Virus replication assays. Monolayers of cells in 24-well plates (Corning) were
adsorbed in triplicate with each reovirus strain at an MOI of 0.01, 0.1, or 1 PFU/cell
at room temperature for 1 h in serum-free medium, washed once with phosphate-
buffered saline (PBS), and incubated in serum-containing medium for various in-
tervals. Cells were frozen and thawed twice prior to determination of viral titer by
plaque assay using L929 cells (43). Viral yields were calculated according to the
following formula: log10yieldtx  log10(PFU/ml)tx  log10(PFU/ml)t0, where tx is the
time postinfection.
Assessment of 1s expression by indirect immunofluorescence. Monolayers of
HeLa cells (2  105 cells/well) grown on coverslips in 24-well plates were
adsorbed with reovirus at an MOI of 50 PFU/cell at room temperature for 1 h.
Following removal of the inoculum, cells were washed with PBS and incubated
in complete medium at 37°C for 18 h to permit completion of a single cycle of
viral replication. Monolayers were fixed with 1 ml of methanol at 20°C for at
least 30 min, washed twice with PBS, and blocked with 0.1% gelatin, 0.1% Tween
20 (Sigma), and 20% normal goat serum (Vector Laboratories) in PBS. For
detection of 1s, cells were washed with PBS and incubated with mouse mono-
clonal anti-1s antibody 2F4 (32) at a dilution of 1:500 in PBS with 0.1% gelatin,
2% normal goat serum, and 0.1% Tween 20. For detection of reovirus proteins,
cells were washed once with PBS and stained with polyclonal rabbit anti-reovirus
serum at a 1:1,000 dilution in PBS–0.5% Triton X-100 at room temperature for
1 h. Monolayers were washed twice with PBS–0.5% Triton X-100 and incubated
with a 1:1,000 dilution of Alexa 488- or Alexa 546-labeled anti-rabbit or anti-
mouse IgG (Invitrogen), respectively. Monolayers were washed with PBS, and
infected cells were visualized by indirect immunofluorescence using an Axiovert
200 fluorescence microscope (Carl Zeiss).
Infection of mice. C57BL/6J mice were obtained from Jackson Laboratory.
Swiss Webster mice were obtained from Harlan Biosciences. Animal husbandry
and experimental procedures were performed in accordance with Public Health
Service policy and approved by the Vanderbilt University School of Medicine
Institutional Animal Care and Use Committee.
Two-day-old mice were inoculated intramuscularly or intracranially with pu-
rified reovirus diluted in PBS. Intramuscular inoculations (10 l) were delivered
into the left hind limb (hamstring muscle) using a Hamilton syringe and 30-gauge
needle. Intracranial inoculations (5 l) were delivered into the left cerebral
hemisphere using a Hamilton syringe and 30-gauge needle (40). For analysis of
viral virulence, mice were monitored for weight loss and symptoms of disease for
25 days postinoculation. For survival experiments, mice were euthanized when
found to be moribund (defined by rapid or shallow breathing, lethargy, or
paralysis). Death was not used as an endpoint. Data from these experiments are
reported as “percent survival.” For analysis of virus replication, mice were eu-
thanized at various intervals following inoculation, and organs were collected
into 1 ml of PBS and homogenized by freezing, thawing, and sonication. For
analysis of viremia, mice were euthanized and decapitated at various intervals
following inoculation, and whole blood was collected from the neck into a 1-ml
syringe containing 100 l Alsever’s solution (Sigma). Viral titers in organ ho-
mogenates were determined by plaque assay using L929 cells.
Sciatic nerve sectioning. Two-day-old C57/BL6 mice were anesthetized by
hypothermia. The proper depth of anesthesia was assessed visually by absence of
a withdrawal reflex and lack of response to external stimuli. The area around the
incision site was cleaned with Betadine using a cotton swab. A 0.5-cm incision
was made along the back of the thigh using surgical scissors (Fine Science Tools).
The sciatic nerve was isolated using forceps (Fine Science Tools), and a segment
of the nerve was excised using surgical scissors. The incision was closed by
bringing the skin flaps into apposition and applying liquid skin (Webster Veter-
inary). The pups were warmed gradually by placement in a room temperature
cage. Following recovery of activity, pups were moved to a cage that had been
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placed atop a warming pad (Braintree Scientific). Pups were then inoculated
intramuscularly with 1  106 PFU of rsT3D or rsT3D 1s-null reovirus prior to
returning them to the dam. Mice were euthanized at 2 or 4 days following
inoculation, and organs were collected into 1 ml of PBS and homogenized by
freezing, thawing, and sonication.
Quantification of viral RNA using RT-qPCR. Total RNA was extracted from
200 l of whole blood/Alsever’s mixture using the High Pure viral RNA kit
(Roche). RNA was eluted into a final volume of 40 l. Reverse transcription-
quantitative PCR (RT-qPCR) was performed using the ABI 7000 sequence
detection system (Applied Biosystems) and EZ RT-PCR System (Roche) ac-
cording to the manufacturer’s instructions with minor modifications. Reovirus
RNA was quantified using 10 l of RNA extract. Forward (S4 83F, 5-CGCTT
TTGAAGGTCGTGTATCA-3) and reverse (S4 153R, 5-CTGGCTGTGCTG
AGATTGTTTT-3) primers corresponding to the viral S4 gene were used for
reverse transcription and quantitative PCR amplification. The S4-specific fluo-
rogenic probe used was 5-dFAM-AGCGCGCAAGAGGGATGGGA-BHQ-
1-3 (Biosearch Technologies). Reverse transcription was performed at 50°C for
2 min, followed by incubation at 60°C for 30 min. The reaction was terminated
by incubation at 95°C for 5 min. Subsequently, 40 cycles of quantitative PCR
were performed at 95°C for 15 s followed by incubation at 60°C for 30 s. Standard
curves relating threshold cycle values to copies of plasmid DNA template were
generated using 10-fold dilutions of a T3D S4-encoding plasmid (pT7-T3D S4)
(19). The concentration of viral RNA in each sample was extrapolated from
standard curves. The final S4 RNA copy number was calculated by multiplying by
4 the copy number obtained by extrapolation from the standard curve to account
for using one-quarter of the extracted RNA as a template.
Preparation of murine cortical neuron cultures. Primary cultures of mouse
cortical neurons were established using cerebral cortices of C57/BL6 embryos at
developmental day E15 (1). Fetuses were decapitated, brains were removed, and
cortical lobes were dissected and submerged in Hanks’ balanced salt solution
(Gibco) on ice. Cortices were incubated in 0.6 mg/ml trypsin solution at room
temperature for 30 min, washed twice, and manually dissociated twice with a
Pasteur pipette. Viable cells were plated at a density of 2.75  105 cells/ml in
24-well plates or on glass coverslips (BD Biosciences) placed in 24-well plates.
Wells were treated prior to plating with a 10-g/ml poly-D-lysine solution (BD
Biosciences) and a 1.64-g/ml laminin solution (BD Biosciences). Cultures were
incubated for the first 24 h in neurobasal medium (Gibco) supplemented to
contain 10% FBS (Gibco), 0.6 mM L-glutamine, 50 U/ml penicillin, and 50 g/ml
streptomycin. Cultures were thereafter maintained in neurobasal medium sup-
plemented to contain 1 B27 (Gibco), 50 U/ml penicillin, and 50 g/ml strep-
tomycin. One-half of the medium was replaced with fresh medium every 3 to 4
days. Neurons were allowed to mature for 7 days prior to use.
Statistical analysis. A log-rank test was used for comparison of survival curves.
For experiments in which viral titers were determined in an organ or blood, the
Mann-Whitney test was used to calculate two-tailed P values. This test is appro-
priate for experimental data that display a non-Gaussian distribution (31). When
all values are less than the limit of detection, a Mann-Whitney test P value cannot
be calculated. Statistical analyses were performed using Prism software (Graph-
Pad Software, Inc.).
RESULTS
Construction and characterization of a 1s-deficient type 3
reovirus. To determine the function of 1s in the pathogenesis
of type 3 reovirus, we used plasmid-based reverse genetics to
engineer a recombinant reovirus deficient in 1s expression
(19). The start codon for the 1s open reading frame was
disrupted by introducing a single nucleotide change (71AUG to
71ACG) into the plasmid encoding the cDNA for the S1 gene
segment derived from prototype type 3 reovirus strain T3D
(Fig. 1A). This mutation alters the 1s translational start site;
however, the coding sequence of the overlapping 1 open
reading frame is not affected. Viable viruses were recovered
that contain nine gene segments from T3D in combination
FIG. 1. Construction and characterization of a 1s-deficient type 3 reovirus. (A) Schematic of the reovirus S1 gene segment. The 1 ORF is
shown in black, the 1s ORF in white, and the 5 and 3 untranslated regions (UTRs) in gray. The wild-type (upper panel) and 1s-null (lower
panel) S1 gene alleles are shown. (B) rsT3D 1s-null does not express the 1s protein. HeLa cells were either mock infected or adsorbed with
rsT3D or rsT3D 1s-null at an MOI of 10 PFU/cell. At 24 h postinfection, cells were fixed and stained with a T3D 1s-specific monoclonal antibody
or reovirus-specific polyclonal antiserum. Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI).
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with either the wild-type or 1s-null T3D S1 gene segment.
Analysis of genomic dsRNA from each virus verified that the
rescued viruses contain the expected combination of gene seg-
ments (data not shown). The sequence of the S1 gene segment
and the integrity of the 1s translational start site from each
virus were confirmed by direct sequencing of viral RNA using
serotype-specific S1 primers (data not shown). The S1 genes of
both strains contained no additional mutations.
To confirm that altering the 1s translational start site pre-
vents 1s synthesis, we assessed 1s expression following in-
fection of HeLa cells with rsT3D or rsT3D 1s-null by indirect
immunofluorescence using T3D 1s-specific monoclonal anti-
body 2F4 (Fig. 1B). At 24 h postinfection, 1s protein was
detected in cells infected with wild-type virus but not in those
infected with the 1s-null mutant. In parallel, staining with
reovirus-specific polyclonal antiserum showed equivalent lev-
els of infection for both viruses. Thus, rsT3D and rsT3D 1s-
null are isogenic viruses that differ only in 1s expression.
The 1s protein is not required for reovirus replication in
cell culture. To determine whether 1s influences reovirus
growth in cell culture, we quantified viral yields following in-
fection of mouse L929 cells (Fig. 2A). Cells were infected with
rsT3D or rsT3D 1s-null at MOIs of 0.01 or 1 PFU per cell,
and viral titers were determined by plaque assay over a 48-h
time course. At each MOI tested, the replication kinetics and
yields of viral progeny for the 1s-null virus were indistinguish-
able from those of wild-type virus. Furthermore, no differences
in replication kinetics or viral yields were observed between
wild-type and 1s-deficient viruses following infection of HeLa
cells at an MOI of 0.1 or 1 PFU per cell (Fig. 2B). To deter-
mine whether 1s expression contributes to reovirus protein
production, we assessed steady-state viral protein levels by
immunoblotting using reovirus-specific antiserum after infec-
tion of murine L929 cells with rsT3D or rsT3D 1s-null (Fig.
2C). At both 24 and 48 h postinfection, no differences in
protein levels were observed between the wild-type and mutant
viruses. Together, these data are consistent with previous stud-
ies showing that 1s is dispensable for reovirus replication in
cultured cells (6, 32).
The 1s protein is a determinant of reovirus virulence fol-
lowing intramuscular inoculation. To determine whether 1s
contributes to reovirus virulence, we inoculated newborn C57/
BL6 mice intramuscularly with 106 PFU of rsT3D or rsT3D
1s-null (Fig. 3A). Reovirus normally infects by the oral route,
and spread to the CNS is required for reovirus-induced dis-
ease. However, reovirus strain T3D replicates poorly in the
gastrointestinal tract due to cleavage of its attachment protein
by intestinal proteases (4, 5, 23). Inoculation of type 3 reovi-
ruses intramuscularly leads to invasion of the brain by neural
routes (41). Infected mice were monitored for signs of disease
and euthanized when moribund. Approximately 75% of mice
infected with rsT3D succumbed to infection, whereas only 25%
of mice died following infection with rsT3D 1s-null. These
data indicate that 1s influences reovirus virulence following
inoculation of the virus at a peripheral site.
The 1s protein is dispensable for reovirus spread to the
CNS by neural routes. To determine whether 1s is required
for reovirus transmission by neural routes, we quantified viral
titers in hind limb muscle, spinal cord, and brain at days 4, 8,
and 12 following intramuscular inoculation of 106 PFU of
rsT3D or rsT3D 1s-null virus (Fig. 3B). In the hind-limb
muscle, the 1s-null virus produced higher titers than wild-type
virus at day 4. Titers at day 8 were equivalent for the two
viruses. At day 12, higher titers of the wild-type virus than of
the 1s-null mutant were detected. These data indicate that
the levels of infection were comparable between the wild-type
virus and 1s-null mutant at the site of inoculation.
In the spinal cord, titers of wild-type and 1s-null viruses at
days 4 and 8 were comparable. At day 12, wild-type virus
produced higher titers than mutant virus, but this difference
was not statistically significant. In the brain, titers of wild-type
virus were greater than those of the 1s-null mutant at days 1,
2, and 4. However, titers of the two viruses were equivalent at
days 8 and 12. Both viruses reached a peak titer approaching
107 PFU/brain. Sequence analysis of the S1 gene from 5 viruses
recovered from the spinal cord and brain of mice inoculated
with rsT3D 1s-null indicate that the mutant virus retained the
1s-null mutation. This finding indicates that the 1s-null virus
is stable in the murine CNS. Together, these data suggest that
the 1s protein is not required for reovirus spread by neural
routes. Rather, 1s appears to either facilitate reovirus trans-
port to the brain or enhance viral replication at that site.
The 1s protein modestly enhances reovirus neurovirulence
following intracranial inoculation. To determine whether 1s
influences reovirus virulence in the murine CNS, we inoculated
newborn C57/BL6 mice intracranially with 100 PFU of rsT3D
or rsT3D 1s-null (Fig. 4A). Mice were monitored for signs of
disease and euthanized when moribund. Animals infected with
either virus developed clinical signs of encephalitis and suc-
cumbed to infection. However, mice infected with rsT3D 1s-
null survived approximately 1 day longer than those inoculated
with wild-type virus. The average survival times for mice in-
fected with rsT3D or rsT3D 1s-null were 12 or 13 days,
respectively. Similar results were obtained in experiments per-
formed using Swiss Webster mice (Fig. 4B). The average sur-
vival time for mice infected with rsT3D 1s-null was slightly
longer than that for rsT3D-infected mice. However, the differ-
ence was not statistically significant. Together, these data sug-
gest that 1s contributes only modestly to reovirus virulence
following intracranial inoculation.
The 1s protein is not required for reovirus replication in
the murine CNS. To determine whether 1s expression is
required for reovirus replication within the murine CNS, we
inoculated newborn C57/BL6 mice intracranially with 100 PFU
of rsT3D or rsT3D 1s-null and quantified viral titers in the
brain at days 4, 8, and 12 postinoculation (Fig. 4C). Wild-type
and 1s-null viruses produced equivalent titers at days 4 and 8.
At day 12, the 1s-null mutant produced higher titers than
wild-type virus, although the difference was not statistically
significant. Similar results were obtained following intracranial
inoculation of Swiss Webster mice (Fig. 4D). Titers of wild-
type and 1s-null viruses were equivalent in the brain at each
time point assessed. These data indicate that 1s is dispensable
for reovirus replication in the murine CNS.
To test directly whether 1s influences reovirus replication
in neurons, we compared replication of wild-type and 1s-null
virus in primary cultures of murine cortical neurons (Fig. 5).
Viral yields following infection of primary neuronal cultures
were quantified at 24, 48, and 72 h following infection with
rsT3D or rsT3D 1s-null at an MOI of 1 PFU per cell. Wild-
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type virus produced slightly higher (although not statistically
significant) yields than the 1s-null virus at 24 h postinfection.
However, at 48 and 72 h, yields of the 1s-null virus were
indistinguishable from those of wild-type virus. Thus, 1s is
dispensable for reovirus replication in neurons.
The 1s protein enhances reovirus dissemination by hema-
togenous routes. To determine whether 1s is required for
reovirus spread by the bloodstream, newborn C57/BL6 mice
were inoculated intramuscularly with 106 PFU of rsT3D or
rsT3D 1s-null, and viral loads in the blood were quantified by
RT-qPCR at days 1, 2, and 4 postinoculation (Fig. 6). Low
levels of both viruses were detected at day 1. However, al-
though levels of wild-type virus increased substantially by days
2 and 4, loads of the 1s-null virus in the blood remained low
at these time points. By day 4, loads of wild-type virus were
approximately 10-fold higher than those of the 1s-null mu-
tant. These data indicate that 1s functions to promote the
establishment of reovirus viremia.
To determine whether 1s is required for hematogenous
spread of type 3 reovirus to tissues that support secondary
FIG. 2. The 1s protein is dispensable for reovirus growth in cell culture. (A) L cells were adsorbed with rsT3D or rsT3D 1s-null at MOIs
of 0.01 (left) or 1 (right) PFU/cell. (B) HeLa cells were adsorbed with rsT3D or rsT3D 1s-null at MOIs of 0.1 (left) or 1 (right) PFU/cell. Titers
of virus in cell lysates were determined by plaque assay at the indicated times postinfection. Results are expressed as mean viral yield or titers for
triplicate samples. Error bars indicate standard deviations. (C) Expression of reovirus proteins by wild-type and 1s-null viruses. Whole-cell lysates
from infected cells were immunoblotted using reovirus-specific antiserum.
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rounds of viral replication, we inoculated newborn C57/BL6
mice intramuscularly with 106 PFU of rsT3D or rsT3D 1s-null
virus (Fig. 7A). Viral titers were quantified in peripheral or-
gans that reovirus infects via the bloodstream, including heart,
liver, intestine, and spleen. At each time point assessed, titers
of wild-type virus in the organs assayed were greater than those
of the 1s-null virus. To determine whether 1s is required for
hematogenous reovirus spread following intracranial inocula-
tion, we inoculated newborn C57/BL6 mice intracranially with
100 PFU of rsT3D or rsT3D 1s-null and determined titers in
the heart, intestine, liver, and spleen at days 4, 8, and 12
postinoculation (Fig. 7B). Again, titers of wild-type virus were
higher than those of 1s-deficient virus in each of the target
organs tested at days 4 and 8. Only at day 12 did titers of the
1s-null mutant approximate, or in some cases exceed, those of
wild-type virus. These data suggest that 1s is required for
efficient reovirus spread by hematogenous routes, regardless of
the site of inoculation.
Analysis of S1 gene sequences of virus isolates from organs
containing disseminated 1s-null virus following intracranial
inoculation revealed a reversion to wild-type sequence in 20 of
47 viruses tested (43%). These data provide further support for
the contention that 1s acts to facilitate hematogenous reovi-
rus dissemination.
Reovirus disseminates to the brain by hematogenous and
neural routes. To determine whether type 3 reovirus can dis-
seminate to the brain using hematogenous pathways, we tran-
sected the sciatic nerve prior to hind limb inoculation. The
sciatic nerve is the principal neural conduit by which reovirus
spreads from the hind limb to the spinal cord (41). Sectioning
the sciatic nerve should inhibit virus transmission to the CNS
by neural routes but not affect spread by hematogenous path-
ways (41). The left sciatic nerve of two-day-old C57/BL6 mice
was transected prior to inoculation in the left hind limb muscle
with 106 PFU of rsT3D or rsT3D 1s-null virus. In parallel,
mice that were not subjected to sciatic nerve section were
inoculated intramuscularly with 106 PFU of rsT3D or rsT3D
1s-null virus. At 2 and 4 days postinoculation, viral titers were
quantified in the hind limb muscle, spinal cord, brain, heart,
intestine, liver, and spleen (Fig. 8). Titers of wild-type and
1s-null virus at the site of inoculation were unaffected by the
neurectomy (Fig. 8A). However, sciatic nerve sectioning re-
sulted in a modest decrease in spinal cord titers of both viruses
at day 2 and a 100-fold decrease at day 4 in comparison to
those in mice with intact sciatic nerves. This finding suggests
that viral spread to the spinal cord by neural pathways was
successfully interrupted by sciatic nerve transection. The resid-
ual virus in the spinal cord likely results from spread via the
femoral nerve, which enervates the quadriceps muscle that
opposes the hamstring muscle into which virus was inoculated.
Following disruption of neural transmission by sciatic nerve
section, rsT3D was still detected in the brain (Fig. 8A). Al-
though titers of wild-type virus in the spinal cord were reduced
100-fold compared to those in controls following sciatic nerve
transection, neurectomy reduced viral titers in the brain less
than 10-fold. In addition, viral titers in organs that reovirus
infects via the blood, including the heart, intestine, liver, and
spleen, were largely unaffected by sciatic nerve transection.
These findings confirm that spread to these organs is achieved
by hematogenous routes and indicate that hematogenous path-
ways disseminate type 3 reovirus to every organ system in the
animal, including the brain. Most strikingly, titers of the 1s-
null virus in the brain were markedly reduced following sciatic
nerve section. Thus, type 3 reovirus uses both neural and he-
matogenous routes to spread to the brain, and 1s is required
for dissemination only by the hematogenous pathway.
DISCUSSION
In this study, we found that nonstructural protein 1s is a
critical determinant of type 3 reovirus dissemination within its
host by hematogenous routes but is dispensable for spread by
neural pathways. Following intramuscular inoculation of new-
born mice, viral loads were markedly higher in the blood of
animals infected with wild-type virus than in those inoculated
with 1s-null virus. Concordantly, wild-type virus produced
higher titers in organs that reovirus targets via the blood-
stream, including the heart, intestine, liver, and spleen. In
contrast, wild-type and 1s-null viruses traffic to the spinal cord
with equivalent efficiency. Together, these data support a role
for 1s in promoting reovirus spread through the bloodstream
FIG. 3. (A) The 1s protein enhances reovirus virulence following
intramuscular inoculation. Newborn C57/BL6 mice were inoculated in
the left hind limb with 106 PFU of rsT3D or rsT3D 1s-null. Mice (n
19 for each virus strain) were monitored for survival for 25 days. *, P
0.001 as determined by log-rank test in comparison to rsT3D. (B) The
1s protein is not required for reovirus spread by neural routes. New-
born C57/BL6 mice were inoculated in the left hind limb with 106 PFU
of rsT3D or rsT3D 1s-null. At days 1, 2, 4, 8, and 12 postinoculation,
mice were euthanized, hind-limb muscle, spinal cord, and brain were
resected, and viral titers were determined by plaque assay. Results are
expressed as mean viral titers for 6 to 9 animals for each time point.
Error bars indicate standard errors of the means. *, P  0.05 as
determined by Mann-Whitney test in comparison to rsT3D.
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and indicate that 1s is dispensable for reovirus neurotrans-
mission.
Type 3 reoviruses disseminate within their hosts by hema-
togenous (1) and neural (41) pathways. Severing the sciatic
nerve prior to hind-limb inoculation blocks virus spread to the
spinal cord (41). This finding indicates that neural, but not
hematogenous, pathways are important for delivering reovirus
to the CNS. Consistent with the hypothesis that type 3 reovi-
ruses invade the CNS by neural routes, we found that titers of
wild-type and 1s-null viruses were equivalent in the spinal
FIG. 4. (A and B) The 1s protein modestly enhances reovirus neurovirulence after intracranial inoculation. (A) Newborn C57/BL6 mice were
inoculated intracranially with 100 PFU of rsT3D or rsT3D 1s-null. Mice (n  17 for each virus strain) were monitored for survival for 14 days.
*, P  0.005 as determined by log-rank test in comparison to rsT3D. (B) Newborn Swiss Webster ND4 mice were inoculated intracranially with
100 PFU of rsT3D or rsT3D 1s-null. Mice (n  8 to 12) were monitored for survival for 17 days. (C and D) The 1s protein is dispensable for
reovirus replication in the CNS. (C) Newborn C57/BL6 mice were inoculated intracranially with 100 PFU of rsT3D or rsT3D 1s-null. At days 4,
8, and 12 postinoculation, viral titers in the brain were determined by plaque assay. Results are expressed as mean viral titers for 5 to 8 animals
for each time point. Error bars indicate standard errors of the means. (D) Newborn Swiss Webster ND4 mice were inoculated intracranially with
100 PFU of rsT3D or rsT3D 1s-null. At days 4, 8, and 12 postinoculation, viral titers in the brain were determined by plaque assay. Results are
expressed as mean viral titers for 5 to 8 animals for each time point. Error bars indicate standard errors of the means.
FIG. 5. The 1s protein is not required for reovirus replication in
primary mouse neurons. Cortical neurons were harvested from C57/
BL6 mouse embryos at developmental day E15 and cultured for 7 days
prior to infection. Neurons were adsorbed with rsT3D or rsT3D 1s-
null at an MOI of 1 PFU/cell. Titers of virus in cell lysates were
determined by plaque assay at the indicated times postinfection. Re-
sults are expressed as mean viral yield for triplicate samples. Error bars
indicate standard deviations.
FIG. 6. The 1s protein is required for the establishment of reovi-
rus viremia. Newborn C57/BL6 mice were inoculated intramuscularly
with 106 PFU of rsT3D or rsT3D 1s-null. At days 1, 2, or 4 postin-
oculation, mice were euthanized, blood was collected, and viral ge-
nome copies in blood were determined by RT-qPCR. Results are
expressed as mean viral genome copies per animal for 3 to 5 animals
at each time point. Error bars indicate standard errors of the means. *,
P  0.05 as determined by Mann-Whitney test in comparison to
rsT3D.
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cord at each time point examined (Fig. 3B). In contrast, viral
titers in the brain were substantially higher at day 4 for mice
inoculated with wild-type virus in comparison to those infected
with the 1s-null mutant (Fig. 3B). These data suggest that
invasion of the brain by type 3 reovirus by neural pathways is
preceded by virus delivered hematogenously. At days 8 and 12
postinoculation, titers in the brain were equivalent for wild-
type and 1s-null virus (Fig. 3B), suggesting that the majority
of reovirus transport to the brain by neural pathways occurs
subsequent to delivery of virus to the brain via the blood-
stream.
To determine whether hematogenous mechanisms can dis-
seminate type 3 reovirus to the brain, we interrupted virus
transmission via neural routes by sectioning the sciatic nerve
prior to hind limb inoculation. Consistent with previous work
(41), we found that sciatic nerve transection markedly reduced
viral titers in the spinal cord (Fig. 8A), presumably as a con-
sequence of limited neural transmission. However, although
brain titers were diminished by sciatic nerve section, significant
levels of wild-type virus were detected at this site. In addition,
section of the sciatic nerve prior to inoculation with the 1s-
null virus almost completely eliminated its spread to the brain.
These results indicate that both hematogenous and neural
pathways function to disseminate type 3 reovirus to the brain.
How reovirus accesses the bloodstream after intramuscular
inoculation is not known. It also has not been determined
whether reovirus disseminates hematogenously using cell-free
or cell-associated mechanisms. Following viral replication in
the hind limb muscle (12), virus may reach the blood by in-
fecting endothelial cells that form the lymphatic and blood
FIG. 7. (A) The 1s protein is required for hematogenous reovirus
dissemination following intramuscular inoculation. Newborn C57/BL6
mice were inoculated in the left hind limb with 106 PFU of rsT3D or
rsT3D 1s-null. At days 1, 2, 4, 8, and 12 postinoculation, mice were
euthanized, the organs shown were resected, and viral titers were
determined by plaque assay. Results are expressed as mean viral titers
for 6 to 9 animals for each time point. Error bars indicate standard
errors of the means. *, P  0.05 as determined by Mann-Whitney test
in comparison to rsT3D. (B) The 1s protein enhances reovirus dis-
semination following intracranial inoculation. Newborn C57/BL6 mice
were inoculated intracranially with 100 PFU of rsT3D or rsT3D 1s-
null. At days 4, 8, and 12 postinoculation, mice were euthanized, the
organs shown were resected, and viral titers were determined by
plaque assay. Results are expressed as mean viral titers for 5 to 8
animals for each time point. Error bars indicate SEM. *, P  0.05 as
determined by Mann-Whitney test in comparison to rsT3D.
FIG. 8. Reovirus disseminates to the CNS by hematogenous and
neural routes. The left sciatic nerve of newborn C57/BL6 mice was
sectioned prior to inoculation in the left hind limb with 106 PFU of
rsT3D or rsT3D 1s-null. In parallel, mice in which the left sciatic
nerve was not sectioned were inoculated in the left hind limb with 106
PFU of rsT3D or rsT3D 1s-null. At days 2 and 4 postinoculation,
mice were euthanized, hind limb muscle, spinal cord, and brain
(A) and heart, intestine, liver, and spleen (B) were resected, and viral
titers were determined by plaque assay. Results are expressed as mean
viral titers for 6 animals for each time point. Error bars indicate
standard errors of the means. *, P  0.05 as determined by Mann-
Whitney test in comparison to animals in which the sciatic nerve was
not sectioned.
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vessels that supply muscle tissue. Alternatively, virus may infect
phagocytic cells that subsequently migrate to lymphatic chan-
nels and eventually the bloodstream. Based on these possibil-
ities, we think that there are three mechanisms by which 1s
may promote reovirus dissemination following intramuscular
inoculation. First, 1s may be essential for replication in a cell
type that is required for hematogenous spread, such as lym-
phocytes or mononuclear cells. Second, 1s may trigger apop-
tosis in cells at the site of viral inoculation (16), which is
required for viral release and subsequent bloodstream inva-
sion. Third, 1s may inhibit some component of the host an-
tiviral response to reovirus infection. It is possible that 1s
disrupts innate or adaptive immune mechanisms that allow
reovirus to evade immune detection. In this scenario, the ab-
sence of 1s would lead to more efficient reovirus clearance.
Although titers of wild-type and 1s-null virus in the brain
are equivalent at day 4 following intracranial inoculation, only
a small fraction of infected animals contain 1s-null virus in
other organs in comparison to those infected with wild-type
virus (Fig. 7B). The percentage of organs with disseminated
1s-null virus increases at day 8, and by day 12, titers of the
1s-null virus approximate those of wild-type virus. We envi-
sion three possibilities to explain the kinetics of reovirus dis-
semination from the brain following intracranial inoculation.
First, the block to hematogenous dissemination for the 1s-
null virus may not be absolute, and a small percentage of the
virus may reach the bloodstream even in the absence of 1s
expression. Thus, the low titers of 1s-null virus in peripheral
organs results from this limited level of disseminated virus that
is capable of seeding organs such as the heart, liver, and spleen.
Second, virus might spread from the brain by neural pathways
and thus not require functional 1s for this mode of transit.
Much like the vasculature, neuronal pathways traverse every
organ in the animal and provide a direct conduit for virus to
access peripheral sites. The delayed kinetics with which the
1s-null virus spreads to peripheral organs would be consistent
with the idea that bloodstream dissemination is more rapid
than neural dissemination. Third, hematogenous spread of the
1s-null virus may result from reversion of the 1s-null muta-
tion to the wild type. In our experiments, a substantial portion
of the disseminated 1s-null virus had reverted to the wild
type, supporting this possibility and further underscoring the
importance of 1s in promoting viremic spread. These
mechanisms are not mutually exclusive, and it is possible
that reovirus disseminates systemically from the brain fol-
lowing intracranial inoculation by a combination of neural
and hematogenous pathways.
The means by which reovirus traffics within neurons is not
known. The administration of colchicine to inhibit fast axonal
transport (18, 35) prior to intramuscular inoculation inhibits
spread of virus to the spinal cord (41). In contrast, transport to
the spinal cord is not affected by treatment with 	-	-imino-
dipropronitrile (41), which selectively inhibits slow axonal
transport (14). These data indicate that fast axonal transport
pathways facilitate virus spread from the hind-limb muscle
through the sciatic nerve to the spinal cord and presumably to
the brain. However, the delay in invasion of the brain by the
1s-null virus suggests that neural transmission of virus from
the spinal cord to the brain is not rapid. Other viruses that
traffic by neural routes from peripheral sites to the brain using
fast axonal transport reach the brain with rapid kinetics (25,
48). For example, poliovirus is detected in the spinal cord
within 2 h and reaches the brain by 24 h following intramus-
cular inoculation (21). Thus, it is possible that a mechanism
other than fast axonal transport mediates transit of reovirus
from the spinal cord to the brain.
Reovirus serotypes differ in tropism within the murine CNS
(22, 45, 46). These differences segregate with the S1 gene (10,
38), which encodes attachment protein 1 and nonstructural
protein 1s (33, 44). We previously demonstrated that type 1
reovirus 1s protein is not required for viral infection and
replication in the mouse brain (6). In this study, we found that
a type 3 1s-null virus replicates in the murine CNS as effi-
ciently as wild-type virus (Fig. 4B and C). Moreover, identical
cell types and brain regions are infected by wild-type and
1s-null viruses (data not shown). The 1s protein also is
dispensable for replication in primary cultures of neurons (Fig.
5). Collectively, these findings demonstrate that 1s is not a
determinant of viral tropism or replication in the brain. In-
stead, 1s mediates hematogenous spread within the infected
host. Differences in viral tropism in the murine CNS appear to
be governed by attachment protein 1. It remains unclear why
infection with type 1 and type 3 reoviruses differs in the mouse
brain. However, our work clearly indicates that 1s does not
influence this difference; rather, the basis for this distinction is
likely differential binding to host cell receptors by the 1 pro-
tein.
Following intramuscular inoculation, the survival of mice
infected with the 1s-null mutant was markedly increased com-
pared to that of mice infected with wild-type virus (Fig. 3A). It
is possible that systemic infection, leading to disease in multi-
ple organ systems, is a major contributor to reovirus-induced
mortality. In experimental mouse models, reovirus can cause a
variety of diseases, including myocarditis (34), hepatitis (17, 26,
27), and biliary obstruction (2). Following intramuscular inoc-
ulation, higher titers of wild-type virus than of the 1s-null
mutant at sites of secondary replication may cause increased
injury to other organ systems that leads to the dramatic differ-
ences in survival. The kinetics of reovirus delivery to the CNS
also may be critical for the onset of encephalitis. Susceptibility
to reovirus encephalitis is age dependent, and mice are refrac-
tory to reovirus disease when inoculated later than 8 days of
age (37). It is possible that titers of the 1s-null mutant in the
brain do not reach the threshold required to cause disease
within the necessary time frame.
We previously showed that the 1s protein is required for
hematogenous spread of type 1 reoviruses (6), which dissemi-
nate within the host by strictly blood-borne mechanisms. A
type 1 1s-null virus replicates equivalently to wild-type virus
in the intestine following peroral inoculation. Although both
viruses are taken up by Peyer’s patches, only the wild-type virus
spreads to the mesenteric lymph node and bloodstream. These
findings suggest that 1s is essential for reovirus spread from
intestinal lymphatics to the circulation, thereby allowing the
establishment of viremia and dissemination to sites of second-
ary replication. Here, we demonstrate that type 3 reovirus 1s
promotes viral bloodstream dissemination but is dispensable
for transmission by neural routes. Collectively, these studies
suggest that following replication at a site of inoculation, reo-
viruses use a serotype-independent pathway that requires 1s
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to disseminate through the lymphatic-hematogenous system to
organs that support secondary viral replication. This work re-
veals how different mechanisms of dissemination contribute to
reovirus pathogenesis and provides insight into the events at
the pathogen-host interface that lead to systemic infection and
disease.
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CD14KO, but not TLR2KO, mice (Fig. 4B and
table S1). Thus, our results support a model (fig.
S7) whereby LPS-induced signaling drives a
viral “subversion” pathway via IL-10 production
that promotes viral transmission to successive
generations.
Detailed analysis of the actual viral load in
subsequent generations of infected IL-10KO and
IL-6KO mice revealed that it was reduced grad-
ually and that it took different numbers of pas-
sages for various families to completely eliminate
the virus (table S1 and fig. S8). Thus, it appears
that, in early generations, a high viral load can
compensate for the loss of the TLR4-dependent
subversion pathway and overpower the adaptive
immune response. However, the virus is eventu-
ally lost in each infected mouse pedigree, as the
virus load is reduced with each subsequent pas-
sage (fig. S8).
Commensal microbiota are required for many
homeostatic functions of the intestinal mucosa
and other barrier tissues. Microbiota control tis-
sue repair (16), induction of tolerance to self
[including tolerance to itself (17) and to auto-
antigens of the host (18)], and oral tolerance of
adults to ingested antigens (19, 20). At present, it
is unknown whether neonatal oral tolerance is
also dependent onmicrobiota or whetherMMTV
induces neonatal oral tolerance to itself by a
uniquemechanism available to retroviruses. Com-
mensals interact with various pathogens and pro-
tect the host against infection with pathogenic
and opportunistic bacteria (21), protozoa (22),
and fungi (23) or facilitate infection with hel-
minthes (24). However, the role of commensal
bacteria in viral transmission and/or pathogenesis
is only beginning to unravel. It is highly likely
that bacterial microbiota can play both protective
(25) and abetting roles (present report) in their
interactions with viruses. The lack of knowledge
in this area makes it important to expand such
investigations to other systems. It is not yet clear
whether other viruses take advantage of bacte-
rial products, such as LPS, to achieve successful
transmission. Retroviruses transmitted through
mucosal surfaces may also use similar strat-
egies. In humans, the highest risk of human
immunodeficiency virus (HIV) transmission oc-
curs across mucosal surfaces among individuals
who practice receptive anal intercourse (26), and
risk is also high in infants breastfed by HIV-
infected mothers (27, 28). This study sheds light
on the previously unknown role of commensal
microbiota in retroviral pathogenesis and suggests
new approaches to the prevention ofmucosal trans-
mission, viral-specific vaccination, and therapies.
References and Notes
1. E. P. Browne, D. R. Littman, PLoS Pathog. 5, e1000298
(2009).
2. A. W. Hardy, D. R. Graham, G. M. Shearer,
J. P. Herbeuval, Proc. Natl. Acad. Sci. U.S.A. 104,
17453 (2007).
3. M. Kane et al., Immunity 35, 135 (2011).
4. M. H. Malim, M. Emerman, Cell Host Microbe 3, 388 (2008).
5. U. Dittmer et al., Immunity 20, 293 (2004).
6. B. A. Jude et al., Nat. Immunol. 4, 573 (2003).
7. R. Medzhitov, P. Preston-Hurlburt, C. A. Janeway Jr.,
Nature 388, 394 (1997).
8. A. Poltorak et al., Science 282, 2085 (1998).
9. T. Kawai, S. Akira, Nat. Immunol. 11, 373 (2010).
10. J. C. Rassa, J. L. Meyers, Y. Zhang, R. Kudaravalli,
S. R. Ross, Proc. Natl. Acad. Sci. U.S.A. 99, 2281 (2002).
11. T. V. Golovkina, J. P. Dudley, S. R. Ross, J. Immunol. 161,
2375 (1998).
12. P. Marrack, E. Kushnir, J. Kappler, Nature 349, 524
(1991).
13. D. A. Hill, D. Artis, Annu. Rev. Immunol. 28, 623 (2010).
14. T. V. Golovkina, M. Shlomchik, L. Hannum,
A. Chervonsky, Science 286, 1965 (1999).
15. F. E. Dewhirst et al., Appl. Environ. Microbiol. 65, 3287
(1999).
16. S. Rakoff-Nahoum, J. Paglino, F. Eslami-Varzaneh,
S. Edberg, R. Medzhitov, Cell 118, 229 (2004).
17. S. Rakoff-Nahoum, R. Medzhitov, Mucosal Immunol. 1,
(Suppl 1), S10 (2008).
18. L. Wen et al., Nature 455, 1109 (2008).
19. M. C. Moreau, G. Corthier, Infect. Immun. 56, 2766
(1988).
20. N. Sudo et al., J. Immunol. 159, 1739 (1997).
21. B. Stecher, W. D. Hardt, Trends Microbiol. 16, 107
(2008).
22. A. Benson, R. Pifer, C. L. Behrendt, L. V. Hooper,
F. Yarovinsky, Cell Host Microbe 6, 187 (2009).
23. M. J. Wargo, D. A. Hogan, Curr. Opin. Microbiol. 9,
359 (2006).
24. K. S. Hayes et al., Science 328, 1391 (2010).
25. T. Ichinohe et al., Proc. Natl. Acad. Sci. U.S.A. 108,
5354 (2011).
26. R. A. Royce, A. Seña, W. Cates Jr., M. S. Cohen, N. Engl.
J. Med. 336, 1072 (1997).
27. R. Nduati et al., JAMA 283, 1167 (2000).
28. J. H. Humphrey et al.; ZVITAMBO study group, BMJ 341,
c6580 (2010).
Acknowledgments: We thank B. Theriault and A. Vest for
their help in monitoring gnotobiotic animals. This
work was supported by T32GM007183 to M.K., K.K.,
and C.M.; by T32 AI065382-01 to L.C.; by Juvenile
Diabetes Research Foundation grants 2005-204 and
2007-353; by the National Institute of Allergy and
Infectious Diseases (NIAID) NIH AI082418 and the
National Institute of Diabetes and Digestive and Kidney
Diseases, NIH, Digestive Disease Research Core Center
grant DK42086 to A.V.C.; by National Cancer Institute,
NIH, grant CA100383 and NIAID grant AI090084 to
T.V.G.; and by a grant (P30 CA014599) to The University
of Chicago. A material transfer agreement is required
for use of the SPF and GF C3H-based mutant strains of
mice. The data reported in this paper are tabulated in the
main paper and the supporting online material.
Supporting Online Material
www.sciencemag.org/cgi/content/full/334/6053/245/DC1
Materials and Methods
Figs. S1 to S8
Table S1
References (29–48)
5 July 2011; accepted 24 August 2011
10.1126/science.1210718
Intestinal Microbiota Promote
Enteric Virus Replication and
Systemic Pathogenesis
Sharon K. Kuss,1 Gavin T. Best,1 Chris A. Etheredge,1* Andrea J. Pruijssers,2,3
Johnna M. Frierson,3,4 Lora V. Hooper,1,5,6 Terence S. Dermody,2,3,4 Julie K. Pfeiffer1†
Intestinal bacteria aid host health and limit bacterial pathogen colonization. However, the influence
of bacteria on enteric viruses is largely unknown. We depleted the intestinal microbiota of mice with
antibiotics before inoculation with poliovirus, an enteric virus. Antibiotic-treated mice were less
susceptible to poliovirus disease and supported minimal viral replication in the intestine. Exposure to
bacteria or their N-acetylglucosamine–containing surface polysaccharides, including lipopolysaccharide
and peptidoglycan, enhanced poliovirus infectivity. We found that poliovirus binds lipopolysaccharide,
and exposure of poliovirus to bacteria enhanced host cell association and infection. The pathogenesis
of reovirus, an unrelated enteric virus, also was more severe in the presence of intestinal microbes.
These results suggest that antibiotic-mediated microbiota depletion diminishes enteric virus infection
and that enteric viruses exploit intestinal microbes for replication and transmission.
Enteric viruses encounter up to 10
14 bacteria
in the mammalian intestine (1). It is un-
clear whether commensal microorganisms
affect enteric viruses. Poliovirus is an enteric hu-
man pathogen transmitted by the fecal-oral route
and serves as a model for enteric virus infec-
tions (2). Orally acquired poliovirus undergoes a
primary replication cycle in the gastrointestinal
tract before dissemination. Poliovirus occasion-
ally disseminates from the intestine to the central
nervous system, which results in paralytic polio-
myelitis days to weeks after initial infection in the
gastrointestinal tract. A key question is whether
microbiota influence viral replication in the gastro-
intestinal tract to augment systemic dissemination.
To investigate the effect of intestinal micro-
biota on poliovirus infection, mice susceptible to
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diatrics, Vanderbilt University School of Medicine, Nashville,
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munology, University of Texas Southwestern Medical Center,
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poliovirus were treated with antibiotics to deplete
microbes, and viral diseasewasmonitored (fig. S1)
(3). Murine poliovirus infection requires expres-
sion of the human poliovirus receptor, PVR (4–6).
PVR-transgenic mice (PVRtg), however, are not
susceptible to oral poliovirus infection unless ren-
dered immunodeficient by interferon-a/b recep-
tor gene inactivation (PVRtg-Ifnar1−/−) (7, 8).
PVRtg-Ifnar1−/− mice were untreated or treated
orally with four antibiotics before oral inocu-
lation with poliovirus. Antibiotic treatment re-
duced culturable intestinal bacteria by amillionfold
(Fig. 1A). The mortality of untreated mice was
twice that of antibiotic-treated mice (Fig. 1B).
Reintroduction of fecal bacteria into antibiotic-
treated mice enhanced poliovirus disease, which
suggested that microbiota promote poliovirus
pathogenesis. However, when the intestinal
lumenwas bypassed by intraperitoneal inocula-
tion of poliovirus, pathogenesis was microbiota-
independent (Fig. 1C and fig. S2). Given that
orally inoculated poliovirus enters the intestine
and encounters the large number of bacteria that
reside there, the microbiota-mediated enhance-
ment of poliovirus pathogenesis in orally inocu-
lated mice is likely initiated in the intestine.
To determine whether mice harboring micro-
biota support more efficient poliovirus replication
than mice with depleted microbiota, we quanti-
fied viral titers from fecal samples (Fig. 1D and
fig. S3A), because poliovirus was undetectable
in intestinal tissue (fig. S4), and minimal intesti-
nal pathology was evident (fig. S5). Peak polio-
virus titers in feces from antibiotic-treated animals
were lower than those from untreated mice, but
titers from antibiotic-treated mice were higher at
later times. Prolonged shedding from antibiotic-
treated mice was due to slower peristalsis, because
dye transit also was delayed (fig. S6) (9). We
postulated that increased poliovirus titers from
antibiotic-treated mice at late times might be due
to extended shedding of unreplicated inoculum
virus. To differentiate between replicated and in-
oculum virus, we first quantified fecal shedding of
poliovirus from nonpermissive mice lacking PVR
and observed elevated late titers in antibiotic-
treated mice, which suggested that total viral titers
in feces and replication are not linked (fig. S3B).
We then quantified viral replication in PVR mice
using light-sensitive poliovirus. Poliovirus propa-
gated in the presence of neutral red dye is sensitive
to light-induced inactivation by RNA cross-linking
but loses light sensitivity upon replication in the
dark inside mice, facilitating assessment of rep-
lication (10). We orally inoculated untreated or
antibiotic-treated mice with light-sensitive po-
liovirus and collected feces in the dark. Fecal
viruses were light-exposed or unexposed and
quantified to determine replication status (fig.
S7). PVRtg-Ifnar1−/− and PVRtgmice harboring
microbiota supported efficient intestinal polio-
virus replication, whereas antibiotic-treated mice
did not (Fig. 1, E and F). Therefore, total fecal
titers do not reflect viral replication, a fact only
revealed by using light-sensitive viruses. More-
over, poliovirus intestinal replication was equiv-
alent in Ifnar1M +/+ and Ifnar1−/− mice, which
suggested that intestinal replication was IFNAR-
independent. Because poliovirus infection was le-
thal for a fraction of antibiotic-treated mice (Fig.
1B), it is possible that either minimal viral rep-
lication was sufficient for lethality or inoculum
virus breached the epithelium and replicated
in extraintestinal sites, occasionally initiating dis-
ease. Collectively, these results indicate that the
microbiota enhance gastrointestinal poliovirus
replication.
We gathered several lines of evidence sug-
gesting that diminished poliovirus replication and
disease in antibiotic-treated mice is due to mi-
crobiota depletion rather than direct effects of
antibiotic treatment. We first tested whether an-
tibiotics directly affect poliovirus and found that
Fig. 1. Poliovirus pathogenesis, shedding, and replication in microbiota-depleted mice. (A) Bacterial
loads in feces. PVRtg-Ifnar1−/− mice (n = 4 to 7) were untreated, antibiotic-treated (Abx) for 10 days, or
antibiotic-treated for 8 days and recolonized for 2 days with fecal bacteria (Abx + recol). Feces were plated
and grown anaerobically, yielding colony-forming units (CFU) per milligram of feces. (B) Survival of
PVRtg-Ifnar1−/−mice orally inoculated with poliovirus (untreated, n = 30; Abx, n = 26; Abx + recol, n = 8).
*P = 0.012, log-rank test. (C) Survival of PVRtg-Ifnar1−/−mice intraperitoneally inoculated with poliovirus
(n = 10 mice each). (D) Poliovirus shedding from PVRtg-Ifnar1−/− mice. Mice were orally inoculated with
poliovirus, feces were collected (n = 2 to 26 per interval), and poliovirus was isolated and quantified by
plaque assay, yielding plaque-forming units (PFU) per milligram of feces. (E and F) Poliovirus replication
in intestinal tracts of PVRtg-Ifnar1−/− (E) or PVRtg (F) mice orally inoculated with light-sensitive poliovirus
(n = 3 to 9 mice per interval). Feces were harvested, and virus was quantified with or without light
exposure to determine percent replication. Symbols represent means + SEM, *P < 0.05, **P < 0.01,
Student’s t test. n = 2 to 6 experiments for all.
Fig. 2. The effects of an-
tibiotic treatment on po-
liovirus replication and
pathogenesis. (A) Polio-
virus replication kinetics
in MEFs and HeLa cells
with or without antibi-
otics. (B) Fecal bacterial
loads from untreated or
antibiotic-treatedmice har-
boring antibiotic-resistant
(abxR) bacteria. Feces were
plated on rich medium
with or without four an-
tibiotics. (C) Survival of
PVRtg-Ifnar1−/−mice oral-
ly inoculated with polio-
virus premixed with four
antibiotics (Untreated+abx
PV, n = 9 mice) or polio-
virus alone in antibiotic-treated mice harboring AbxR bacteria (Abx + abxR, n = 8 mice). (Results from
untreated and antibiotic-treated mice are from Fig. 1B.) (D) Replication of light-sensitive poliovirus in
untreated mice receiving poliovirus + antibiotics inoculum and antibiotic-treated mice harboring abxR
bacteria in comparison with antibiotic-treated mice. (Results from antibiotic-treated mice are from
Fig. 1E.) Each symbol represents mean T SEM. (A) and (B), n = 2 to 5 experiments, (C) and (D) are
from a representative experiment.
14 OCTOBER 2011 VOL 334 SCIENCE www.sciencemag.org250
REPORTS
 
o
n
 S
ep
te
m
be
r 4
, 2
01
2
w
w
w
.s
ci
en
ce
m
ag
.o
rg
D
ow
nl
oa
de
d 
fro
m
 
poliovirus replication kinetics were identical in
the presence and absence of antibiotics in HeLa
cells andPVRtgmouse embryo fibroblasts (MEFs)
(Fig. 2A). We next assayed poliovirus replication
and pathogenesis in antibiotic-treated mice har-
boring antibiotic-resistant bacteria. For these ex-
periments, we treated PVRtg-Ifnar1−/−micewith
antibiotics to select antibiotic-resistant micro-
biota (fig. S8). After several weeks, fecal bac-
teria were insensitive to antibiotics in vitro (Fig.
2B). The strain resistant to multiple antibiotics
was identified as Ochrobactrum intermedium,
a Gram-negative aerobe, by 16S ribosomal DNA
sequencing of fecal-derived subclones (fig. S9).
Poliovirus replicated and was pathogenic in
antibiotic-treated mice harboringO. intermedium
(Fig. 2, C and D). Finally, poliovirus mixed with
antibiotics before oral inoculation of mice repli-
cated and was pathogenic (Fig. 2, C and D).
Therefore, diminished poliovirus replication and
pathogenesis in antibiotic-treated mice is not due
to direct antiviral effects of antibiotics.
Because all enteric viruses encounter intes-
tinal bacteria within the host, we examined the
specificity of the microbiota effects using reo-
virus, an enteric virus that infects most mam-
mals (11). Although immunocompetent adult
mice do not display overt reovirus disease symp-
toms, immunocompromised adult mice devel-
op nonfatal disease after oral inoculation with
reovirus strain T3SA+. We orally inoculated un-
treated or antibiotic-treated immunocompromised
PVRtg-Ifnar1−/− mice with reovirus. Feces from
untreated mice were yellow, oily, and hardened,
typical of biliary obstruction from T3SA+ reo-
virus replication and damage (12), whereas fe-
ces from antibiotic-treated mice appeared normal
(Fig. 3, A and B). Furthermore, analysis of in-
testines revealed severe reovirus-induced pathol-
ogy, with enlarged Peyer’s patches in untreated,
but not antibiotic-treated, mice (Fig. 3, C and
D). Reovirus titers in intestines from untreated
mice were significantly higher than those from
antibiotic-treated mice (Fig. 3E). These results
suggest that intestinal microbes promote reovirus
disease and, therefore, may promote infection
with other enteric viruses.
The microbiota-dependent enhancement of
poliovirus replication and pathogenesis could be
mediated by microbiota-induced host effects, vi-
ral effects, or both. To discriminate between these
possibilities, we investigated whether intestinal
microbes alter poliovirus infectivity. First, we
tested whether poliovirus infectivity was altered
by exposure to intestinal microbiota in vivo. We
orally inoculated untreated, antibiotic-treated, and
germ-free mice with poliovirus; harvested lume-
nal contents from the lower small intestine 2 hours
postinfection; and quantified infectivity of iso-
lated poliovirus in primary MEFs and HeLa cells.
The infectivity in MEFs of poliovirus isolated
from untreated mice was twice that of tissue
culture–derived virus and antibiotic-treated and
germ-free intestinal virus (fig. S10). Second, we
developed an ex vivo–in vitro assay to examine
Fig. 3. Reovirus pathogenesis inmicrobiota-
depleted mice. (A) PVRtg-Ifnar1−/− mice
were uninfected, untreated (n = 5), or
antibiotic-treated (n = 5) or infected
perorally with reovirus, untreated (n =
13) or antibiotic-treated (n = 15). Feces
were collected 24 hours post inoculation.
(B) Fecal pathology (table S1). (C) Up-
per (top) and lower (bottom) small intes-
tines were harvested from untreated and
antibiotic-treated PVRtg-Ifnar1−/− mice on day 4 post infection or from uninfected mice. Arrows indi-
cate Peyer’s patches. (D) Quantification of Peyer’s patch sizes [from (C)] from uninfected and infected
mice. (E) Reovirus titers from day 4 post infection PVRtg-Ifnar1−/−mouse tissues. Plaque assays were
performed using murine L929 cells, yielding PFU per milligram of tissue. For (B) to (E), n = 4 to 9
untreated mice, n = 2 to 9 antibiotic-treated mice. Each symbol or bar denotes the mean + SEM. *P <
0.05, **P < 0.01, Student’s t test. Scale bars in (A) and (C), 5 mm. (A) and (C), representative of 3 to 5
experiments; n = 2 to 4 experiments for (B), (D), and (E).
Fig. 4. Effects of bacteria and polysaccharides on poliovirus. (A) Strategy for in vitro poliovirus infectivity
experiments. (B) Poliovirus recovered after incubation in PBS. (C) Poliovirus infectivity after exposure to PBS,
feces, or feces supplemented with B. cereus or LPS (6 hours at 37°C). (D) Poliovirus infectivity after exposure
to medium (DME) or bacterial strains (107, 108, or 109 CFU) (6 hours at 37°C). (E) Poliovirus infectivity after
incubation with compounds (1 mg/ml) (6 hours at 42°C). (F) Poliovirus infectivity after incubation with
various concentrations of compounds (6 hours at 42°C). (G) Poliovirus binding to LPS. Poliovirus was
incubated with or without biotinylated LPS for 1 hour at 37°C. A monomeric avidin column was loaded with
samples and washed with PBS to collect fractions 1 to 6. Excess biotin was added to elute (fractions 7 to 12).
Poliovirus was quantified yielding PFU per fraction, P < 0.0001, two-way analysis of variance (ANOVA). (H)
Binding of radiolabeled poliovirus to HeLa cells. 35S-labeled poliovirus was incubated with PBS or 108 CFU B.
cereus for 1 hour at 37°C. An equal volume of PBS or B. cereus was added, followed by immediate
incubation with HeLa cells. After washing, cell-associated radioactivity was quantified. For all, n = 2 to 8
experiments, and bars and symbols denote mean T SEM, *P < 0.05, **P < 0.01, Student’s t test.
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poliovirus infectivity (Fig. 4A). Poliovirus was
incubated at 37° or 42°C, and viable virus was
quantified by plaque assay. Poliovirus incubated
in phosphate-buffered saline (PBS), feces from
antibiotic-treated mice, and germ-free feces lost
viability (Fig. 4, B and C). However, poliovirus
incubated in untreated feces or germ-free feces
supplemented with bacteria had significantly in-
creased viability (Fig. 4C). Similarly, poliovirus
incubated with Gram-negative (Escherichia coli
or O. intermedium) or Gram-positive (Bacillus
cereus or Enterococcus faecalis) bacteria had sig-
nificantly increased viability (Fig. 4D). Exposure
to B. cereus increased poliovirus infectivity more
than 500%. Enhancement of poliovirus infectiv-
ity did not require live bacteria (fig. S11). More-
over, poliovirus incubated with certain bacterial
surface polysaccharides, including lipopolysac-
charide (LPS) and peptidoglycan (PG), had sig-
nificantly enhanced yield over PBS-treated controls
(Fig. 4, C and E, and fig. S12). The enhancement
was not due to cellular effects of LPS or PG treat-
ment (fig. S13).We tested a variety of glycans and
other compounds, and only N-acetylglucosamine
(GlcNAc)–containing polysaccharides (e.g.,
chitin) demonstrated activity (Fig. 4E). Mucin,
a host protein modified with GlcNAc-containing
polysaccharides, also had activity (13). Of the
purified components tested, LPS was the most
potent enhancer of poliovirus infectivity, with ac-
tivity at concentrations 1/20th those of chitin or
mucin (Fig. 4F).Using biotinylatedLPSandmono-
meric avidin columns, we found that poliovirus
binds LPS (Fig. 4G). Because B. cereus exposure
produced the largest increase in poliovirus yield,
we testedwhether exposure toB. cereus enhanced
radiolabeled poliovirus binding to HeLa cells,
which would aid infection. Poliovirus incubated
with B. cereus displayed adherence to HeLa cells
2 times that of controls (Fig. 4H). Overall, polio-
virus infectivity was enhanced in the presence of
intestinal microbiota in vitro and in vivo, which
likely contributed to the enhanced replication and
pathogenesis in microbiota-harboring mice.
Despite the well-known beneficial effects of
intestinal microbes, we discovered that they aug-
ment enteric virus pathogenesis by enhancing
viral replication. Intestinal microbes also induce
egg hatching of an intestinal nematode in mice
(14), which suggests that diverse pathogens ex-
ploit intestinal microbes for propagation. Our
work implies that antibiotic-mediated microbiota
depletion can have antiviral effects, although we
do not advocate the use of antibiotics to prevent
viral disease. However, understanding howmicro-
biota promote enteric virus infections may reveal
new antiviral strategies. Our results suggest that
poliovirus binds specific microbe–associated sur-
face polysaccharides, which enhances viral ther-
mostability and attachment to host cells. Contrary
to the known benefits of intestinal microbiota to
the host (1), enteric viruses may have evolved to
use intestinal microbes as a trigger for replication
at a site optimal for transmission.
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MED12, the Mediator Complex Subunit
12 Gene, Is Mutated at High Frequency
in Uterine Leiomyomas
Netta Mäkinen,1* Miika Mehine,1* Jaana Tolvanen,1 Eevi Kaasinen,1 Yilong Li,1
Heli J. Lehtonen,1 Massimiliano Gentile,2 Jian Yan,3 Martin Enge,3 Minna Taipale,1,3
Mervi Aavikko,1 Riku Katainen,1 Elina Virolainen,4 Tom Böhling,4,5 Taru A. Koski,1
Virpi Launonen,1 Jari Sjöberg,6 Jussi Taipale,1,3 Pia Vahteristo,1 Lauri A. Aaltonen1†
Uterine leiomyomas, or fibroids, are benign tumors that affect millions of women worldwide and
that can cause considerable morbidity. To study the genetic basis of this tumor type, we examined
18 uterine leiomyomas derived from 17 different patients by exome sequencing and identified
tumor-specific mutations in the mediator complex subunit 12 (MED12) gene in 10. Through analysis
of 207 additional tumors, we determined that MED12 is altered in 70% (159 of 225) of tumors from
a total of 80 patients. The Mediator complex is a 26-subunit transcriptional regulator that bridges
DNA regulatory sequences to the RNA polymerase II initiation complex. All mutations resided
in exon 2, suggesting that aberrant function of this region of MED12 contributes to tumorigenesis.
Uterine leiomyomas, also called fibroids,are benign tumors that occur in 60% ofwomen by the age of 45 years and that
cause symptoms in about half of the cases (1).
These symptoms include abdominal pain and
discomfort and abnormal bleeding. Uterine leio-
myomas are also an important cause of infertility
[reviewed in (2, 3)], and they are the most com-
mon medical reason for hysterectomy (4). Several
recurrent genetic aberrations such as deletions
in 7q, trisomy of chromosome 12, and various re-
arrangements affecting the high mobility group
AT-hook 2 (HMGA2) gene mapping to chromo-
some 12q14 (5–7) have been observed in uterine
leiomyomas, but these occur at low frequency.
To investigate whether these tumors have high-
frequency genetic alterations, we investigated all
protein-coding genes by exome sequencing in
18 uterine leiomyomas and the respective normal
tissue DNAs. These tumors came from 17 dif-
ferent patients.
The most frequent tumor-specific alterations
in the set of 18 tumors affected theMED12 gene
on chromosome Xq13.1. MED12 is a subunit of
the Mediator complex, which is thought to regu-
late global, as well as gene-specific, transcription
(8). Ten tumors displayed a mutation, and eight
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ABSTRACT 17 
Mammalian reoviruses display serotype-specific patterns of tropism and disease in the 18 
murine central nervous system (CNS) attributable to polymorphisms in viral attachment 19 
protein σ1. While all reovirus serotypes use junctional adhesion molecule-A as a cellular 20 
receptor, they differ in utilization of carbohydrate coreceptors. This observation raises the 21 
possibility that carbohydrate binding by σ1 influences reovirus pathology in the CNS. In 22 
this study, we sought to define the function of carbohydrate binding in reovirus 23 
neuropathogenesis. Newborn mice were inoculated intramuscularly with wild-type strain 24 
type 3 Dearing (T3D) and T3D-σ1R202W, a point-mutant T3D derivative that does not 25 
bind sialic acid (SA). Infected mice were monitored for survival, and viral loads at sites 26 
of primary and secondary replication were quantified. Fewer mice inoculated with wild-27 
type virus survived in comparison to those inoculated with the mutant virus. Wild-type 28 
virus also produced higher titers in the spinal cord and brain at late times post-inoculation 29 
but lower titers in the liver in comparison to those produced by the mutant virus. In 30 
addition, wild-type virus was more virulent and produced higher titers in the brain than 31 
the mutant following intracranial inoculation. These animal infectivity studies suggest 32 
that T3D-σ1R202W harbors a defect in neural growth. Concordantly, compared with 33 
wild-type virus, mutant virus displayed a decreased capacity to infect and replicate in 34 
primary cultures of cortical neurons, a property dependent on cell-surface SA. These 35 
results suggest that SA binding enhances the kinetics of reovirus replication in neural 36 
tissues and highlight a functional role for sialylated glycans as reovirus coreceptors in the 37 
CNS. 38 
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INTRODUCTION 39 
Attachment to specific cell-surface molecules is the initial step in viral infection. As such, 40 
receptor engagement can influence many aspects of viral pathogenesis, perhaps most 41 
prominently systemic dissemination and tropism for distinct host cells and tissues. 42 
Tropism of human immunodeficiency virus (HIV) (27), poliovirus (32), and SARS-43 
coronavirus (15), among others, is strongly influenced by the capacity of the virus to bind 44 
specific receptors. Infection of discrete regions within the central nervous system (CNS) 45 
by strains of adeno-associated virus (AAV) is dependent on carbohydrate-binding 46 
specificity. AAV4 infects ependymal cells and utilizes α(2,3)-linked sialic acid (SA) as a 47 
receptor. In contrast, AAV5 uses both α(2,3)- and α(2,6)-linked SA to infect neurons (22). 48 
While much is known about the importance of these receptor-mediated functions in viral 49 
spread and tropism, precise mechanisms by which receptor utilization regulates viral 50 
infection in the CNS are not fully understood. 51 
Mammalian orthoreoviruses (reoviruses), members of the Reoviridae, are 52 
nonenveloped viruses comprised of two concentric protein shells that enclose the 10 53 
segments of the viral double-stranded RNA genome (37). These viruses are genetically 54 
tractable tools for studies of virus-receptor interactions and viral pathogenesis. In 55 
neonatal mice, reovirus serotypes 1 and 3 disseminate from sites of primary replication to 56 
the CNS. However, tropism for neural cells and resulting disease outcomes vary in a 57 
serotype-specific manner. Type 1 reovirus strains spread to the CNS via hematogenous 58 
routes and infect ependymal cells in the brain, which leads to a non-lethal hydrocephalus 59 
(40, 43, 44). In contrast, type 3 reovirus strains spread to the CNS using both neural and 60 
hematogenous routes and target neurons in the brain, which results in lethal encephalitis 61 
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(1, 6, 28, 40). These serotype-specific differences in tropism and disease segregate 62 
genetically with the viral S1 gene (43, 44), which encodes attachment protein σ1 (26, 45) 63 
and nonstructural protein σ1s (9, 17, 35). Both S1 gene products influence reovirus 64 
pathogenesis (1, 5-7, 23), with the σ1 protein thought to target the virus to discrete cell 65 
types in the CNS (14, 39). 66 
Reovirus attachment protein σ1 is a filamentous trimer with three discrete 67 
domains: the tail, body, and head (11, 19, 31). Residues 1 to 160 encompass the tail 68 
domain, which inserts into the virion capsid (11, 20). This region of the molecule is 69 
predicted to form an α-helical coiled coil (16, 29). The body domain encompasses 70 
residues 170 to 309 and is comprised of a β-spiral repeat motif interrupted by a short α-71 
helical coiled coil (31). The globular head domain incorporates residues 310 to 455 and 72 
folds into an 8-stranded β-barrel (11, 24, 36). 73 
 Receptors for reovirus are engaged by a multistep adhesion-strengthening process 74 
in which σ1 first binds to an abundant cell-surface carbohydrate with low affinity (3), 75 
which is followed by high-affinity interactions with junctional adhesion molecule-A 76 
(JAM-A) (2, 4). Sequences in the σ1 body domain mediate SA binding by type 3 strains 77 
(10, 31), whereas sequences in the σ1 head domain engage JAM-A (24). Interactions 78 
between σ1 and SA involve residues at the N-terminal portion of the body domain, 79 
between β-spiral repeats 2 and 3, where the SA moiety docks into a shallow pocket that is 80 
formed mainly by residues in the third β-spiral repeat (31). 81 
While all reovirus serotypes engage JAM-A (8, 30), they differ in carbohydrate 82 
coreceptor utilization, suggesting that carbohydrate binding by σ1 influences reovirus 83 
pathology in the CNS. Studies comparing pathogenesis in newborn mice of reovirus 84 
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strains that differ in glycan utilization revealed that SA-binding enhances spread from the 85 
intestine to peripheral sites of replication such as the liver, spleen, and brain (5). In 86 
addition, the capacity to bind SA confers reovirus tropism for bile duct epithelium (5). 87 
However, it is not known whether SA-binding influences reovirus dissemination, tropism, 88 
and replication within the CNS. 89 
In this study, we sought to define the function of carbohydrate binding in reovirus 90 
neuropathogenesis. We monitored survival of newborn mice inoculated with wild-type 91 
type 3 Dearing (T3D) and T3D-σ1R202W, a T3D point-mutant virus that does not bind 92 
SA (31), and quantified viral loads in various organs of infected animals. We found that 93 
the wild-type virus was more virulent and produced higher titers in neural tissues than the 94 
mutant virus following intramuscular or intracranial inoculation. Furthermore, we found 95 
that wild-type virus displayed an increased capacity to infect and replicate in primary 96 
cultures of cortical neurons in an SA-dependant manner. Collectively, these results 97 
suggest that binding to SA enhances the kinetics of reovirus replication in neural tissues 98 
and point to a functional role for sialylated glycan engagement in reovirus neurovirulence. 99 
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MATERIALS AND METHODS 100 
Cells and viruses. L929 cells (34) were maintained in Joklik's minimum essential 101 
medium supplemented to contain 5% fetal bovine serum, 2 mM L-glutamine, 100 U/ml 102 
of penicillin, 100 µg/ml of streptomycin, and 25 ng/ml of amphotericin B (Invitrogen). 103 
Strains T3D (25) and T3D-σ1R202W (31) used for this study were generated by 104 
plasmid-based reverse genetics. Purified reovirus virions were obtained using second- or 105 
third-passage L929 cell-lysate stocks of twice-plaque-purified reovirus as described (20). 106 
Viral particles were Freon-extracted from infected cell lysates, layered onto 1.2- to 1.4-107 
g/cm3 CsCl gradients, and centrifuged at 62,000 × g for 18 h. Bands corresponding to 108 
virions (1.36 g/cm3) (38) were collected and dialyzed in virion-storage buffer (150 mM 109 
NaCl, 15 mM MgCl2, 10 mM Tris-HCl [pH 7.4]). The concentration of reovirus virions 110 
in purified preparations was determined from an equivalence of one OD unit at 260 nm 111 
equals 2.1 × 1012 virions (38). Viral titer was determined by plaque assay using L929 112 
cells (42). The average particle-to-PFU ratios for T3D and T3D-σ1R202W were 893 113 
(n=4) and 1050 (n=5), respectively. These values do not differ statistically. 114 
Infection of mice. C57BL/6J mice were obtained from Jackson Laboratory to 115 
establish breeding colonies. Newborn mice 2-3 days old were inoculated intramuscularly 116 
or intracranially with purified reovirus diluted in PBS. Intramuscular (IM) inoculations (5 117 
μl) were delivered into the right hindlimb, and intracranial (IC) inoculations (5 μl) were 118 
delivered into the left cerebral hemisphere, in both cases using a Hamilton syringe and 119 
30-gauge needle. For analysis of viral virulence, mice were monitored for symptoms of 120 
disease for 21 days post-inoculation. For survival experiments, mice were euthanized 121 
when found to be moribund (defined by rapid or shallow breathing, lethargy, or paralysis). 122 
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Death was not used as an endpoint. For analysis of virus replication, mice were 123 
euthanized at various intervals following inoculation, and organs were collected into 1 ml 124 
of phosphate-buffered saline (PBS) and homogenized by freezing, thawing, and 125 
sonication. For analysis of viremia, mice were euthanized and decapitated at various 126 
intervals following inoculation, and whole blood was collected from the neck into a 1 ml 127 
syringe containing 100 μl Alsever’s solution (Sigma). Viral titers in organ homogenates 128 
were determined by plaque assay using L929 cells (42). 129 
For experiments in which viral titers were determined in an organ or blood, the 130 
Mann-Whitney test was used to calculate two-tailed P values. This test is appropriate for 131 
experimental data that display a non-Gaussian distribution (33). P values of less than 0.05 132 
were considered to be statistically significant. When all values are less than the limit of 133 
detection, a Mann-Whitney test P value cannot be calculated. Statistical analyses were 134 
performed using Prism software (GraphPad Software, Inc.). 135 
All animal husbandry and experimental procedures were performed in accordance 136 
with Public Health Service policy and approved by the Vanderbilt University School of 137 
Medicine Institutional Animal Care and Use Committee. 138 
Histology and immunohistochemical staining for reovirus antigen. Newborn 139 
mice 2-3 days old were inoculated intramuscularly or intracranially with reovirus diluted 140 
in PBS. Mice were euthanized 8 days post-inoculation, and organs were resected and 141 
incubated in 10% formalin at room temperature for 24 to 48 h. Fixed organs were 142 
embedded in paraffin, and consecutive 6 mm sections were stained with hematoxylin and 143 
eosin (H&E) for evaluation of histopathologic changes or processed for 144 
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immunohistochemical detection of reovirus proteins (5) or the activated form of caspase-145 
3 (Cell Signaling, Inc.) (12). 146 
Quantification of viral RNA using RT-qPCR. Total RNA was extracted from 147 
200 μl of whole blood/Alsever's mixture using the High Pure Viral RNA kit (Roche). 148 
RNA was eluted into a final volume of 40 μl. Reverse transcription-quantitative PCR 149 
(RT-qPCR) was performed using an ABI 7000 sequence detection system (Applied 150 
Biosystems) and EZ RT-PCR (Roche) according to the manufacturer's instructions with 151 
minor modifications. Reovirus RNA was quantified using 10 μl of RNA extract. Forward 152 
(S4 83F, 5′-CGCTTTTGAAGGTCGTGTATCA-3′) and reverse (S4 153R, 5′-153 
CTGGCTGTGCTGAGATTGTTTT-3′) primers corresponding to the viral S4 gene were 154 
used for RT and qPCR amplification. The S4-specific fluorogenic probe used was 5′-155 
dFAM-AGCGCGCAAGAGGGATGGGA-BHQ-1-3′ (Biosearch Technologies). RT was 156 
performed at 50°C for 2 min, followed by incubation at 60°C for 30 min. The reaction 157 
was terminated by incubation at 95°C for 5 min. Subsequently, 40 cycles of qPCR were 158 
performed at 95°C for 15 s followed by incubation at 60°C for 30 s. Standard curves 159 
relating threshold cycle values to copies of plasmid DNA template were generated using 160 
10-fold dilutions of a T3D S4-encoding plasmid (pT7-T3D S4) (25). The concentration 161 
of viral RNA in each sample was extrapolated from standard curves. The final S4 RNA 162 
copy number was calculated by multiplying the copy number obtained by extrapolation 163 
from the standard curve by four to account for using one-quarter of the extracted RNA as 164 
a template. 165 
 166 
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 Preparation of cortical neuron cultures from embryonic mice. Primary 167 
cultures of mouse cortical neurons were established using cerebral cortices of C57/BL6 168 
embryos at developmental day E15 (1). Fetuses were decapitated, brains were removed, 169 
and cortical lobes were dissected and submerged in Hanks’ balanced salt solution (Gibco) 170 
on ice. Cortices were incubated in 0.6 mg/ml trypsin solution at room temperature for 30 171 
min, washed twice, and manually dissociated twice using a Pasteur pipette. Viable cells 172 
were plated at a density of 2.5 × 105 cells/ml in 24-well plates. Wells were treated prior to 173 
plating with a 10 μg/ml poly-D-lysine solution (BD Biosciences) and a 1.64 μg/ml 174 
laminin solution (BD Biosciences). Cultures were incubated for the first 24 h in 175 
neurobasal medium (Gibco) supplemented to contain 10% FBS (Gibco), 0.6 mM L-176 
glutamine, 50 units/ml penicillin, and 50 μg/ml streptomycin. Cultures were thereafter 177 
maintained in neurobasal medium supplemented to contain B27 (Gibco), 50 units/ml 178 
penicillin, and 50 μg/ml streptomycin. One-half of the medium was replaced with fresh 179 
medium every 3 to 4 days. Neurons were cultivated for 7 days prior to use. 180 
Assessment of reovirus infectivity by indirect immunofluorescence. 181 
Monolayers of murine cortical neurons (2.5 × 105 cells/well) seeded in 24-well plates 182 
were adsorbed with reovirus at a multiplicity of infection (MOI) of 1000 plaque-forming 183 
units (PFU)/cell at room temperature for 1 h. Cells were incubated with either PBS or 40 184 
mU Arthrobacter ureafaciens neuraminidase at 37°C for 1 h and washed three times with 185 
PBS prior to virus adsorption. Following removal of the virus inoculum, cells were 186 
washed with PBS and incubated in complete medium at 37°C for 21 h to permit 187 
completion of a single cycle of viral replication. Monolayers were fixed with 1 ml of 188 
methanol at -20°C for at least 30 min, washed twice with PBS, and blocked with 0.1% 189 
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Tween-20 (Sigma) and 20% normal goat serum (Vector Laboratories) in PBS. Cells were 190 
washed once with PBS and stained with polyclonal rabbit anti-reovirus serum at a 1:1000 191 
dilution in PBS-0.5% Triton X-100 at room temperature for 1 h. Neurons were visualized 192 
after washing three times with PBS and staining with a monoclonal mouse anti-β-tubulin 193 
antibody (TUJ1; Covance) at a 1:1000 dilution in PBS-0.5% Triton X-100 at room 194 
temperature for 1 h. Monolayers were washed twice with PBS-0.5% Triton X-100 and 195 
incubated with a 1:1000 dilution of Alexa488-labeled anti-rabbit and Alexa546-labeled 196 
anti-mouse IgG (Invitrogen). Nuclei were stained with 4′,6-diamidino-2-phenylindole 197 
(DAPI; Invitrogen) at a 1:10,000 dilution. Monolayers were washed with PBS, and 198 
infected cells were visualized by indirect immunofluorescence using an Axiovert 200 199 
fluorescence microscope (Carl Zeiss). 200 
Assessment of reovirus replication by plaque assay. Murine primary cortical 201 
neurons (105 cells/well) were adsorbed with reovirus strains at an MOI of 1 PFU/cell. 202 
Cells were incubated with either PBS or 40 mU A. ureafaciens neuraminidase at 37°C for 203 
1 h and washed three times with PBS prior to virus adsorption. Following incubation with 204 
virus at room temperature for 1 h, cells were washed three times with PBS and incubated 205 
at 37°C for various intervals. Samples were frozen and thawed twice, and viral titers were 206 
determined by plaque assay using L929 cells (42). For each experiment, samples were 207 
infected in triplicate. Viral yields were calculated according to the following formula: 208 
log10 yieldtx = log10(PFU/ml)tx − log10(PFU/ml)t0, where tx is the time postinfection. Mean 209 
values from two independent experiments were compared using an unpaired Student’s t 210 
test as applied in Microsoft Excel. P values of less than 0.05 were considered to be 211 
statistically significant. 212 
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RESULTS 213 
SA binding enhances reovirus neurovirulence and spinal cord injury. To determine 214 
whether SA binding influences reovirus neuropathogenesis, we monitored survival and 215 
clinical signs of disease in two-day-old mice following IM inoculation with 5 × 106 PFU 216 
of either wild-type T3D or mutant T3D-σ1R202W (Fig. 1A). Reovirus strain T3D-217 
σ1R202W contains a point mutation in σ1 that ablates SA-binding capacity (31). Mice 218 
were observed for 21 days after inoculation and euthanized when moribund. Significantly 219 
fewer mice infected with T3D survived in comparison to those infected with T3D-220 
σ1R202W. The survival frequency of mice infected with T3D was 25.9% compared with 221 
63.6% for mice infected with T3D-σ1R202W (P < 0.005). These results suggest that SA 222 
binding enhances reovirus virulence. 223 
Following IM inoculation of newborn mice, serotype 3 reovirus causes acute 224 
flaccid paralysis (AFP) between 8 and 10 days post-inoculation (21). Infected mice 225 
exhibit ipsilateral, followed by contralateral, hindlimb paralysis as a consequence of 226 
injury within the anterior horn of the spinal cord associated with motor neuron loss and 227 
spread of viral antigen (21). We observed differences in development of AFP in mice 228 
infected with wild-type and mutant virus. On day 8 post-inoculation, mice infected with 229 
wild-type virus displayed hindlimb paralysis at a five-fold greater frequency than those 230 
infected with the mutant virus (33% vs. 6%, respectively) (Fig. 1B). Furthermore, the 231 
percentage of mice infected with wild-type virus exhibiting bilateral hindlimb paralysis 232 
was almost four times greater than that in mice infected with the mutant virus (11% vs. 233 
3%, respectively) (Fig. 1B). These data are concordant with results gathered from the 234 
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survival experiments and provide further evidence that SA binding enhances reovirus 235 
virulence. 236 
To investigate whether enhanced virulence and AFP development in mice 237 
infected with wild-type virus compared with mutant virus corresponds with more 238 
extensive reovirus infection and tissue damage in the spinal cord, we compared histologic 239 
sections of spinal cords resected from mice inoculated intramuscularly with 5 × 106 PFU 240 
of either T3D or T3D-σ1R202W (Fig. 2). Transverse sections of the inferior spinal cord 241 
were sectioned and processed for H&E staining, staining for reovirus antigen, or staining 242 
for the activated form of caspase-3, a marker of apoptosis. Following H&E staining, 243 
spinal cords of mice infected with wild-type virus displayed more widespread injury, as 244 
indicated by increased apoptotic bodies, reactive endothelium, inflammatory infiltrates, 245 
and neurons with eosinophilic cytoplasmic inclusions. Immunohistochemistry for 246 
reovirus antigen showed correspondingly more abundant and intense staining in mice 247 
infected with wild-type virus compared with spinal cords from mice infected with the 248 
mutant virus. Staining for the activated form of caspase-3 demonstrated more apoptotic 249 
neurons in spinal cord tissues of mice infected with wild-type virus in comparison to 250 
those from mutant-infected mice. Quantification of caspase-3-positive cells revealed that 251 
mice infected with wild-type virus contained a significantly higher number of apoptotic 252 
cells in spinal cord sections (P < 0.005) (Fig. 3). These findings suggest that binding to 253 
SA leads to increased reovirus infection and apoptotic injury to motor neurons in the 254 
spinal cord. 255 
SA binding influences reovirus replication at sites of secondary replication. 256 
To better understand how SA-binding capacity influences reovirus virulence, we 257 
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inoculated two-day-old mice intramuscularly with 5 × 106 PFU of either T3D or T3D-258 
σ1R202W and quantified viral titers in the hindlimb, spinal cord, brain, and liver on days 259 
2, 4, 8, and 10 post-inoculation (Fig. 4). In the hindlimb muscle, titers of both viruses 260 
were comparable, except on day 4 when the mutant virus produced higher titers than the 261 
wild-type virus (P < 0.005). In the spinal cord and brain, the mutant virus produced 262 
significantly higher titers than the wild-type virus at day 4 (P < 0.05). However, on days 263 
8 and 10, titers of the wild-type virus were significantly higher than those of the mutant 264 
(P < 0.05). Interestingly, titers in the liver of mice infected with the wild-type virus were 265 
significantly less than those in mice infected with the mutant virus throughout the 266 
experimental time course of infection (P < 0.05 on day 2 and P < 0.005 on days 4 and 8).  267 
To determine whether SA-binding capacity influences the kinetics of 268 
hematogenous spread, we again inoculated two-day-old mice intramuscularly with 5 × 269 
106 PFU of either T3D or T3D-σ1R202W. In this experiment, we quantified viral titers in 270 
the heart and spleen (Fig. 5A) and monitored viral genome copies in the serum (Fig. 5B). 271 
There were statistically significant differences in titers produced by wild-type and mutant 272 
virus in the heart on day 4 post-inoculation and in the spleen on days 4 and 10 post-273 
inoculation. On day 4 post-inoculation, the wild-type virus produced higher titer in the 274 
heart but lower titer in the spleen in comparison to the mutant virus. On day 10 post-275 
inoculation, the wild-type virus produced higher titer than the mutant virus in the spleen. 276 
Although these differences are statistically significant, because of the modest magnitude 277 
of the differences, we do not think that they are biologically relevant. Furthermore, the 278 
number of viral genome copies detected in the serum of mice infected with either virus 279 
also was comparable. Thus, SA-binding capacity enhances overall peak titers in the 280 
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murine CNS. However, utilization of SA is not required for infection of the liver and 281 
does not appear to influence hematogenous dissemination in mice. 282 
SA binding enhances reovirus neurovirulence and replication in the brain. 283 
Differences in titers produced by T3D and T3D-σ1R202W in the spinal cord and brain 284 
could result from more efficient spread of wild-type virus from the muscle to the CNS, 285 
enhanced replication of wild-type virus in the CNS, or both effects. To distinguish 286 
between these possibilities, we inoculated three-day-old mice intracranially with 2 PFU 287 
of either wild-type or mutant virus. We monitored infected mice for survival and clinical 288 
signs of disease for 21 days and quantified viral loads in the brain at days 4, 8, and 12 289 
following inoculation (Fig. 6). We again observed that mice infected with the wild-type 290 
virus displayed a lower frequency of survival (33%) compared with those infected with 291 
the mutant virus (85%) (P < 0.001) (Fig. 6A). In addition, wild-type virus produced 292 
higher titers in the brain than did the mutant following IC inoculation (Fig. 6B), reaching 293 
statistical significance on day 8 post-inoculation (P < 0.05). Taken together, these 294 
findings suggest that SA binding enhances reovirus virulence by augmenting viral 295 
replication in the CNS. 296 
SA binding does not alter reovirus tropism in the brain. To test whether σ1-297 
SA interactions are required for neural tropism of type 3 reovirus, we compared 298 
histologic sections of brains resected from mice inoculated intracranially with 100 PFU 299 
of either T3D or T3D-σ1R202W (Fig. 7). Brains chosen for histologic analysis were 300 
matched anatomically based on the size and shape of landmarks such as the hippocampus 301 
as well as displaying comparable viral titers. The intensity of reovirus antigen staining as 302 
well as the cellular distribution of reovirus antigen was similar in brain sections from 303 
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mice infected with either T3D or T3D-σ1R202W. Characteristic reovirus tropism 304 
involving several areas the brain including the cortex, the C2-C4 region of the 305 
hippocampus, and the thalamus was apparent in mice infected with either virus (Fig. 7A). 306 
In addition, involvement of the cerebellum, specifically infection of the Purkinje cells, 307 
was observed in brain sections of mice infected with either virus (Fig. 7B). Staining for 308 
the activated form of caspase-3 demonstrated apoptotic foci in sections of brain tissue 309 
from animals infected with either T3D or T3D-σ1R202W. However, the number of 310 
apoptotic cells did not appear to differ in these sections (data not shown), perhaps due to 311 
the inoculum dose used in this experiment. Therefore, SA-binding capacity of type 3 312 
reovirus does not influence targeting of reovirus to specific regions within the brain, but 313 
rather appears to influence replication efficiency in brain tissue. 314 
SA binding enhances infection of murine primary cortical neurons. Results 315 
gathered thus far reveal that SA-binding enhances the capacity of reovirus to replicate in 316 
the brain following IM or IC inoculation. We hypothesized that this difference is 317 
attributable to enhanced infection and replication in neurons by SA-binding reovirus 318 
strains. To test this hypothesis, we quantified infection of primary cortical neuron 319 
cultures using an immunoflorescence assay (Figs. 8A and 8B) and compared titers of 320 
T3D and T3D-σ1R202W following replication in primary cortical neuron cultures at 24, 321 
48, and 72 h post-infection (Fig. 8C). Primary cultures of mouse cortical neurons were 322 
established using cerebral cortices of C57/BL6 embryos at developmental day E15 and 323 
cultured for 7 days prior to infection (1). Wild-type virus infected a significantly higher 324 
percentage of cortical neurons (5%) in comparison to the mutant (1%) (P < 0.0001) (Fig. 325 
8B). Concordantly, at 24 h post-infection, yields of wild-type and mutant virus were 326 
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comparable (Fig. 8C). However, by 48 and 72 h post-infection, wild-type virus produced 327 
significantly higher yields than those produced by the mutant (P < 0.05) (Fig. 8C). These 328 
findings suggest that engagement of SA by reovirus enhances infection and replication 329 
efficiency in neurons. 330 
To confirm the importance of SA binding for infectivity and replication of 331 
primary cultures of neurons, cells were treated with A. ureafaciens neuraminidase to 332 
remove cell-surface SA. A. ureafaciens neuraminidase is a broad-spectrum enzyme that 333 
cleaves α-2,3-, α-2,6-, and α-2,8- terminally-linked SA present on glycan chains (41). 334 
Neuraminidase treatment diminished the infectivity and replication of wild-type virus to 335 
the levels observed for the mutant virus (Fig. 8A-C). These findings demonstrate that 336 
both infectivity and replication in primary neuronal cultures by type 3 reovirus is 337 
enhanced by SA binding. Collectively, these results suggest that the capacity of reovirus 338 
to bind cell-surface SA enhances the efficiency of infection of cells in the murine CNS. 339 
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DISCUSSION 340 
In this study, we found that the capacity to bind cell-surface SA enhances the 341 
neurovirulence of type 3 reovirus. Following either IM or IC inoculation of newborn 342 
mice, wild-type strain T3D was more virulent and produced higher titers in neural tissues 343 
compared with non-SA-binding mutant virus T3D-σ1R202W. Furthermore, mice infected 344 
with wild-type virus displayed a higher frequency of AFP and enhanced tissue injury 345 
compared with mutant-infected mice. Injury in the spinal cord and the brain is associated 346 
with apoptosis, with the number of apoptotic neurons in the spinal cord correlating with 347 
the extent of neurological symptoms. The key finding of this study is that SA-binding 348 
capacity dictates increased reovirus infectivity and replicative capacity in murine neurons. 349 
These data suggest that SA binding enhances the neurovirulence of type 3 reovirus by 350 
mediating efficient infection of target cells in the CNS, resulting in increased replication 351 
and pathology. 352 
We found that wild-type T3D displays increased infectivity and replicative 353 
capacity in primary cultures of murine cortical neurons, a phenotype that is dependent on 354 
cell-surface SA. Binding of type 3 reovirus strains to SA facilitates viral attachment 355 
through low-affinity adhesion that places the virus on the cell surface where access to the 356 
higher-affinity, but lower-abundance, proteinaceous receptor is thermodynamically 357 
favored (3). This adhesion-strengthening mechanism may be the basis for the enhanced 358 
replication and neurovirulence of T3D. Although the proteinaceous receptor on neurons 359 
for type 3 reovirus is not known, our findings suggest that its optimal engagement likely 360 
requires initial low-affinity glycan binding to anchor the virus to the cell surface. We 361 
favor this scenario because neuraminidase treatment of primary murine cortical neurons 362 
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decreases but does not abolish infection or replication (Fig. 8), consistent with the 363 
existence of other host mediators of infection. 364 
We previously identified residues in type 3 σ1 that are required for functional 365 
binding of reovirus to SA, i.e., binding that results in productive infection (31). Using 366 
reverse genetics, we introduced structure-guided mutations in the type 3 σ1 molecule and 367 
characterized the resultant mutant viruses using assays to quantify SA-binding capacity. 368 
This analysis highlighted the importance of Arg202 in the interaction of type 3 σ1 with 369 
SA. The Arg202 sidechain forms a bidentate salt bridge with the carboxylate moiety of 370 
SA, which is an important electrostatic contact between the protein and its carbohydrate 371 
ligand. Replacement of Arg202 with a tryptophan in T3D-σ1R202W would remove the 372 
electrostatic interaction between the arginine and SA and introduce a structural clash with 373 
the glycan (Fig. 9). It is therefore unlikely that the mutant can bind to SA, even in the 374 
improbable case that the overall structure of the binding site is not altered by the mutation. 375 
This model provides a structural framework for understanding the decreased virulence 376 
displayed by T3D-σ1R202W. 377 
Following IM inoculation, wild-type T3D produced lower titers in the livers of 378 
infected mice than did non-SA binding stain T3D-σ1R202W (Fig. 4). This is an 379 
interesting result because previous studies from our laboratory revealed that SA binding 380 
confers tropism of reovirus for bile duct epithelium and reovirus-induced injury to the 381 
liver (5). The SA-binding strain used in that study, T3SA+, produces higher titers in liver 382 
tissue than its non-SA-binding counterpart, T3SA-, at early times after infection. 383 
However, SA-binding-capacity is not strictly required for infection and replication in the 384 
liver, as T3SA- produces titers in the liver that approximate those of T3SA+ at late times 385 
 19
of infection (1, 5). It is possible that the genetic backgrounds of the strains used by 386 
Barton et al (5) (T1L) and here (T3D) account for the observed differences. It also is 387 
possible that the routes of inoculation, peroral (5) vs. IM (current study) influence hepatic 388 
tropism. We also noted that T3D-σ1R202W produced higher titers than wild-type virus in 389 
the spinal cord and brain of infected mice on day 4 post-inoculation. Since reovirus is 390 
delivered initially to the CNS by hematogenous routes (1, 6), it is possible that 391 
bloodstream dissemination of the mutant virus is subtly enhanced in comparison to wild-392 
type virus, although if so, this difference was not sufficient to permit detection in our 393 
assays. 394 
Data presented in this study and others (5) indicate that the capacity of type 3 395 
reovirus to bind cell-surface SA can target the virus to specific sites of replication and 396 
lead to enhanced replication and disease. These observations suggest that SA-binding 397 
capacity confers a fitness advantage for reovirus. For example, it is possible that an SA-398 
mediated replication enhancement leads to increased viral shedding and transmission of 399 
virus from host to host. However, there are naturally circulating strains of reovirus that do 400 
not bind to SA (13), suggesting that SA-binding capacity is a balanced polymorphism in 401 
nature that also imposes a fitness cost. For example, SA-binding capacity diminishes 402 
reovirus infection of polarized human airway epithelial cells (18). Strain T3SA+ does not 403 
efficiently infect these cells, whereas T3SA- does. Moreover, neuraminidase pre-404 
treatment to remove cell-surface SA enhances T3SA+ infection of these cells (18). 405 
Determination of the precise contribution of SA binding to viral fitness will require 406 
competition studies using strains that vary solely in SA-binding capacity and populations 407 
of susceptible mice. 408 
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For many viruses, including several important human pathogens, glycan 409 
engagement plays an important role in infection and pathogenesis. Here, we demonstrate 410 
that utilization of sialylated glycans as coreceptors enhances the neurovirulence of type 3 411 
reovirus. This study broadens an understanding of mechanisms of reovirus attachment to 412 
neuronal cells and supports the hypothesis that type 3 reovirus-glycan interactions are key 413 
determinants of reovirus neurovirulence in the CNS. 414 
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FIGURE LEGENDS 563 
FIG 1 SA-binding capacity enhances reovirus virulence and paralysis following IM 564 
inoculation. Newborn C57/BL6 mice were inoculated in the right hindlimb with 5 × 106 565 
PFU of either T3D or T3D-σ1R202W (R202W). (A) Mice (n = 22-27 for each virus 566 
strain) were monitored for survival for 21 days. *, P < 0.005, as determined by log-rank 567 
test in comparison to T3D. (B) Mice were monitored for development of reovirus-568 
induced AFP on day 8 post-inoculation (n = 32-44 for each virus strain). Complete 569 
paralysis was first observed at this time point; survival frequencies of wild-type and 570 
mutant-infected mice at this time point were comparable. 571 
 572 
FIG 2 SA-binding capacity enhances reovirus-induced injury in the spinal cord 573 
following IM inoculation. Newborn C57/BL6 mice were inoculated in the right 574 
hindlimb with 5 × 106 PFU of either T3D or T3D-σ1R202W (R202W). The inferior 575 
spinal cord was resected on day 8 post-inoculation, and consecutive lumbosacral sections 576 
were stained with hematoxylin and eosin (H&E), polyclonal reovirus antiserum 577 
(Reovirus), or antibodies specific for the cleaved (active) form of caspase-3 (Caspase-3). 578 
Representative sections of spinal cord matched for lumbar depth are shown. Boxes 579 
indicate areas of enlargement. 580 
 581 
FIG 3 Quantification of apoptotic cells in the spinal cord of reovirus-infected mice. 582 
Lumbosacral sections of the inferior spinal cord resected from newborn mice inoculated 583 
intramuscularly in the right hindlimb with 5 × 106 PFU of either T3D or T3Dσ1-R202W 584 
(R202W) were stained for the cleaved form of caspase-3. Cells staining positive for 585 
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caspase-3 were enumerated in individual sections obtained from four animals infected 586 
with each virus strain. Results are expressed as mean caspase-3-positive cells per tissue 587 
section. Error bars represent SD. *, P < 0.005, as determined by Student’s t test in 588 
comparison to T3D. 589 
 590 
FIG 4 SA binding is associated with higher peak titers of reovirus in neural tissues. 591 
Newborn C57/BL6 mice were inoculated in the right hindlimb with 5 × 106 PFU of either 592 
T3D or T3D-σ1R202W. At days 2, 4, 8, and 10 post-inoculation, mice were euthanized, 593 
hindlimb muscle, spinal cord, brain, and liver were resected, and viral titers in organ 594 
homogenates were determined by plaque assay. Results are expressed as mean viral titers 595 
for 6-9 animals for each time point. Error bars indicate SEM. *, P < 0.05 and **, P < 596 
0.005, as determined by Mann-Whitney test in comparison to T3D. 597 
 598 
FIG 5 Binding to SA is not required for dissemination by hematogenous routes. 599 
Newborn C57/BL6 mice were inoculated in the right hindlimb with 5 × 106 PFU of either 600 
T3D or T3D-σ1R202W. (A) At days 2, 4, 8, and 10 post-inoculation, mice were 601 
euthanized, and heart and spleen were resected. Viral titers in organ homogenates were 602 
determined by plaque assay. Results are expressed as mean viral titers for 7 to 10 animals 603 
for each time point. Error bars indicate SEM. *, P < 0.05, as determined by Mann-604 
Whitney test in comparison to T3D. (B) At days 2, 4, 8, and 10 post-inoculation, mice 605 
were euthanized, blood was collected, and viral genome copies in serum were determined 606 
by RT-qPCR. Results are expressed as mean viral genome copies per animal for 3 to 5 607 
animals at each time point. Error bars indicate SEM. 608 
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 609 
FIG 6 SA-binding capacity enhances reovirus neurovirulence and replicative 610 
capacity following IC inoculation. Newborn C57/BL6 mice were inoculated 611 
intracranially with 2 PFU of either T3D or T3D-σ1R202W. (A) Mice (n = 18-21 for each 612 
virus strain) were monitored for survival for 21 days. **, P < 0.001, as determined by 613 
log-rank test in comparison to T3D. (B) At days 4, 8, and 12 post-inoculation, viral titers 614 
in brain homogenates were determined by plaque assay. Results are expressed as mean 615 
viral titers for 4 to 7 animals for each time point. Error bars indicate SEM. *, P < 0.05, as 616 
determined by Mann-Whitney test in comparison to T3D. 617 
 618 
FIG 7 Binding to SA does not alter reovirus tropism in the brain. Newborn C57/BL6 619 
mice were inoculated intracranially with 100 PFU of either T3D or T3D-σ1R202W 620 
(R202W). On day 8 post-inoculation, brains of infected mice were resected. The brains 621 
were bisected, and the left hemispheres were processed for histopathology and the right 622 
hemispheres were prepared for viral titer determination by plaque assay. Consecutive 623 
coronal sections of the brain were stained with hematoxylin and eosin (H&E) or 624 
polyclonal reovirus antiserum (Reovirus). Representative sections of brain hemisphere 625 
matched for hippocampal depth (A) and cerebellum (B) are shown. T3D-infected brain 626 
sections are from the right hemisphere of a brain with a titer of 8 × 108 PFU, and T3D-627 
σ1R202W-infected brain sections are from the right hemisphere of a brain with a titer of 628 
3.5 × 108 PFU.  629 
 630 
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FIG 8 SA-binding capacity increases the efficiency of reovirus infection of primary 631 
cortical neurons. Cortical neurons were harvested from C57/BL6 mouse embryos at 632 
developmental day E15.5 and cultured for 5-7 days prior to infection. (A) Neurons were 633 
adsorbed with either T3D or T3D-σ1R202W at an MOI of 1000 PFU/cell following pre-634 
treatment with either PBS or 40 mM A. ureafaciens neuraminidase and incubated for 21 h. 635 
Cells were stained with TUJ1 neural-specific marker to detect neurons (red), DAPI to 636 
detect nuclei (blue), and polyclonal reovirus antiserum to detect reovirus antigen (green) 637 
and visualized using indirect immunofluorescence microscopy. Representative wells 638 
from duplicate experiments are shown. (B) The percentage of infected cells was 639 
quantified by dividing the number of neurons exhibiting reovirus staining by the total 640 
number of cell nuclei exhibiting DAPI staining in three fields of 400X view in triplicate 641 
wells (n=2). Fields of view contained between 200 and 600 nuclei. Error bars indicate 642 
SEM. *, P < 0.0001, as determined by Student’s t test in comparison to T3D. (C) 643 
Neurons were adsorbed with either T3D or T3D-σ1R202W at an MOI of 1 PFU/cell. 644 
Titers of virus in cell lysates were determined by plaque assay at the indicated times post-645 
adsorption. Results are expressed as mean viral yield for duplicate samples. Error bars 646 
indicate SD. *, P < 0.05, as determined by Student’s t test in comparison to T3D. 647 
 648 
FIG 9 Comparison of T3D and T3D-σ1R202W σ1 interactions with the terminal SA 649 
of α(2,3) sialyllactose. (A) Ribbon drawing of the T3D σ1 body and head domains in 650 
complex with α(2,3) sialyllactose. The σ1 monomers are shown in red, blue, and yellow. 651 
The body domain consists of seven triple β-spiral repeats (β1–β7) and an α-helical coiled-652 
coil domain (cc) that is inserted between β-spiral repeats β4 and β5. The bound α(2,3) 653 
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sialyllactose is shown in stick representation and colored in orange (enclosed by the red 654 
box). (B) An enlarged view of the T3D σ1 SA-binding domain. The σ1 residue 202 of a 655 
single σ1 monomer is drawn in stick representation, while the remainder of the monomer 656 
is shown as a ribbon tracing. The other monomers are shown in a surface-shaded 657 
representation. The SA moiety of α(2,3) sialyllactose is shown in stick representation, 658 
with carbons colored orange, oxygens colored red, and nitrogens colored blue. Residue 659 
Arg202 (cyan) of wild-type T3D forms a salt bridge with the carboxylate group of SA 660 
(31). This bond is represented by a dashed red line, illustrating that it is likely lost when 661 
Arg202 is replaced with a tryptophan (yellow) in T3D-σ1R202W.  662 
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